



## Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline

A. J. Ullmann, J. M. Aguado, S. Arikan-Akdogli, D. W. Denning, A. H. Groll,  
K. Lagrou, C. Lass-Flörl, R. E. Lewis, P. Munoz, P. E. Verweij, et al.

### ► To cite this version:

A. J. Ullmann, J. M. Aguado, S. Arikan-Akdogli, D. W. Denning, A. H. Groll, et al.. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. *Clinical Microbiology and Infection*, 2018, 24 Suppl 1, pp.e1-e38. 10.1016/j.cmi.2018.01.002 . hal-01953645

**HAL Id: hal-01953645**

**<https://hal.science/hal-01953645>**

Submitted on 19 Nov 2019

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Diagnosis and Management of Aspergillus Diseases: Executive Summary of the 2017 ESCMID-ECMM-ERS Guideline

Andrew J. Ullmann<sup>1,61,62</sup>, Jose M. Aguado<sup>2,61,62</sup>, Sevtap Arikan-Akdagli<sup>3,61,62</sup>, David W. Denning<sup>4,5,6,62</sup>,  
Andreas H. Groll<sup>7,61,62</sup>, Katrien Lagrou<sup>8,61,62</sup>, Cornelia Lass-Flörl<sup>9,61,62</sup>, Russel E. Lewis<sup>10,61</sup>, Patricia  
Munoz<sup>11,12,13,61,64</sup>, Paul E. Verweij<sup>14,61,62</sup>, Adilia Warris<sup>15,61,62</sup>, Florence Ader<sup>16,17,63</sup>, Murat Akova<sup>18,61,62</sup>,  
Maiken C. Arendrup<sup>19,61,62</sup>, Rosemary A. Barnes<sup>20,62</sup>, Catherine Beigelman-Aubry<sup>21,63</sup>, Stijn  
Blot<sup>22,23,63</sup>, Emilio Bouza<sup>11,12,13,61,62</sup>, Roger J. M. Brüggemann<sup>24,61</sup>, Dieter Buchheidt<sup>25,61,62</sup>, Jacques  
Cadranel<sup>26,63</sup>, Elio Castagnola<sup>27,61</sup>, Arunaloke Chakrabarti<sup>28,62</sup>, Manuel Cuenca-Estrella<sup>29,61,62</sup>, George  
Dimopoulos<sup>30,63</sup>, Jesus Fortun<sup>31,61,62</sup>, Jean-Pierre Gangneux<sup>32,61,62</sup>, Jorge Garbino<sup>33,61,62</sup>, Werner J.  
Heinz<sup>1,61,62</sup>, Raoul Herbrecht<sup>34,61</sup>, Claus P. Heussel<sup>35,2</sup>, Christopher C. Kibbler<sup>36,62</sup>, Nikolai Klimko<sup>37,62</sup>,  
Bart Jan Kullberg<sup>24,61,62</sup>, Christoph Lange<sup>38,39,40,63</sup>, Thomas Lehrnbecher<sup>41,62</sup>, Jürgen Löffler<sup>1,61,62</sup>,  
Olivier Lortholary<sup>42,61,62</sup>, Johan Maertens<sup>43,61,62</sup>, Oscar Marchetti<sup>44,61,62</sup>, Jacques F. Meis<sup>45,61,62</sup>, Livio  
Pagano<sup>46,62</sup>, Patricia Ribaud<sup>47</sup>, Malcolm Richardson<sup>4,61,62</sup>, Emmanuel Roilides<sup>48,49,61,62</sup>, Markus  
Ruhnke<sup>50,61,62</sup>, Maurizio Sanguinetti<sup>51,61,62</sup>, Donald C. Sheppard<sup>52,61,62</sup>, János Sinkó<sup>53,61</sup>, Anna  
Skiada<sup>54,61,62</sup>, Maria J. G. T. Vehreschild<sup>55,56,57,62</sup>, Claudio Viscoli<sup>58,61,62</sup>, Oliver A. Cornely<sup>55,57,59,60,61,62,64</sup>

1 Department of Infectious Diseases, Hematology and Oncology, University Hospital Wuerzburg,  
Wuerzburg, Germany

2 Infectious Diseases Unit, University Hospital Madrid, Madrid, Spain

3 Department of Medical Microbiology, Hacettepe University Medical School, Ankara, Turkey

4 The National Aspergillosis Centre, Wythenshawe Hospital, ECMM Excellence Center of Medical  
Mycology, Manchester, United Kingdom

5 The University of Manchester, Manchester, United Kingdom

6 Manchester Academic Health Science Centre, Manchester, United Kingdom

- 26 7 Department of Paediatric Hematology/Oncology, Center for Bone Marrow Transplantation,  
27 University Children's Hospital Münster, Münster, Germany
- 28 8 Department of Microbiology and Immunology, ECMM Excellence Center of Medical Mycology,  
29 University Hospital Leuven, Leuven, Belgium
- 30 9 Institute of Hygiene, Microbiology and Social Medicine, ECMM Excellence Center of Medical  
31 Mycology, Medical University Innsbruck, Innsbruck, Austria
- 32 10 Infectious Diseases Clinic, Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
- 33 11 Department of Medical Microbiology and Infectious Diseases, Hospital General Universitario  
34 Gregorio Marañón, Madrid, Spain
- 35 12 CIBER Enfermedades Respiratorias - CIBERES (CB06/06/0058), Madrid Spain
- 36 13 Medicine Department, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain
- 37 14 Department of Medical Microbiology, Radboud University Medical Centre, Center of Expertise in  
38 Mycology Radboudumc/CWZ, ECMM Excellence Center of Medical Mycology, Nijmegen,  
39 Netherlands
- 40 15 MRC Centre for Medical Mycology, Institute of Medical Sciences, University of Aberdeen,  
41 Aberdeen, United Kingdom
- 42 16 Department of Infectious Diseases, Hospices Civils de Lyon, Lyon, France
- 43 17 Inserm 1111, French International Centre for Infectious Diseases Research (CIRI), Université  
44 Claude Bernard Lyon 1, Lyon, France
- 45 18 Department of Medicine, Section of Infectious Diseases, Hacettepe University Medical School,  
46 Ankara, Turkey
- 47 19 Department Microbiological Surveillance and Research, Statens Serum Institute, Copenhagen,  
48 Denmark
- 49 20 Department of Medical Microbiology and Infectious Diseases, Institute of Infection and  
50 Immunity, School of Medicine, Cardiff University, Cardiff, UK

51 21 Department of Diagnostic and Interventional Radiology, Centre Hospitalier Universitaire Vaudois  
52 (CHUV), Lausanne, Switzerland

53 22 Department of Internal Medicine, Ghent University, Ghent, Belgium

54 23 Burns, Trauma and Critical Care Research Centre, University of Queensland, Brisbane, Australia

55 24 Radboud Center for Infectious Diseases, Radboud University Medical Centre, Center of Expertise  
56 in Mycology Radboudumc/CWZ, ECMM Excellence Center of Medical Mycology, Nijmegen,  
57 Netherlands

58 25 Medical Clinic III, University Hospital Mannheim, Mannheim, Germany

59 26 Department of Pneumology, University Hospital of Tenon and Sorbonne, University of Paris,  
60 Paris, France

61 27 Infectious Diseases Unit, Istituto Giannina Gaslini Children's Hospital, Genoa, Italy

62 28 Department of Medical Microbiology, Postgraduate Institute of Medical Education & Research,  
63 Chandigarh, India

64 29 Instituto de Salud Carlos III, Madrid, Spain

65 30 Department of Critical Care Medicine, Attikon University Hospital, National and Kapodistrian  
66 University of Athens, Medical School, Athens, Greece

67 31 Infectious Diseases Service, Ramón y Cajal Hospital, Madrid, Spain

68 32 Univ Rennes, CHU Rennes, Inserm, Irset (Institut de Recherche en santé, environnement et  
69 travail) – UMR\_S 1085, Rennes, France

70 33 Division of Infectious Diseases, University Hospital of Geneva, Geneva, Switzerland

71 34 Department of Hematology and Oncology, University Hospital of Strasbourg, Strasbourg, France

72 35 Diagnostic and Interventional Radiology, Thoracic Clinic, University Hospital Heidelberg,  
73 Heidelberg, Germany

74 36 Centre for Medical Microbiology, University College London, London, UK

75 37 Department of Clinical Mycology, Allergy and Immunology, North Western State Medical  
76 University, St. Petersburg, Russia

77 38 International Health and Infectious Diseases, University of Lübeck, Lübeck, Germany  
 78 39 Clinical Infectious Diseases, Research Center Borstel, Leibniz Center for Medicine & Biosciences,  
 79 Borstel, Germany  
 80 40 German Center for Infection Research (DZIF), Tuberculosis Unit, Hamburg-Lübeck-Borstel-Riems  
 81 Site, Lübeck, Germany  
 82 41 Division of Paediatric Haematology and Oncology, Hospital for Children and Adolescents, Johann  
 83 Wolfgang Goethe-University, Frankfurt, Germany  
 84 42 Department of Infectious and Tropical Diseases, Children's Hospital, University of Paris, Paris,  
 85 France  
 86 43 Department of Haematology, ECMM Excellence Center of Medical Mycology, University Hospital  
 87 Leuven, Leuven, Belgium  
 88 44 Infectious Diseases Service, Department of Medicine, Lausanne University Hospital, Lausanne,  
 89 Switzerland  
 90 45 Department of Medical Microbiology and Infectious Diseases, Canisius-Wilhelmina Hospital,  
 91 Center of Expertise in Mycology Radboudumc/CWZ, ECMM Excellence Center of Medical  
 92 Mycology, Nijmegen, Netherlands  
 93 46 Department of Hematology, Università Cattolica del Sacro Cuore, Roma, Italy  
 94 47 Quality Unit, Pôle Prébloc, Saint-Louis and Lariboisière Hospital Group, Assistance Publique-  
 95 Hôpitaux de Paris, Paris, France  
 96 48 Infectious Diseases Unit, 3rd Department of Paediatrics, Faculty of Medicine, Aristotle University  
 97 School of Health Sciences, Thessaloniki, Greece  
 98 49 Hippokration General Hospital, Thessaloniki, Greece  
 99 50 Department of Hematology and Oncology, Paracelsus Hospital, Osnabrück, Germany  
 100 51 Institute of Microbiology, Fondazione Policlinico Universitario A. Gemelli – Università Cattolica  
 101 del Sacro Cuore, Rome, Italy

- 102 52 Division of Infectious Diseases, Department of Medicine, Microbiology and Immunology, McGill  
 103 University, Montreal, Canada
- 104 53 Department of Hematology and Stem Cell Transplantation, Szent István and Szent László  
 105 Hospital, Budapest, Hungary
- 106 54 First Department of Medicine, Laiko Hospital, National and Kapodistrian University of Athens,  
 107 Athens, Greece
- 108 55 Department I of Internal Medicine, ECMM Excellence Center of Medical Mycology, University  
 109 Hospital of Cologne, Cologne, Germany
- 110 56 Center for Integrated Oncology, Cologne-Bonn, University of Cologne, Cologne, Germany
- 111 57 German Centre for Infection Research (DZIF) partner site Bonn-Cologne, Cologne, Germany
- 112 58 Ospedale Policlinico San Martino and University of Genova (DISSAL), Genova, Italy
- 113 59 CECAD Cluster of Excellence, University of Cologne, Cologne, Germany
- 114 60 Clinical Trials Center Cologne, University Hospital of Cologne, Cologne, Germany
- 115 61 ESCMID Fungal Infection Study Group (EFISG)
- 116 62 European Confederation of Medical Mycology (ECMM)
- 117 63 European Respiratory Society (ERS)
- 118 64 ESCMID European Study Group for Infections in Compromised Hosts (ESGICH)

119

120 **Acknowledgement:** Professor William Hope was a member of the TDM group, however, he stepped  
 121 down during the process of guideline development due to his new post as guideline director of ESCMID  
 122 to avoid any conflicts of interest. His contributions were very much appreciated to the entry guideline  
 123 group. We are thankful for his help. We also thank Dr Vincent Dunet (Department of Diagnostic and  
 124 Interventional Radiology, CHUV, Lausanne, Switzerland) and Dr Frédéric Lamothe (Department of  
 125 Infectious Disease, CHUV, Lausanne, Switzerland) for their help and contribution to this guideline. We  
 126 are indebted to Kerstin Albus, MSc, for her critical review and corrections of the manuscript.

127

128 **Funding:** European Society of Clinical Microbiology and Infectious Diseases (ESCMID), European  
129 Confederation of Medical Mycology (ECMM) and European Respiratory Society (ERS)

130

131 **Corresponding author**

132 Prof. Oliver A. Cornely, MD, FECMM, FIDSA, FAAM, FACP

133 Department I for Internal Medicine

134 ECMM Excellence Center of Medical Mycology

135 University Hospital

136 Kerpener Str. 62

137 50937 Cologne

138 Germany

139 Tel. +49 221 478 85523

140 Fax +49 221 478 1421 445

141 E-mail: [Oliver.cornely@uk-koeln.de](mailto:Oliver.cornely@uk-koeln.de)

## Abstract

The European Society for Clinical Microbiology and Infectious Diseases, the European Confederation of Medical Mycology and the European Respiratory Society Joint Clinical Guidelines focus on diagnosis and management of aspergillosis. Of the numerous recommendations a few are summarized here. Chest computed tomography as well as bronchoscopy with bronchoalveolar lavage (BAL) in patients with suspicion of pulmonary invasive aspergillosis (IA) are strongly recommended. For diagnosis, direct microscopy preferably using optical brighteners, histopathology and culture are strongly recommended. Serum and BAL galactomannan is recommended as markers for the diagnosis of IA. PCR should be considered in conjunction with other diagnostic tests. Pathogen identification to species complex level is strongly recommended for all clinically relevant *Aspergillus* isolates; antifungal susceptibility testing should be done in patients with invasive disease in regions with resistance found in contemporary surveillance programmes. Isavuconazole and voriconazole are the preferred agents for first line treatment of pulmonary IA, while liposomal amphotericin B is moderately supported. Combinations of antifungals as primary treatment options are not recommended. TDM is strongly recommended for patients receiving posaconazole suspension or any form of voriconazole for IA treatment, and in refractory disease, where a personalized approach considering reversal of predisposing factors, switching drug class and surgical intervention is also strongly recommended. Primary prophylaxis with posaconazole is strongly recommended in patients with acute myelogenous leukaemia or myelodysplastic syndrome receiving induction chemotherapy. Secondary prophylaxis is strongly recommended in high-risk patients. We strongly recommend treatment duration based on clinical improvement, degree of immunosuppression and response on imaging.



## Introduction

This is the third fungal diagnosis and management clinical guideline published in cooperation with various European scientific societies [1-9]. This part of the guideline regarding invasive and chronic aspergillosis is a condensation of all the recommendations made by the guideline subcommittees and presented in tables for easier and faster reading. More details on how the recommendations were arrived at are planned in supplementary publications. This *Aspergillus* guideline will follow the style of other guidelines by including diagnostic and therapeutic guidance. Other scientific groups have published guidelines on this topic previously and all follow the common goal to provide clinicians with best guidance in their everyday working environment. Our goal was to provide a comprehensive European guideline focusing on the life-threatening diseases caused by *Aspergillus* spp.

## Methods

Author panel recruitment and organisation was similar to what was done previously [10]. In brief, experts in the field were nominated by the three societies ESCMID, ECMM, and ERS. The total 53 authors were grouped into their special fields of expertise. Subgroup coordinators were responsible for the first draft of recommendations. There were two face-to-face meetings followed by numerous electronic exchanges. Some of the first recommendations were presented at ECCMID 2014. This summary was reviewed and approved by all authors and sent to the ESCMID guideline director for public review. Then the final version was submitted to Clinical Microbiology and Infection for additional peer review and subsequent publication. Only the rationale of the chronic pulmonary aspergillosis (CPA) guideline was published ahead of time [11].

Questions were predefined and modified where appropriate and the strength of recommendation and quality of evidence was slightly modified (Table 1) [12]. Diagnostic tests are regarded as interventions.

## Summary of Recommendations

### Diagnostic Procedures

Early diagnosis of invasive aspergillosis (IA) is a challenge and should be based on the integration of clinical, radiological and microbiological data.

### **Thoracic Imaging**

In patients at risk for IA with fever of unknown origin or clinical symptoms of lower respiratory tract infection who remain febrile despite broad-spectrum antibacterial treatment, thin-section chest computed tomography (multidetector (MDCT), multislice (MSCT), spiral CT, high resolution CT) at optimized dose (according to ALARA “As Low As Reasonably Achievable” principle) is the imaging modality of choice **(AII)** [13-23]. Pulmonary CT angiography may be of interest in the early diagnosis of IA by depicting directly vessel occlusion at the level of a suspicious fungal lesion with a potential high negative predictive value regarding imaging evaluation [24-26], and is required in case of haemoptysis **(AII)**. In selected patients where CT is not wanted or feasible, MRI of the lungs may represent an alternative imaging to thin-section MSCT [27-32], PET-CT being of modest interest in the diagnostics of IA [33, 34].

No CT scanning technique is 100% sensitive or specific for pulmonary IA [35-37]: Classical CT findings of angioinvasive aspergillosis include macronodule(s) >1 cm, which may be surrounded by a halo of ground-glass attenuation (halo sign, early phase, inconstant) [36, 38-40], pleural based wedge-shaped areas of consolidation [41], alveolar consolidations [36, 42, 43], masses (especially in SOT recipients) [15, 38], internal low attenuation[44], reverse halo sign [45], cavity or air-crescent sign (delayed finding), ground glass opacities and pleural effusion [17, 35, 46]. Bronchoinvasive forms may appear as tracheal or bronchial wall thickening, centrilobular nodules with tree in bud appearance [14] in a patchy distribution, predominant peribronchial areas of consolidation [47] or bronchopneumonia [46] (Table 2).

### **Bronchoalveolar Lavage and Biopsies**

Other diagnostic procedures include early bronchoalveolar lavage (BAL) **(AII)** [48-54], guided by CT-findings [55, 56], and less frequently CT-guided transthoracic biopsies, video-assisted thoracoscopic surgery (VATS), open lung biopsies, transbronchial biopsies or convex endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA), the latter technique appearing to be a promising procedure in this setting [28, 57-72]. Contraindications to these techniques need to be considered.

### **Imaging of other Sites**

Moreover, according to clinical symptoms, paranasal CT, CT or MRI of the CNS as well as abdominal CT may also be required. In particular, findings of sinusitis with bone erosion may be observed, intracranial and/or intraorbital extension of the disease being best evaluated by MRI [73-75]. In the brain, due to direct spread from paranasal sinuses or haematogenous dissemination, meningeal enhancement or empyema, cerebral abscess, mycotic aneurysms as well as haemorrhagic lesions and rarely stroke may be seen [76-79].

### **Microscopy and Culture**

Both microscopy and culture should be attempted on appropriate specimens from patients at risk for IA **(AII)** with a priority for culture in most cases where insufficient material is available. Demonstrating tissue invasion by hyphae through microscopic examination of biopsy or autopsy material provides a diagnosis of proven invasive fungal infection. However, the sensitivity of microscopy for IA is 50% at best [80]. Specimens may be examined as a wet mount preparation with or without the addition of 10% potassium hydroxide. Fluorescent dyes such as Calcofluor White™ or Blancophor™ have the advantages of increased sensitivity, rapid turnaround time, and broad applicability but are not specific for *Aspergillus* **(AII)**. Gomori's methenamine silver stain (GMS) and periodic acid-Schiff (PAS) can be applied to histological sections and smears and should be conducted in all cases in which IA is considered a possibility (Table 3). Respiratory secretions from patients with suspected aspergillosis must be processed rapidly for culture to prevent overgrowth by bacteria and yeasts. To achieve

optimal recovery of *Aspergillus* from BAL fluid, centrifugation of the sample is advised with investigation of the sediment (**AIII**). It is recommended that cultures of high volume untreated sputum and BAL should be performed as opposed to culturing small volumes of digested, liquefied samples [81] (Table 4). Specific media to support fungal growth are recommended. Species identification to the complex level should be done for clinically relevant isolates from patients who need antifungal treatment, and for epidemiological purposes (AIII) (Table 5).

### **Non-Culture Based Assays**

Galactomannan (GM) detection in fluids (especially BAL) is more sensitive than culture for diagnosis of IA. GM is reported as optical density index (ODI). In serum samples an ODI cut-off of 0.5 results in high sensitivity in haematological patients in the absence of mould-active prophylaxis (**AI**) (Table 6). Serial screening for serum GM in prolonged neutropenia and in allogeneic stem cell transplantation recipients during the early engraftment phase has a high sensitivity and negative predictive value (NPV) for IA (**AII**) [82]. Serial screening is not recommended in patients on mould-active prophylaxis [83].

Sensitivity of serum GM testing is significantly lower in non-neutropenic versus neutropenic patients [84]. Decrease of the ODI during the first two weeks of antifungal therapy is a reliable predictor of a satisfactory response in cancer patients [85]. GM detection in BAL specimens has an excellent performance with evidence that ODI of 0.5–1.0 has decreased predictive values compared with results of >1.0 [86] (**AII**) (Table 7). The test also has diagnostic value in patients undergoing lung transplantation or who are in intensive care [87-89]; a sensitivity of 100% and a specificity of 90.4% was defined at cut-off of 1.5 [87].

(1-3)- $\beta$ -D-glucan (BDG) is a constituent of the cell wall of many species and genera of fungi and is released into body fluids in association with fungal infection. A limited role is given for the exclusive testing of the BDG in diagnosing IA (**BII**) (Table 8), however, the combination with GM or PCR improves specific detection [90].

The *Aspergillus* lateral flow LFD assay can be performed on serum and on BAL samples, but at the time of writing this assay is not commercially available [91] (Table 9).

*Aspergillus* PCR has been applied mostly to blood and BAL fluid. For both sample types, a combination with other biomarkers increases the likelihood of IA [92, 93]. The performance of serum PCR is not significantly different from that of whole blood [94-97]. Prospective screening of high-risk haematological patients by a combination of GM and PCR improves the diagnostic accuracy and is associated with an earlier diagnosis [98, 99] (Table 10 and 11).

On hyphal positive biopsy samples molecular detection of fungi is strongly recommended **(AII)**. If no hyphae are visible the diagnostic yield of molecular methods is lower (Table 12). Recommendations for storage of original samples and isolates are given in table 13. Antibody detection tests are not supported for the diagnosis of IA **(CII)** (Table 14).

#### **Antifungal Susceptibility Testing**

Resistance to antifungal agents is an increasing problem in *Aspergillus* diseases [100-102]. *Aspergillus* species can be intrinsically resistant to polyenes and azoles [103], or may acquire resistance following exposure to azole compounds [104]. Acquired resistance to azoles is mainly found in *Aspergillus fumigatus* and is reported globally [100, 101, 105-108]. Resistance may also develop through exposure to azole fungicides in the environment [109-112]. As resistant spores are present in ambient air, patients may present with azole-resistant *Aspergillus* disease without previous azole therapy [113, 114]. Individual *Aspergillus* colonies from a single specimen may harbour different resistance profiles [117], hence multiple colony testing (up to 5 colonies) is recommended to increase sensitivity for azole-resistance detection **(BIII)**.

In clinical laboratories, species identification to complex level is recommended for all clinically significant isolates **(BIII)**. Some species are intrinsically resistant to either azoles or amphotericin B (AmB) (Tables 5, 15, 16 and 17).

Antifungal susceptibility testing of *Aspergillus* isolates should be performed in patients with invasive disease with the exception of azole naïve patients in regions with no resistance found in contemporary surveillance programmes and regularly for epidemiological purposes including  $\geq 100$  isolates. This is particularly important in patients who are unresponsive to antifungal treatment, or in patients who are clinically suspected having an azole-resistant pathogen **(AIII)** (Table 15). If MIC-testing is not available, routine agar screening can be used to detect azole resistance (Table 16) [118]. However, such isolate should be referred to a mycology reference laboratory for MIC testing. Clinical breakpoints for interpretation of azole and AmB MICs against *Aspergillus* are currently available for European Committee on Antimicrobial Susceptibility Testing (EUCAST) microdilution method but remain undetermined for Clinical & Laboratory Standards Institute (CLSI) methodology. Accordingly, EUCAST **(AII)** or CLSI broth microdilution methods **(BII)** can be used for determination of routine MICs for clinical guidance and for epidemiological resistance surveillance **(AII)**. Both itraconazole and voriconazole **(AII)** should be tested to ensure detection of the voriconazole-resistance mutation TR<sub>46</sub>/Y121F/T289A [118]. Posaconazole resistance without itraconazole resistance has not been reported (Table 17). EUCAST **(BIII)** or CLSI broth microdilution methods **(CIII)** can be used to determine AmB MICs but although a correlation between MIC and clinical outcome exist for *A. terreus* and *A. flavus* it remains to be documented for *A. fumigatus* due to the scarcity of resistant isolates (Table 17).

Voriconazole and isavuconazole are recommended for the treatment of IA due to species showing high AmB MICs (Table 19). Liposomal AmB (L-AmB) or AmB lipid complex (ABLC) are recommended for species with intrinsic high azole MICs (Table 18 and 20). In aspergillosis due to *A. fumigatus* specifically, voriconazole or isavuconazole are recommended if the isolate is voriconazole susceptible (EUCAST MIC  $\leq 1$  mg/l) **(AI)**. If resistant (voriconazole MIC  $> 2$  mg/l), L-AmB therapy is recommended **(AII<sub>u</sub>)**. It is unknown if patients infected with *A. fumigatus* with voriconazole MIC 2 mg/l (intermediate), respond less well to voriconazole monotherapy. These patients may have an increased probability of failing voriconazole monotherapy, and combination therapy with an echinocandin or L-AmB monotherapy

should be considered for invasive disease **(AIII)** (Table 20). In azole-resistant CPA, L-AmB or micafungin can be considered **(BII)** if surgical intervention is precluded [11]. In settings with environmental azole resistance, no change to the primary regimen for IA is recommended when resistance rates are <10% **(AIII)**. If azole resistance rates are >10%, first line therapy with voriconazole plus echinocandin **(BIII)** or L-AmB **(BIII)** is recommended.

### **Therapeutic Drug Monitoring (TDM)**

Patients with IA often have multiple conditions associated with their underlying disease and its treatment that affects the absorption, distribution, metabolism, and clearance of antifungal medications [119]. As a result, standardized dosing recommendations for antifungals used in the prevention or treatment of IA may not achieve effective or safe drug exposures in all patients. Moreover, a subset of patients with severe infections or difficult to treat sites (e.g. CNS) or infections caused by *Aspergillus* spp. with elevated MICs may require higher drug exposures. Therapeutic drug monitoring (TDM) is often the most direct laboratory approach for identifying patients at jeopardy for treatment failure or toxicity because of inadequate or excessive drug exposures, and can be used to fine-tune antifungal dosing to improve the probability of optimal outcomes (Table 21).

### **Itraconazole**

For itraconazole, a serum trough of 0.5-4 mg/L (measured by HPLC) is recommended for prophylaxis **(All [efficacy], BII [safety])** and a trough of 1-4 mg/L is recommended during the treatment of IA **(All [efficacy], BII [safety])** [120-125]. Itraconazole has an active metabolite, OH-itraconazole that is present in similar (1:1) concentrations as the parent itraconazole compound when patients are at pharmacokinetic steady state. OH-itraconazole concentrations may be reported separately when samples are analysed by HPLC or LC/MS/MS, but will included in the overall report of “itraconazole” concentrations if samples are analysed by bioassay [126, 127]. Therefore, the target range for itraconazole is higher when reported by bioassay (i.e. 3-17 mg/L) but may vary by lab depending on

the reference standards used. Samples should be acquired within 5-7 days of starting therapy. Repeat TDM is recommended the following week to confirm the patient remains in the therapeutic range, and repeated thereafter as clinically indicated if there are changes in the patient's clinical condition, concomitant medications known to interact, or suspected toxicity (Table 22). Steady-state concentrations can often be predicted from earlier (non-steady) state samples through pharmacokinetic models or computerized dosage-assistance. In centres where these tools are available, sampling before day 5-7 may be preferable.

### **Voriconazole**

A plasma trough concentration of 1-5.5 mg/L is considered adequate for most patients receiving voriconazole prophylaxis or treatment (**All, safety and efficacy**) [128-133]. However, a trough of 2-6 mg/L (**All, safety and efficacy**) is recommended in patients treated for severe infections (multifocal or disseminated disease, CNS infections, infection with pathogen with elevated MICs, e.g. an MIC of 2 ml/L) [130, 131]. TDM is strongly recommended in children due to the much higher rates of drug elimination and potential for underdosing, especially with the lower voriconazole doses recommended in the past (**All**) [134, 135]. Plasma levels should be monitored between 2-5 days after initiation of therapy, and repeated the following week to confirm the patient remains in the therapeutic range. Repeated monitoring is indicated until steady state level in the therapeutic range is confirmed, if there are changes in the patient's clinical condition, concomitant medications, or suspected toxicity (Table 23).

### **Posaconazole**

For patients receiving posaconazole suspension, a plasma trough of >0.7 mg/L is recommended during prophylaxis (**BII efficacy**) [136, 137]; and a trough of >1 mg/L is recommended if the patient is receiving treatment for suspected or documented IA (**All efficacy**) [138]. Currently, no studies have defined an upper plasma target that is associated with toxicity, although pharmacokinetic studies supporting the



registration of the new posaconazole tablet and intravenous formulations with the EMA used a provisional cut-off of 3.75 mg/L [139-141]. Posaconazole plasma trough levels should be monitored on day 5 of therapy or soon thereafter, and repeated as clinically indicated.

For most patients prescribed posaconazole, we recommend using the newer tablet formulation (or intravenous formulation, if tablet formulation is contraindicated) rather than the suspension **(AII)**, as tablets are more likely to consistently achieve target plasma levels and are less affected by GI-dependent drug interactions [139]. Currently, there is limited evidence to suggest that all patients receiving posaconazole tablets or IV formulation for prophylaxis require routine TDM; however, our opinion is that when treating suspected or documented *Aspergillus* infections, TDM could still be useful if the pathogen has elevated MICs, is unresponsive to treatment, or in the event of unexplained toxicity **(BIII)**. Until further data are available, we recommend using TDM monitoring strategies and plasma trough targets as detailed above suggested for the suspension formulation (Table 24).

#### **Isavuconazole**

Although dose-response and plasma concentration-response relationships for isavuconazole have been reported in animal models, limited data are currently available to define a target therapeutic range or support the need for routine TDM for this agent [142]. Our opinion is that TDM could still be useful in the clinical assessment or monitoring of patients receiving isavuconazole therapy **(CIII)** if patients are unresponsive to treatment, have unexpected toxicity, pharmacokinetic drug-drug interactions, or if isavuconazole is being used to treat pathogens with elevated MICs or sanctuary sites such as the CNS. In the absence of well-defined therapeutic targets, documentation of a plasma trough in the range of 2-3 mg/L (mean concentration range from phase II/III clinical studies) after day 5 (including loading doses) suggests adequate drug exposure (Table 25).

#### **Flucytosine**

In rare circumstances, flucytosine may be used in combination with other antifungals for the treatment of triazole-resistant *Aspergillus* spp. In this scenario, weekly measurement of peak serum concentrations 2 hours following an oral dose **(AII)** are needed to confirm that peak concentrations are 50-100 mg/L in order to reduce the risk of toxicity. Trough concentrations required for efficacy are unknown but a level of 25-50 mg/mL is recommended based upon experience from cryptococcosis [143, 144].

## **Hospital Environment**

Standards for the hospital environment in immunosuppressed adults and children requires special attention. Patients need to be segregated from construction or renovation **(AII<sub>n</sub>)**, potted plants **(BII)**, and flowers in wards and in patients' rooms **(CIII)** [145-150]. Published data support the recommendation to accommodate patients in special hospital rooms with positive air pressure and HEPA filters **(BII)** or laminar airflow **(BII<sub>n</sub>)**. However, data were with historical controls, underpowered, or described by multivariate analysis describing high-risk situations for IA [151-154]. Protective masks for patients are proven not to be effective outside of the protected area **(CII)** [155]. Filters for water supply, especially in showers, are recommended **(BII)** [156-160]. No data are available to support regular environmental air sampling to prevent infections. However, indoor sampling is advisable to monitor filter efficacy **(BIII)** [161, 162].

## **Treatment Strategies**

Two strategies are accepted for managing patients with haematological malignancy at risk for IA: 1) the patient receives primary prophylaxis or 2) the patient receives no prophylaxis but is monitored at least twice weekly using biomarkers. The decision between the two strategies depends on local epidemiology, access to rapid diagnostics and patient characteristics. Breakthrough fungal diseases may appear through either symptoms or a disease-identifying biomarker or imaging result. Figure 1 depicts a consensus algorithm for patient management.

420

## 421 **Primary Prophylaxis**

422 At least three studies describe a number of patients who succumbed with IA missed prior to death  
423 [163-165]. Although diagnostic procedures improved since then, they are not satisfactory. For this  
424 reason, patients known to be at high risk for IA may receive primary prophylaxis, especially patients  
425 with profound and prolonged neutropenia or with active graft-versus-host disease (GvHD) (Table 26).

426

## 427 **Aspergillosis in Haematological Malignancy and Haematopoietic Stem Cell Transplantation**

428 In patients treated for haematological diseases, prolonged severe neutropenia is the most important  
429 risk factor for the development of IA. T cell depleted grafts, glucocorticosteroids and other immune  
430 suppressive drugs have been identified as further risk factors for IA in the later course after HSCT, even  
431 in non-neutropenic patients [166]. In fact, up to two thirds of patients with IA diagnosed after  
432 allogeneic HSCT are not neutropenic [167], and the median time of diagnosis of IA after allogeneic  
433 HSCT is 82 days (range, 3 - 6542 days) [168].

434

## 435 **Treatment**

436 Providing a definite diagnosis of IA is a continuously challenging endeavour for clinicians. The  
437 EORTC/MSG definitions are only designed for clinical studies. For clinical decision-making, these  
438 definitions could have a deleterious outcome since confirmation of a proven or probable diagnosis  
439 would delay the start of therapy [169]. Any patient at risk considered by the responsible clinician as  
440 having IA should receive antifungal therapy (**AIII**) (Tables 27-28). Physicians should consider IV to oral  
441 switch in stable and PK-reliable patients. Treatment duration depends on clinical response and on  
442 immune reconstitution or recovery from GvHD. Good partial or complete remission requires no  
443 persistent clinical, including imaging (scarring allowed) or microbiological evidence of disease. The  
444 range of the duration of treatment (3 to >50 weeks) is huge and the evidence base to support any

particular recommendation is weak [170-173]. Close monitoring (e.g. non-enhanced CT or, if applicable, biomarkers) is suggested once antifungal treatment is discontinued.

Additional adjunctive therapy such as the administration of G-CSF or G-CSF-primed granulocyte infusions (data mainly from paediatric populations) received only a weak supportive recommendation (CIII). In refractory cases, G-CSF (or IFN $\gamma$ ) has immunomodulatory effects [174-179]. No controlled trials have been performed and only anecdotal data with small numbers of patients exist. Persistent neutropenia is related with treatment failure, recovery from neutropenia enhances the efficacy of antifungal agents. A recent Cochrane review investigating the efficacy of granulocyte transfusions indicated no mortality difference for any kind of infection in patients with neutropenia [180].

#### **Fever-driven (“Empiric”), and Diagnosis-driven (“Pre-emptive”) Therapy**

As an alternative to prophylaxis, patients could receive the classical empirical administration of antifungal agents during fever refractory to broad-spectrum antibacterial agents. Empiric treatment is defined as a fever-driven treatment approach. Patients who would qualify for this approach are patients receiving induction or remission chemotherapy for acute leukaemia or MDS or conditioning chemotherapy for haematopoietic stem cell transplantation. Empiric antifungal treatment is expected to reduce morbidity [181-186] and mortality [187, 188] (Table 29). The duration of empiric antifungal treatment is set by the following rules applied in randomized clinical trials: If the patient is afebrile and has no active infection or infiltrates, then antifungal therapy can be discontinued after recovery of leukocyte counts [188-190]. Today, antifungal stewardship may warrant clinical trials on empiric treatment duration, but no such trial has been conducted so far.

Pre-emptive treatment is a diagnosis driven strategy. In most cases, it is defined by positive GM testing. However, chest CT with pulmonary infiltrates could apply as well. The use of BDG and PCR testing as alternative biomarkers for galactomannan have considerable merit [191, 192], though BDG is not specific for *Aspergillus* disease. In haematological patients, false positive BDG often results from contaminated infusions [193-196]. Very few authors wait for *Aspergillus*-associated suggestive

radiological signs including nodule, halo sign, wedge-shaped area of consolidation, or – late in the course of invasive aspergillosis – the air crescent sign, before starting antifungal treatment. Treatment choices are as recommended in targeted treatment.

## **Adult Patients without Haematological Malignancy**

### **Epidemiology**

Approximately 43-80% of the cases of IA appear in patients without a haematological malignancy [52, 197-200], although these patients are rarely included in the seminal studies of antifungals [170, 171, 173]. The proportion of these patients is even increased when exposed to spore concentrations of >25 cfu/m<sup>3</sup> in hospital air [201-204]. The non-haematological populations at risk for IA include solid organ transplant recipients (SOT), patients treated with prolonged high dose glucocorticosteroids, or with other immunosuppressants, patients with advanced AIDS or neoplasia, COPD, liver failure, liver cirrhosis, influenza as well as critically ill patients requiring ICU admission [52, 197-199, 205-208]. These patients frequently do not fulfil the EORTC/MSG criteria for invasive aspergillosis [169]. Confirmation of diagnosis may be delayed resulting in high mortality rates. At the same time drug-drug interactions and toxicity can occur more frequently compared to haematological patients [52]. Physicians need to be aware of the specific risk factors, clinical manifestations and management challenges in order to improve outcome. In SOT recipients the average incidence of IA ranges from 0.1 to 11.6% [209, 210], with the highest risk in small bowel (11.6%) and lung (8.6%) transplant recipients, followed by patients receiving liver (4.7%), heart (4.0%), pancreas (3.4%), and kidney (1.3%) grafts [209-211]. Half the cases will occur in the first three months after transplantation, in patients with post-surgical risk factors. Late aspergillosis is more common in elderly recipients, and patients with pronounced immunosuppression due to rejection or post-transplant neoplasia or chronically impaired graft function [210, 212]. With the exception of lung transplantation, in which universal prophylaxis is still common, antifungal prophylaxis will target SOT recipients with additional risk factors [211]. Risk factors for early IA in all SOT recipients – Including heart transplants – comprise renal failure requiring

replacement therapy, re-intervention, CMV disease, and high environmental exposure to mould spores [211, 213-215]. In liver transplantation, high model for end-stage liver disease (MELD) score, transplantation in fulminant hepatic failure, high intraoperative transfusion needs or re-transplantation are considered indications for post-surgical prophylaxis [216-224]. In lung transplant recipients, risk factors include previous respiratory tract colonization with *Aspergillus*, single lung transplant, CMV disease and acquired hypogammaglobulinaemia [225-227]. In kidney transplantation risk factors include COPD, delayed graft function, bloodstream infection, and acute graft rejection [228] and an >1.25 mg/kg/day average dose of prednisone [229]. Finally, some polymorphisms in defence genes have also been suggested to increase risk in transplant recipients [230, 231].

The incidence of IA in HIV patients has decreased since the advent of new antiretroviral therapy (2.2 cases per 10,000/year), but mortality remains high (38%) [232]. IA typically appears in patients with low CD4 counts and associated conditions such as neutropenia, advanced cirrhosis, liver transplantation or glucocorticosteroid therapy [233-241]. As in other non-haematological populations, EORTC/MSG criteria only detect half of the IA cases diagnosed among HIV-infected patients [232] and in a recent series of autopsies of AIDS patients, only 12% of the patients with IA had been diagnosed ante mortem [242] (Table 30).

IA may affect 0.3% of patients with liver cirrhosis [243]. Both acute liver failure and advanced cirrhosis, mainly alcoholic hepatitis treated with glucocorticosteroids, have been recognized as risk factors for IA [205, 244-246]. A low level of clinical suspicion explains that 53% of the cases of IA in cirrhotic patients are only recognized post-mortem [247] and that liver disease is independently associated with IA-related mortality [199, 248].

IA has also been described in apparently immunocompetent patients in a critical condition as a complication of ARDS, COPD, influenza, pneumonia, burns, severe bacterial infection, surgery, and malnutrition. Incidence is 4-6/1,000 ICU admissions and the mortality is higher than 70% in most series [245, 249-252]. Glucocorticosteroid treatment was the major host factor [253, 254] and as in cirrhotic or HIV positive patients delayed diagnosis is common [255, 256]. COPD patients requiring

glucocorticosteroids represent a group with especially high mortality [249, 257, 258]. Risk factors include admission to ICU, chronic heart failure, and antibiotic treatment and, above all, the cumulative dose of glucocorticosteroids [257].

Pulmonary and CNS aspergillosis predominates in these populations, but disseminated disease, fulminant and atypical forms may occur [203, 214, 225, 251, 259-267]. The sensitivity of most diagnostic methods is lower in non-haematological patients. Isolation of *Aspergillus* from respiratory cultures has a much lower positive predictive value so over-diagnosis has to be prevented [197, 268-272]. Regarding imaging findings, angioinvasive presentation included in the EORTC/MSG criteria is uncommon in this setting [273]. Airway invasive radiological presentation was present in 37% of heart transplant recipients and was associated with delayed diagnosis and poorer prognosis [214, 274]. In COPD and HIV-positive patients, the most common radiological presentation was an alveolar infiltrate [273, 275, 276]. Experience with biomarkers and PCR is still scarce in these populations, but the combination of at least two different methods appears to be the best diagnostic approach [277-285] (Table 31).

## **Treatment**

Despite no comparative studies of antifungal therapy in non-haematological patients voriconazole remains the first option, since it has been related to reduced mortality [216, 286-288] (Table 32). Combination therapy is uncommon, although retrospective data was encouraging in SOT recipients [289]. The risks of drug-drug interactions and toxicity are very important in these populations and TDM is advisable [290-295]. In patients with liver insufficiency, L-AMB is usually the first therapeutic option. Antifungal resistance is not a common problem despite prophylaxis [296, 297], although some cases have been reported [298-300]. Finally, immune reconstitution syndrome may occur after therapy initiation [301].

Most lung recipients receive antifungal prophylaxis. Targeted prophylaxis is preferred in the remaining SOT with risk factors [211, 213, 302-305]. However, significant variation in practice has been noted

[221, 304, 306, 307]. In order to avoid drug-drug interactions and toxicity, echinocandins or inhaled amphotericin are preferentially used [308-311], although voriconazole has also demonstrated its efficacy and safety in this setting [217, 220, 312-314]. Duration of prophylaxis is adjusted to the presence of risk factors and, with the exception of lung recipients, is usually limited to 3-4 weeks [215] (Table 33).

### **Special Considerations in Children**

Presenting symptoms, distributions and patterns of diseases and vulnerability to IA are similar between children and adults. However, differences exist in epidemiology and underlying conditions, usefulness of newer diagnostic tools, pharmacology of antifungal agents and evidence from interventional phase III studies. Recommendations for paediatric patients are based on efficacy in phase II and III trials in adults, the availability of paediatric pharmacokinetic data, safety data and supportive efficacy data. In addition, regulatory approval is considered as well. Therapeutic drug monitoring is always recommended when mould-active azoles are used as prophylaxis or treatment. Primary antifungal prophylaxis may be indicated in paediatric patients at 'high risk' for developing invasive fungal diseases, and specifically IA. An incidence rate of IFDs of  $\geq 10\%$  is usually considered as high risk. High-risk populations include children with de novo or recurrent leukaemia (e.g. AML, ALL depending on treatment protocol), bone marrow failure syndromes with profound and persistent neutropenia (e.g. MDS, VSAA), allogeneic HSCT recipients, patients with chronic granulomatous disease and those undergoing lung transplantation. For patients with haematological disorders, the mould-active oral azoles are the first choice to prevent IA in children, although neither itraconazole nor posaconazole are licensed for use in patients <18 years of age. Due to the lack of paediatric data, recommendations for lung and high-risk liver transplant patients correspond to those given for adults [213, 315]. Secondary prophylaxis to prevent recurrence of IA when risk factors are persisting is recommended with an antifungal targeted at the previous *Aspergillus* species, which caused the first episode (see below and Table 34).



Diagnostic procedures used in children are not different from those used in adults but their performance may differ. Suggestive abnormalities (e.g. halo sign, air crescent sign) on CT-chest as described in adults are less common in children in which non-specific masses or infiltrates predominate [316-318]. The GM test on blood and BAL samples has a similar sensitivity and specificity profile compared to adults [319-327]. The BDG test is not specific for *Aspergillus* and is not validated in children. Higher baseline levels are reported in healthy children and therefore the cut-off is yet unknown [328-332].

General management principles of IA are consistent with those in adults and include prompt initiation of antifungal therapy, control of predisposing conditions (e.g. reduction or discontinuation of glucocorticosteroids in immunosuppressed, administration of colony-stimulating factors in neutropenic patients), and surgical interventions on a case by case basis using a multidisciplinary approach. Voriconazole is recommended as the first line agent to treat IA in all children except neonates **(AII)**. L-AmB is first choice for neonates **(AIII)** and may replace voriconazole as first line treatment in areas or institutions with a high prevalence of azole-resistant *A. fumigatus*. Upon diagnosis of invasive pulmonary aspergillosis, thorough evaluation for further sites of infection is required and should include the CNS. The optimal duration of therapy is determined by the resolution of all signs and symptoms and reversal of the underlying deficit in host defences. For salvage therapy and breakthrough infections, a switch to a different class of antifungals is recommended [123, 132, 138, 170, 171, 177, 333-341] (Table 35).

If a fever-driven (empiric) strategy is used in at risk paediatric haematological patients, caspofungin or L-AmB are recommended until resolution of fever and neutropenia [342-344]. Treatment recommendations for a diagnosis-driven (pre-emptive) strategy correspond to those made for targeted treatment [185, 186, 345, 346].

## **Secondary Prophylaxis**

Secondary prophylaxis is a treatment strategy to prevent recurrence of IA during a subsequent risk period of immunosuppression. Patients with a history of IA previously successfully treated with antifungals entering a subsequent risk period of immunosuppression, e.g. allogeneic HCT (early phase), chemotherapy resulting in severe neutropenia (i.e.  $<500/\mu\text{L}$  and at least for 7 days), acute GvHD  $>1^\circ$  or extensive chronic GvHD, or T-cell suppressing therapy, including steroids, are at risk. Agents for secondary prophylaxis are listed in table 36.

### **Treatment of Refractory Disease**

Refractory IA is defined as progression of disease and should be differentiated from stable disease [349]. Patients with radiological evidence of progression and persisting elevated GM have a very high probability of treatment failure resulting in death. Assessment of response should use composite outcome parameters including clinical, radiological, and mycological criteria. Radiological progression following or closely preceding neutrophil recovery should be carefully evaluated and is not necessarily indicative of failure. Keeping this in mind, assessing response 2 weeks after treatment initiation generally allows predicting the response, especially recognizing oncoming failure [350]. In case of GM negative IA, early assessment of response may be difficult and could require a longer time of therapy. If failure ascertained, look for poor vascular supply (i.e. sinusitis requiring surgical treatment), microbiological confirmation is recommended since identification of the fungus at the species level is pivotal. If a viable organism is recovered, susceptibility testing is recommended, especially regarding azole resistance. On the other hand, azole concentration should be monitored as well (see chapters on resistance and therapeutic drug monitoring within this guideline) [38, 349, 351-359]. The choices of antifungal agents in refractory disease are listed in table 37.

### **Chronic Pulmonary Aspergillosis (CPA)**

CPA is an indolent destructive disease of the lungs usually complicating other pulmonary conditions occurring in non- or mildly immunocompromised patients [360, 361]. Its manifestations include

chronic cavitary pulmonary aspergillosis (CCPA), which if left untreated may progress to chronic fibrosing pulmonary aspergillosis (CFPA), *Aspergillus* nodule and single aspergilloma [11, 362]. Subacute invasive pulmonary aspergillosis (previously chronic necrotizing pulmonary aspergillosis) is also a cavitating destructive lung disease usually found in moderately immunocompromised patients which progresses more rapidly, typically over 1 to 3 months. The diagnosis of CPA requires a combination of characteristics: one or more cavities with or without a fungal ball present or nodules on thoracic imaging, either direct evidence of *Aspergillus* infection (culture or microscopy from biopsy) or an IgG antibody response to *Aspergillus* spp. and exclusion of alternative diagnoses (especially mycobacterial infection), all present for at least 3 months [11, 363]. Over 90% of patients have circulating *Aspergillus* antibody (precipitins) (**AII**) [364]. A positive culture of *A. fumigatus* respiratory tract secretion (BAL, bronchoscopy aspiration) is not diagnostic because many different pathologies are attributable to the fungus, and it may be an airway colonizing fungus or a plate contaminant in the laboratory.

If a fungal ball is seen, then only a positive test of *Aspergillus* IgG or precipitins confirms pathogenicity. Patients may have CPA and other infections concurrently (see below).

The distinctive hallmark of CCPA is new and/or expanding cavities with thick or thin walls in those with chronic lung disease. An intracavitary fungal ball may be present, often with pleural thickening and extensive parenchymal destruction and/or fibrosis. Patients may have CPA and other infections concurrently, especially bacterial including *Pseudomonas aeruginosa* infection or tuberculosis and non-tuberculous mycobacterial infection. *Aspergillus* nodules, which may be single or multiple, may mimic malignancy as well as nodules seen in rheumatoid arthritis, coccidioidomycosis, tuberculosis, non-tuberculous mycobacterial infection and – rarely – actinomycosis or rheumatoid arthritis. Typically, *Aspergillus* nodules appear rounded, some with low attenuation or cavitation within. Some are spiculated, a common feature of carcinoma [362].

If technically feasible single aspergilloma should be surgically removed, preferably via video-assisted thoracic surgery technique with due consideration to risks as recommended [365]. Long term oral

antifungal therapy is strongly recommended in patients with CCPA, partly to reduce general and respiratory symptoms [366, 367], but also to minimise haemoptysis and prevent lung destruction and fibrosis **(AII)** itraconazole or voriconazole are effective for CCPA **(AIII)** [11]. Oral posaconazole is a potential alternative treatment **(BII)** [11]. Six months of therapy is the recommended minimum **(AI)** [11]. Relapse is common after discontinuation. Intravenous therapy for CPA is useful in patients who fail or are intolerant of triazoles or have triazole resistant *A. fumigatus*. Prednisolone may be considered for underlying symptom control only if patients are adequately treated with antifungals. Mild and moderate haemoptysis usually responds to tranexamic acid; severe haemoptysis should be arrested with bronchial artery embolization (Table 38).

## **Conclusions**

This executive summary is a comprehensive guideline covering many aspects of *Aspergillus* diseases. It provides guidance for clinicians on prevention of disease, diagnostic procedures, resistance issues and treatment of IA as well as chronic pulmonary aspergillosis. The guideline group intends to provide additional publications supporting the rationale of recommendations given. Finally, the guideline group provides comprehensive tables explaining various options for specific situations.

669 **Table 1. Strength of recommendation and quality of evidence**

<b>Strength of Recommendation (SoR)</b>	<b>Definition</b>
Grade A	Societies <u>strongly</u> support a recommendation for use
Grade B	Societies <u>moderately</u> support a recommendation for use
Grade C	Societies <u>marginally</u> support a recommendation for use
Grade D	Societies support a recommendation <u>against</u> use
<b>Quality of Evidence (QoE)</b>	<b>Definition</b>
Level I	Evidence from at least 1 properly* designed randomized, controlled trial (orientated on the primary endpoint of the trial)
Level II	Evidence from at least 1 well-designed clinical trial (incl. secondary endpoints), without randomization; from cohort or case-controlled analytic studies (preferably from >1 centre); from multiple time series; or from dramatic results of uncontrolled experiments
Level III	Evidence from opinions of respected authorities, based on clinical experience, descriptive case studies, or reports of expert committees
<b>Added Index</b>	<b>Source of Level II Evidence</b>
r	Meta-analysis or systematic review of RCT
t	Transferred evidence i.e. results from different patients' cohorts, or similar immune-status situation
h	Comparator group: historical control
u	Uncontrolled trials

a	For published abstract presented at an international symposium or meeting
* poor quality of planning, inconsistency of results, indirectness of evidence etc. would lower the SoR	

670

671 **Table 2. Recommendations for imaging and bronchoalveolar lavage**

Population	Intention	Intervention*	SoR	QoE	Comment	Ref.
Neutropenia, fever or clinical symptom of pneumonia, empiric antibiotics, failing to achieve defervescence, e.g. FUO	To detect pulmonary infiltrates	Chest CT and thin section multi-detector CT (MDCT)	A	II	Within 12-24h after the beginning of fever, dose optimization recommended	[21, 31, 35, 368]
Haemoptysis	To identify vessel occlusion	Chest angio-CT / pulmonary CT angiography	B	II		[24-26]
Haemoptysis	To identify vessel erosion	Chest angio-CT / pulmonary CT angiography	A	II		[24-26, 369, 370]

Any	To identify possible underlying fungal or other infectious disease	BAL	A	II		[21, 49-54]
Any	To obtain appropriate specimens for microscopy, culture and PCR	CT-guided BAL	A	III		[55, 56]

672 \*, Diagnostic tests are interventions; SoR, Strength of recommendation; QoE, Quality of evidence; FUO, fever of unknown origin; CT, computed tomography;

673 BAL, bronchoalveolar lavage; PCR, polymerase chain reaction

674



675 **Table 3. Microscopic examinations**

Popula tion	Intention	Intervention	SoR	QoE	Comment	Ref.
Any	To identify fungal elements in histological sections and stains	Histological examination Gomori's methenamine silver stain Periodic acid-Schiff	A	III	Histopathology is an essential investigation  Inability to definitively distinguish other filamentous fungi  GMS: removes cellular background; more sensitive to hyphal elements  PAS: advantage of counter stain to check cellular detail	[80, 371-373]
Any	To identify fungal elements in histological sections and stains	Fluorescent dyes: Calcofluor white™, Uvitex 2B, Blancophor™	A	II	Not specific to <i>Aspergillus</i> but high sensitivity and the micromorphology may provide info on the fungal class (e.g. <i>Aspergillus</i> : typically dichotomous and septate, Mucorales: pauci-septate and 90° angle branching, yeast: budding)  Rapid turnaround time  Broad applicability  May be applied to frozen sections, paraffin-embedded tissue	[374-378]

Any	To identify fungal elements in histological sections and stains	Immunohistochemistry Monoclonal antibody WF-AF-1 or EB-A1 In situ hybridization	B	II	Have the potential to provide genus and species specific data Commercially available monoclonal antibodies WF-AF-1 is specific for <i>A. fumigatus</i> , <i>A. flavus</i> , and <i>A. niger</i> Time consuming and not broadly available	[374-378]
Any	To identify fungal elements in fresh clinical specimens (e.g. BAL)	Application of fluorescent dyes Calcofluor white™ or Uvitex 2B or Blancophor™	A	II	Essential investigation Not specific for <i>Aspergillus</i> species High sensitivity Rapid turn-around time Broad applicability No species identification but the micromorphology may provide info on the fungal class (e.g. <i>Aspergillus</i> : typically dichotomous and septate, Mucorales: pauci-septate and 90° angle branching, yeast: budding)	[80, 373, 379]

676 SoR, Strength of recommendation; QoE, Quality of evidence; BAL, bronchoalveolar lavage; HE, haematoxylin-eosin; GMS, Gomori's methenamine silver

677 stain; PAS, Periodic acid-Schiff; CNS, central nervous system

678

679 **Table 4. Sample selection and pre-analytical respiratory sample treatment**

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
Any	To achieve a homogenous sample of viscous samples such as sputum	Liquefaction using a mucolytic agent, e.g. Pancreatin®, Sputolysin®, or using sonication and 1,4-dithiothreitol	A	III	Essential investigation High volume sputum culture (entire sample) shown to significantly increase recovery	[81, 380]
Any	To achieve optimal recovery of <i>Aspergillus</i> from BAL by centrifugation and investigation of the sediment	Centrifugation of BALs or bronchial aspirates	A	III	Essential investigation Isolation of <i>Aspergillus</i> dependent on volume cultured	[81]

680 SoR, Strength of recommendation; QoE, Quality of evidence; BAL, bronchoalveolar lavage; PCR, polymerase chain reaction

681

682 **Table 5. Culture and *Aspergillus* species identification**

Popula tion	Intention	Intervention	SoR	QoE	Comment	Ref.
Any	Primary isolation from deep sites samples (e.g. biopsies, blood, CSF)	Culture on SDA, BHI agar, PDA at 30°C and 37°C for 72 h	A	III	Blood inhibits conidiation; BHI can help to recover some isolates; Isolation of several colonies or isolation of the same fungus from a repeat specimen enhance significance	[81, 381, 382]
	Primary isolation from non-sterile samples, e.g. sputum, respiratory aspirates	Culture on SDA, BHI agar, PDA with gentamicin plus chloramphenicol at 30°C and 37°C for 72 h	A	III	High volume sputum culture (entire sample) shown to significantly increase recovery; Quantitative cultures are not discriminative for infection or colonization	
	Identification of species complex	Macroscopic and microscopic examination from primary cultures	A	II	Colony colour, conidium size, shape and septation. Colour of conidia and conidiophore and conidiogenesis (tease or tape mounts are preferred); Expertise needed for interpretation	
	Identification of species complex (and species	Culture on identification media at 25-30°C, 37°C	A	II		

	identification of <i>A. fumigatus</i> specifically)	and 50°C (2% MEA and Czapek-Dox Agar) and microscopic examination			Thermotolerance test (growth at 50 °C for species confirmation of <i>A. fumigatus</i> )	
	Identification at species level	MALDI-TOF MS identification	B	II	In house databases are often used to improve identification rates	[383-386]
	Identification at species level	Sequencing of ITS, beta-tubulin and calmodulin	A	III	Not necessary in organisms with typical growth, but in cases of atypical growth	[387, 388]
	To study outbreaks	Microsatellite and CSP analysis	C	II	To study outbreaks (which in general may comprise more than one genotype)	[389-391]
			B	II	To study colonisation patterns	[392]

SoR, Strength of recommendation; QoE, Quality of evidence; CSF, cerebrospinal fluid; SDA, Sabouraud dextrose agar; BHI, brain heart infusion; PDA, potato dextrose agar; MEA, malt extract agar; MALDI-TOF MS, matrix-assisted laser desorption ionization time-of-flight mass spectrometry identification; ITS, internal transcribed spacer; CSP, Cell surface protein

684 **Table 6. Galactomannan testing in blood samples**

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
Patients with prolonged neutropenia or allogeneic stem cell transplantation recipients <b>not on mould-active prophylaxis</b>	Prospective screening for IA	GM in blood*	A	I	Highest test accuracy requiring 2 consecutive samples with an ODI $\geq 0.5$ or retesting the same sample  Prospective monitoring should be combined with HRCT and clinical evaluation	[82, 94, 393-397]
		Draw samples every 3-4 days	C	III		
Patients with prolonged neutropenic or allogeneic stem cell transplantation recipients <b>on mould active prophylaxis</b>	Prospective screening for IA	GM in blood*	D	II	Low prevalence of IA in this setting with consequently low PPV of blood GM test  Prophylaxis may have a negative impact on sensitivity of the test or the low yield may be due to decreased incidence of IA	[398, 399]
Patients with a haematological malignancy <ul style="list-style-type: none"> <li>• Neutropenic patients</li> <li>• Non-neutropenic patients</li> </ul>	To diagnose IA	GM in blood*	A B	II II	Significantly lower sensitivity in non-neutropenic patients	[319, 394, 400, 401]

ICU patients	To diagnose IA	GM in blood*	C	II	Better performance in neutropenic than in non-neutropenic patients	[89, 402]
Solid organ recipients	To diagnose IA	GM in blood*	C	II	Low sensitivity, good specificity  Most data for lung SOT	[319, 403, 404]
Any other patient	To diagnose IA	GM in blood*	C	II	Piperacillin/tazobactam may no longer be responsible for false positive results according to recent studies  Cross reactivity in case of histoplasmosis, fusariosis, talaromycosis (formerly: penicilliosis) False positive results reported due to ingestion of ice-pops, transfusions, antibiotics, Plasmalyt® infusion	[401, 405-412]
Cancer patients	To monitor treatment	GM in blood*	A	II		[85, 359, 413]

685 SoR, Strength of recommendation; QoE, Quality of evidence; \*, serum or plasma; GM, galactomannan; IA, invasive aspergillosis; ICU, intensive care unit;

686 ODI, optical density index; PPV, positive predictive value; SOT, solid organ transplantation

687



688 **Table 7. Galactomannan testing in samples other than blood**

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
Any	To diagnose pulmonary IA	To apply GM test on BAL fluid	A	II	GM in BAL is a good tool to diagnose, optimal cut-off to positivity 0.5 to 1.0	[86, 414-418]
Any	To diagnose cerebral IA	To apply GM test on cerebrospinal fluid	B	II	No validated cut-off	[419, 420]
Any	To detect GM in tissue	To apply GM test on lung biopsies	B	II	Using a cut-off 0.5 resulted in a sensitivity of 90 % and a specificity of 95%; specimens need to be sliced, precondition for doing so is that sufficient material is available; dilution in isotonic saline	[373, 421]

689 SoR, Strength of recommendation; QoE, Quality of evidence; BAL, bronchoalveolar lavage; GM, galactomannan; IA, invasive aspergillosis

690

691 **Table 8.  $\beta$ -D-glucan assays**

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
Mixed population: adult ICU, haematological disorders, SOT	To diagnose IFD	Diagnostic assay	C	II	5 different assays Overall sensitivity of 77% and specificity of 85% Specificity limits its value in this setting	[90, 422]
		Screening assays	C	II	Two or more consecutive samples: sensitivity: 65%; specificity: 93% Studies included once to thrice weekly. Varies with assay and cut-off: Wako assay sensitivity: 40-97%, specificity: 51-99%	[90, 422]
Adult haematological malignancy and HSCT	To diagnose IFD	Diagnostic assay	C	II	Overall sensitivity: 50-70%, specificity: 91-99%	[193-195, 423-428]
ICU – mixed adult immunocompromised patients (haematology, SOT, IA)	To diagnose IA	Diagnostic assay	C	II	Overall sensitivity: 78 -85%, specificity: 36-75%, NPV: 85-92% Specificity increased at higher cut-off values	[429, 430]

cancer, immunosuppressive therapy, liver failure, HIV)						
ICU – mixed adult population: SOT, liver failure, immunosuppressed		Screening assays	C	III	Sensitivity: 91%, specificity: 58%, PPV: 25%, NPV: 98%.  Positive mean of 5.6 days before positive mould culture  High false positive rate in early ICU admission	[431]
Adult haematological malignancy and HSCT	To diagnose IA	Diagnostic assay	C	II	Overall sensitivity: 57-76%, specificity: 95-97%	[422, 423, 429]
		Screening assays	C	II	Overall sensitivity: 46%, specificity: 97%  Confirmation with GM increases specificity  Data suggests BDG is unsuitable for ruling out diagnosis of IA	

692 SoR, Strength of recommendation; QoE, Quality of evidence; HSCT, haematopoietic stem cell transplantation; ICU, intensive care unit; SOT, solid organ

693 transplantation; IFD, invasive fungal disease; PPV, positive predictive value; NPV, negative predictive value; GM, galactomannan; BDG,  $\beta$ -D-glucan test; IA,

694 invasive aspergillosis

695 **Table 9. Lateral flow device antigen test for IA**

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
Haematological malignancy and solid organ transplant	To diagnose IA	LFD applied on BAL samples	B	II	Retrospective study. Sensitivity and specificity of BAL LFD tests for probable IPA were 100% and 81% (PPV 71%, NPV 100%), 5 pts with possible IPA had positive LFD, no proven IA	[432]
Haematopoietic stem cell transplantation	To diagnose IA	LFD applied on serum samples	B	II	Prospective screening in 101 patients undergoing allogeneic HSCT	[433]
Immunocompromised patients	To diagnose IA	LFD applied on BAL samples	B	II	Retrospective study. Sensitivities for LFD, GM, BDG and PCR were between 70 and 88%. Combined GM (cut off >1.0 OD) with LFD increased the sensitivity to 94%, while combined GM (cut off >1.0 OD) with PCR resulted in 100% sensitivity (specificity for probable/proven IPA 95-98%).	[434]

696 SoR, Strength of recommendation; QoE, Quality of evidence; IA, invasive aspergillosis; BDG,  $\beta$ -D-glucan test; BAL, bronchoalveolar lavage; GM,  
697 galactomannan; HSCT, haematopoietic stem cell transplantation; IFD, invasive fungal diseases; LFD, lateral device flow; NPV, negative predictive value; PCR,  
698 polymerase chain reaction; PPV, positive predictive value

699

**Table 10. PCR on bronchoalveolar lavage or cerebrospinal fluid**

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
Patients undergoing allogeneic stem cell transplantation recipients not on mould-active prophylaxis	To diagnose IA	BAL PCR	B	II		[435]
Patients with pulmonary infiltrates and haematological malignancies and prolonged neutropenia	To diagnose IA	BAL PCR	B	II	Methodically different in-house assays, better performance in patients without antifungal treatment, PCR and galactomannan: increases specificity	[359, 415, 434, 436-456]

ICU patients, mixed populations	To diagnose IA	BAL PCR	B	II	Commercially available Aspergillus PCR assays with good performance data.	[81][414][454][457][458][459]
Patients with haematological malignancies	To diagnose CNS aspergillosis or meningitis	CSF PCR	B	II	113 CSF samples from 55 immunocompromised patients sensitivity 100%, specificity 93% (retrospective)	[419, 460-463]

701 SoR, Strength of recommendation; QoE, Quality of evidence; IA, invasive aspergillosis ; BAL, bronchoalveolar lavage; PCR, polymerase chain reaction; ICU,  
702 intensive care unit; CNS, central nervous system; CSF, cerebrospinal fluid.

703

704 **Table 11. PCR on whole blood, serum or plasma**

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
Patients with haematological malignancies	To diagnose IA	PCR on blood samples	B	II	Meta-analysis: 16 studies PCR single positive test: Sensitivity: 88%, specificity: 75%; PCR 2 consecutive positive tests: Sensitivity: 75%, specificity: 87%	[464]
	To diagnose IA	PCR on serum samples			97% of protocols detected threshold of 10 genomes/ml serum volume >0.5 ml, elution volume <100 µl, sensitivity: 86%; specificity: 94%	[465]
	To diagnose IA	PCR on whole blood samples			First blood PCR assay to be compatible with EAPCRI recommendations, fever driven: Sensitivity: 92%, specificity: 95%, negative PCR result to be used to rule out IA	[466]
Haematopoietic stem cell transplantation	To diagnose IA	Prospective screening PCR on whole blood samples	B	II	Combination of serum and whole blood superior	[94-97]

	To diagnose IA	Prospective screening PCR on blood samples	B	II	Addition of GM and PCR monitoring provides greater accuracy, PPV 50-80%, NPV 80-90%	[98]
	To diagnose IA	PCR and GM in BAL	A	II		[396]

705 SoR, Strength of recommendation; QoE, Quality of evidence; IA, invasive aspergillosis; PCR, polymerase chain reaction; EAPCRI, European *Aspergillus* PCR

706 Initiative; GM, galactomannan, PPV, positive predictive value; NPV, negative predictive value; BAL, bronchoalveolar lavage

707



708 **Table 12. Molecular diagnostics on biopsies**

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
Biopsy with visible hyphae	To detect and specify a fungus	Broad range PCR	A	II	High sensitivity (> 90 %) and high specificity (99 %); various molecular based techniques available	[373, 467]
Biopsy with no visible hyphae	To detect and specify a fungus	Broad range PCR	C	II	Sensitivity (57 %) and specificity (96 %); ability to distinguish other fungi; performance only in addition to other tests	[373, 467]
Biopsy with visible hyphae	To detect and specify a fungus	Broad range PCR on wax embedded specimens	A	II	TaKaRa DEXPAT kit and QIAamp DNA mini kit detected less than 10 conidia/sample	[468, 469]
Any	To detect and specify a fungus	Fresh tissue samples	B	II	<i>Aspergillus</i> PCR performance analysis yielded sensitivity/specificity rates of 86% / 100% (79 patients, retrospective study)	[58]

709 SoR, Strength of recommendation; QoE, Quality of evidence; PCR, polymerase chain reaction

710 **Table 13. Storage of original samples and isolates**

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
Any	To prevent loss of viability of <i>Aspergillus</i> in clinical samples, and to reflect the original fungal content	Clinical samples for culture - short-term storage: 4°C to prevent loss of viability and to reflect the original fungal content	A	III		[98, 381]
	To prevent degradation of biomarkers, e.g. GM in serum or BALs or bronchial washes	Complete assay soon after delivery to laboratory. Avoid short or long-term storage of serum at 4°C	A	I	GM in serum degrades with short-term and long-term storage at 4°C; BAL fluid GM ODI remain stable; testing of pos./neg. serum and BAL fluid pools showed no decline in GM index over 11 months at -20°C	[80, 371-373, 395]
	Short-term maintenance of <i>Aspergillus</i> isolates	Repeated sub-culture	A	I	Viability maintained for several years by frequent sub-culture; Transfer once a month; Maintain at average ambient room temperature	[98, 381]

	Long-term preservation of <i>Aspergillus</i> isolates	Water storage/storage under mineral oil/silica gel storage/freeze-drying freezing (-80°C/ceramic beads/liquid nitrogen)	A	I	Long-term storage means storage periods of 5 years or longer; No further transfers required during this period	
--	---	---	---	---	--	--

711 SoR, Strength of recommendation; QoE, Quality of evidence; GM, galactomannan; BAL, bronchoalveolar lavage; ODI, optical density index

712

713 **Table 14. Antibody based diagnosis of invasive aspergillosis[11]**

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
Any	To diagnose IA	<i>Aspergillus</i> -specific antibodies by EIA: Serion (Germany), Omega (France), Bio-Rad (France), Dynamiker (China)	C	II	Antibodies take a mean of 11 days to develop after onset of illness; detectable in 29% to 100% of patients during course of acute IA	[470-477]
		Precipitating antibodies by agar gel double diffusion (Microgen Ltd. UK) or counter-immuno-electrophoresis	C	III	Consider false-negative results due to hypogammaglobulinaemia	[478]
		Agglutinating antibodies by indirect haemagglutination (EliTech/Fumouze, France)	C	II		[478]
		Specific immunoglobulins to <i>Aspergillus</i> by ImmunoCap®	C	III		No reference found

714 SoR, Strength of recommendation; QoE, Quality of evidence; EIA, enzyme immunoassay; IA, invasive aspergillosis

715 **Table 15. Indications for testing for azole resistance in clinical *Aspergillus* isolates**

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
All clinically relevant <i>Aspergillus</i> isolates (in patient groups or regions with known azole resistance)	Identify azole resistance	Reference MIC testing	A	II	In situations where rapid testing is available	[105, 111, 114, 116, 300, 479-489]
Clinically relevant <i>Aspergillus</i> isolates in patient groups with high prevalence of azole resistance or patients unresponsive to treatment	Identify isolates with intrinsic resistance	Species identification to complex level	A	III	Some species are intrinsically resistant – e.g. <i>A. calidoustus</i> (azole resistant) and <i>A. terreus</i> (AmB resistant)	[103, 490]
Clinically relevant <i>A. fumigatus</i> isolates	Identify azole resistant <i>A. fumigatus</i>	Routine azole agar screening	B	III	Identifies resistant colonies that require MIC-testing	[118, 491]
All isolates –resistance surveillance	Determine the local epidemiology of azole resistance	Periodical reference MIC testing of <i>A. fumigatus</i> complex	A	II	Test at least 100 isolates	[105, 111, 114, 300,

						482-485, 487-489]
Azole-resistant isolates	Determine nature and trends in Cyp51A mutation distribution	Cyp51A-gene mutation analysis	A	II	Test resistant isolates from surveillance survey	[107]

716 SoR, Strength of recommendation; QoE, Quality of evidence; AmB, Amphotericin B; MIC, minimum inhibitory concentration

717 **Table 16. Azole susceptibility testing: Timing, methods, and number colonies**

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
Any	Confirm or reject azole resistance in clinical <i>A. fumigatus</i> isolates when antifungal treatment is considered	Azole agar screening test followed by reference MIC test where needed	A	III	MIC testing as soon as the strain is isolated and without waiting for species ID	[103, 114]
	Detect azole-resistant <i>A. fumigatus</i> genotypes in a single culture	Reference MIC testing of multiple colonies (up to 5 colonies)	B	III	Multiple genotypes, i.e. azole-susceptible and azole-resistant, may be present	[115, 492, 493]
		Routine azole agar screening (up to 5 colonies)	B	III	One resistant colony can be identified among 4 susceptible samples together as recently validated.	[118, 491]
	Confirm or reject azole resistance by a validated method	MIC test using EUCAST method and EUCAST BPs (S, I, R)	A	III	Applicable to all <i>Aspergillus</i> spp. Breakpoints established for most species	[494-496]

		MIC test using CLSI method and CLSI ECVs (wild- type/non-wild-type)	B	III	Breakpoints not established	[496]
	MIC testing of various <i>Aspergillus</i> spp.	Etest®	C	III	Confirmation by reference test recommended.	[497-501]

718 SoR, Strength of recommendation; QoE, Quality of evidence; MIC, minimum inhibitory concentration



719 **Table 17. Azole MIC testing: Choice of azole compounds**

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
Any	To determine susceptibility to itraconazole	MIC (EUCAST/CLSI)	A	III	In general, a sensitive marker for azole resistance in <i>Aspergillus</i> ; test itraconazole and voriconazole as a minimum	[495, 496, 502-506]
Any	To determine susceptibility to voriconazole	MIC (EUCAST/CLSI)	A	III	Resistance/reduced susceptibility to other azole(s) may accompany that of voriconazole; isolated voriconazole resistance described related to TR <sub>46</sub> mutation	[114, 494, 496, 504-507]
Any	To determine susceptibility to posaconazole	MIC (EUCAST/CLSI)	B	III	Posaconazole resistance without itraconazole resistance not reported so far; current EUCAST breakpoint will misclassify approximately 15% susceptible isolates as I/R	[300, 486, 495, 496, 504-509]
Any	To determine susceptibility to isavuconazole	MIC (EUCAST/CLSI)	A	III	MIC often similar to voriconazole, but needs testing separately, if isavuconazole is to be used; lower MIC of isavuconazole as compared	[495, 504, 505, 507, 510-512]

					to itraconazole and voriconazole for <i>A. lentulus</i> and <i>A. udagawae</i> ( <i>A. fumigatus</i> complex) (CLSI)	
--	--	--	--	--	--	--

720 SoR, Strength of recommendation; QoE, Quality of evidence; MIC, minimum inhibitory concentration; EUCAST, European Committee on Antimicrobial

721 Susceptibility Testing; CLSI, Clinical & Laboratory Standards Institute

722

723 **Table 18. Amphotericin B susceptibility testing**

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
Clinically relevant isolate	Confirm or reject AmB resistance when antifungal treatment is considered	MIC test	C	III	Acquired resistance to amphotericin B is very rare and therefore correlation with clinical outcome has not been documented apart from the poorer outcome for high MIC species ( <i>A. terreus</i> and <i>A. flavus</i> compared to <i>A. fumigatus</i> ).	[513-516]
Clinically relevant isolate	Interpretation of MIC (EUCAST)	MIC test using EUCAST method and EUCAST break points (S, I, R)	B	III	MIC break points proposed for <i>A. fumigatus</i> and <i>A. niger</i>	[495, 517, 518]
					Epidemiologic cut-offs established for <i>A. flavus</i> , <i>A. fumigatus</i> , <i>A. niger</i> and <i>A. terreus</i>	
					<i>A. terreus</i> is not considered a good target for AmB. <i>A. flavus</i> may be in vitro resistant	
Clinically relevant isolate	Interpretation of MIC (CLSI)	MIC test using CLSI method and CLSI ECVs (wild-type/non-wild-type)	B	III	ECVs proposed for <i>A. fumigatus</i> , <i>A. flavus</i> , <i>A. nidulans</i> , <i>A. niger</i> , <i>A. terreus</i> , <i>A. versicolor</i> . No clinical break points. <i>A. terreus</i> and <i>flavus</i> , e.g. with MIC below the ECV are not good targets for AmB. No clinical data that <i>A. fumigatus</i> with MIC 2	[519]

					will respond to AmB although classified as wildtype according to CLSI ECVs.	
--	--	--	--	--	---	--

724 SoR, Strength of recommendation; QoE, Quality of evidence; AmB, amphotericin B; CLSI, Clinical & Laboratory Standards Institute; ECV, epidemiological cut-

725 off value; EUCAST, European Committee on Antimicrobial Susceptibility Testing; MIC, minimum inhibitory concentration

726

727 **Table 19. Antifungal regimens in intrinsic resistance**

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
Amphotericin B MIC $\geq 1$ mg/L	To cure IA	Replace AmB with azole, if azole tested susceptible	B	II		[17, 170, 520-525]
IA due to <i>A. terreus</i>	To cure IA	Voriconazole	A	II	Avoid AmB	[162, 526, 527]
		Isavuconazole	A	II		
		Posaconazole	B	III		
		Itraconazole	B	III		
IA due to <i>A. calidoustus</i>	To cure IA	Lipid formulation of AmB	A	II	Avoid azoles	[103, 528]
IA due to <i>A. tubingensis</i> ( <i>A. niger</i> complex)	To cure IA	Other than azole monotherapy	C	III	Higher azole MIC common, but no data on clinical impact	[501, 529, 530]
IA due to <i>A. lentulus</i> ( <i>A. fumigatus</i> complex)	To cure IA	Other than azole monotherapy				
IA due to <i>A. alliaceus</i> ( <i>A. flavus</i> complex)	To cure IA	Other than AmB monotherapy	C	III	Avoid AmB	[531]

IA due to <i>A. niger</i> complex	To cure IA	Other than itraconazole and isavuconazole	B	III	Isavuconazole, posaconazole, and voriconazole MIC in general 1 dilution higher compared to <i>A. fumigatus</i> ; itraconazole MIC in general 2 steps higher; limited clinical data	[501, 512]
IA due to <i>A. nidulans</i>	To cure IA	Voriconazole	C	III	AmB MIC elevated, poor clinical responses in chronic granulomatous disease	[532, 533]

728 SoR, Strength of recommendation; QoE, Quality of evidence; AmB, amphotericin B; IA, invasive aspergillosis; MIC, minimum inhibitory concentration

729 **Table 20. Optimal therapy in documented azole-resistance**

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
Isolate with voriconazole MIC =2 mg/ml	To cure IA	Voriconazole + echinocandin combination therapy or L-AmB monotherapy for IA (as well as for CPA)	A	III	The probability of voriconazole treatment failure may be higher than in voriconazole MIC <2.	[534-536]
Isolate with posaconazole MIC >0.5 mg/ml [537]	To cure IA	L-AmB	A	II <sub>u</sub>		[113, 114, 538]
		AmB lipid complex	C	III		No reference found.
		Voriconazole & anidulafungin	B	III		[534]
		Posaconazole & caspofungin	C	III	Posaconazole not licensed for primary treatment	[539]
		Caspofungin or micafungin	C	III	Patients with contra-indications to AmB & other azoles	No reference found.

730 SoR, Strength of recommendation; QoE, Quality of evidence; AmB, Amphotericin B; CPA, chronic pulmonary aspergillosis; IA, invasive aspergillosis; L-AmB,

731 Liposomal amphotericin B; MIC, minimum inhibitory concentration

732 **Table 21. Therapeutic drug monitoring**

<b>Clinical scenarios where antifungal therapeutic drug monitoring may be indicated</b>	<b>Examples, comments</b>
Populations with increased pharmacokinetic variability	Impaired gastrointestinal function; hepatic dysfunction; children, elderly patients, obese patients, critically-ill patients
Changing pharmacokinetics	Intravenous to oral switch, changing gastrointestinal function, changing hepatic or function, physiological-instability
Interacting medications	<p>Patient receiving medication known to induce cytochrome P450 enzymes especially CYP3A4, antacids, proton-pump inhibitors (itraconazole capsules, posaconazole suspension), antiretroviral medications.</p> <p>Patients should have medication records screened using drug interactions screening database before starting and stopping antifungals (example: <a href="http://www.fungalpharmacology.org">www.fungalpharmacology.org</a>, <a href="http://www.fungal-druginteractions.org">fungal-druginteractions.org</a>, or <a href="http://www.aspergillus.org.uk/content/antifungal-drug-interactions">http://www.aspergillus.org.uk/content/antifungal-drug-interactions</a>)</p>
Poor prognosis disease	Extensive or bulky infection, lesions contiguous with critical structures, CNS infection, multifocal or disseminated infection
Compliance concerns	Important issue with longer-term consolidation therapy or secondary prophylaxis in outpatient setting



Suspected breakthrough infection	TDM can establish whether fungal disease progression occurred in the setting of adequate antifungal exposure
Suspected drug toxicity, especially neurotoxicity (voriconazole)	Exposure-response relationships are described for other toxicities (e.g., hepatotoxicity), the utility of TDM to prevent their occurrence is less well established

733 CNS, central nervous system; TDM, therapeutic drug monitoring

734

735 **Table 22. Itraconazole therapeutic drug monitoring**

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
All patients receiving itraconazole treatment for IA	Improve efficacy	Measure serum trough level on day 5 of therapy or soon after	A	II	Target itraconazole level >1 mg/L to 4 mg/L by HPLC.  Hydroxy-itraconazole metabolite concentrations generally reported separately by HPLC or LC/MS/MS methods, but included in “itraconazole” concentration report by bioassay.  Therapeutic range by bioassay may vary by laboratory but typically fall in the range of (3-17 mg/L)	[122, 127, 540-542]
All patients receiving itraconazole for prophylaxis for IA	Improve efficacy	Measure serum trough level on day 5 of therapy or soon after	A	II	Target itraconazole level >0.5 mg/L (HPLC) or > 3 mg/L (bioassay)	[124]
Patients receiving itraconazole	Reduce toxicity	Measure serum trough level on day 5 of therapy or soon after	B	II	Toxicity was associated with itraconazole levels >17.1 mg/L by itraconazole bioassay, which correspond to ~4 mg/L by HPLC	[127]

736 SoR, Strength of recommendation; QoE, Quality of evidence; IA, invasive aspergillosis; HPLC, high performance liquid chromatography; LC, liquid  
737 chromatography; MS, mass spectrometry

738 **Table 23. Voriconazole therapeutic drug monitoring**

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
All patients receiving voriconazole treatment for IA	Improve efficacy, safety and compliance	Measure plasma trough level after 2-5 days of therapy or soon after	A	II	Target range of 1-5.5 mg/L	[128-131, 133, 543-545]
		Repeat plasma trough level	B	II	Repeat during second week of therapy, additional samples as clinically indicated and outlined in the text	[128-131, 133, 543-545]
All patients receiving voriconazole prophylaxis for IA	Improve efficacy, safety and compliance of prophylaxis	Measure serum trough level after 2-5 days of therapy or soon after, and 4 days after change of dose	A	II	As above; most studies investigated voriconazole treatment rather than prophylaxis	[132, 546, 547]
Patients with IA due to <i>Aspergillus</i> strains of reduced azole	Improve efficacy of treatment for isolates with MIC=2 mg/ml	Measure serum trough level after 2 to 5 days of therapy or soon after and 4 days after change of dose	A	II	Trough >2 mg/L recommended on the basis of PK/PD analysis	[131, 548]

susceptibility MIC =2 mg/ml						
--------------------------------	--	--	--	--	--	--

739 SoR, Strength of recommendation; QoE, Quality of evidence; IA, invasive aspergillosis; MIC, minimum inhibitory concentration; PK, pharmacokinetic; PD,

740 pharmacodynamic

741 **Table 24. Posaconazole therapeutic drug monitoring**

Population	Intention	Intervention	SoR	QoE	Comments	Ref.
Patients receiving posaconazole suspension for <b>treatment of IA</b>	Improve efficacy, compliance	Serum trough level on day 5 of therapy or soon after	A	II	Target level >1 mg/L.  Gastroresistant tablet or intravenous formulation preferred for most patients, consider switch to tablet or IV, if no therapeutic levels with oral suspension  Repeat determination as clinically appropriate  Longed half-life gives similar results for random sampling and true trough samples	[138]
Patients receiving posaconazole suspension for <b>prophylaxis to prevent IA</b>	Improve efficacy, compliance	Serum trough level on day 5 of therapy or soon after.	C	II	Target level >0.7 mg/L  Adequate tissue concentrations may occur despite serum concentration <0.7 mg/L  Repeat determination as clinically appropriate	[136, 137, 549-552]

Patients receiving posaconazole	Improve safety	Measure serum trough level on day 5 of therapy or soon after	C	III	<p>If treatment failure or toxicity suspected, TDM may be indicated in patients receiving gastroresistant tablet or intravenous formulation</p> <p>Posaconazole exposures between 0.5-3.75 mg/L are well studied and considered safe and effective with all three formulations</p> <p>Posaconazole plasma levels above this exposure range may be associated with toxicity</p>	[120,121]
---------------------------------	----------------	--	---	-----	--	-----------

742 SoR, Strength of recommendation; QoE, Quality of evidence; IA, invasive aspergillosis; IV, intravenous; TDM, therapeutic drug monitoring; AML, acute

743 myeloid leukaemia; HSCT, haematopoietic stem cell transplantation; GvHD, graft versus host disease

744

745 **Table 25. Isavuconazole therapeutic drug monitoring**

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
All patients receiving isavuconazole	Improve efficacy safety and compliance	Measure serum trough level on D5 of therapy or soon after	C	III	Limited data to support routine TDM but may be indicated in the setting of treatment failure, drug interactions, or if toxicity is suspected  The long half-life of isavuconazole (130 hours) may support use for TDM in some clinical situations to confirm drug clearance prior to starting medications metabolized by CYP3A4, especially chemotherapy agents	FDA advisory briefing documents

746 SoR, Strength of recommendation; QoE, Quality of evidence; TDM, therapeutic drug monitoring; FDA, Food and Drug Administration

747 **Table 26. Primary prophylaxis**

Population	Intention	Intervention	SoR	QoE	Comment	Ref
Haematological malignancies, e.g. AML with prolonged and profound neutropenia	Lower incidence of IA	Posaconazole 200 mg tid suspension or 300 mg tablet qd	A	I	AML/MDS induction only. TDM especially with oral suspension. Tablets more bioavailable, bridging with posaconazole IV formulation possible	[553]
		L-AmB 12.5 mg biw, nebulized, with undetermined dose of fluconazole	B	I	AML	[554, 555]
		ABLC 3 mg/kg 3x/weekly	C	II <sub>h</sub>	No difference to L-AmB regimen	[556]
		Micafungin 50 mg qd	C	II <sub>t</sub>		[560, 561]
		L-AmB 10 mg/kg q7d	C	II <sub>u</sub>		[562]
		L-AmB 50 mg abs q2d	C	II <sub>u</sub>		[563]
		L-AmB 15 mg/kg q14d	C	II <sub>u</sub>		[564]
		Voriconazole	C	II <sub>t</sub>	Not better than fluconazole	[565]



		Itraconazole 400 mg/d, oral solution	D	II	No difference to fluconazole (n=195) and more toxicity	[121, 557-559]
Acute lymphoblastic leukaemia, remission induction chemotherapy	Lower incidence of IA	L-AmB 5 mg/kg biw	D	I	L-AmB more toxic than placebo, no significant reduction in IA rate	[566]
Autologous HSCT or treatment of haematological malignancies besides acute leukaemia	Lower incidence of IA	Any mould active agent	D	III		No reference found.
Allogeneic HSCT (until neutrophil recovery)	Lower incidence of IA	Posaconazole 200 mg tid suspension or 300 mg tablet qd	B	II <sub>t</sub>	Neutropenia duration approximately identical, TDM*	[553]
		L-AmB 12.5 mg biw, nebulized, with fluconazole	B	II <sub>t</sub>		[554]
		Voriconazole 200 mg bid	C	I	Not better than fluconazole, TDM	[567, 568]

		Micafungin 50 mg/d	C	I	But no difference in subgroup analysis for aspergillosis	[560]
		Itraconazole 400 mg/d oral solution	D	I	Toxicity issues; TDM	[554, 559]
Allogeneic HSCT (after neutrophil recovery and no GvHD)		Any antifungal agent	D	III	No study demonstrated outcome advantage	
Allogeneic HSCT (with moderate to severe GvHD and/or intensified immunosuppression)		Posaconazole 200 mg tid suspension or 300 mg tablet qd	A	I	TDM	[569]
		Voriconazole 200 mg bid	C	II	Not better than fluconazole; TDM	[567, 568]
		Itraconazole 400 mg/d, oral solution	C	II	Toxicity issues; TDM	[559]
		Micafungin 50 mg/d	C	III	Only few patients with GVHD	[560]
Allogeneic HSCT (until neutrophil recovery)	To reduce IA attributable mortality	Posaconazole 200 mg tid suspension or 300 mg tablet qd	B	II <sub>t</sub>	Neutropenia duration approximately identical. TDM	[553]
Allogeneic HSCT (after neutrophil recovery, without GvHD)		Any other antifungal	D	III	No study demonstrated outcome advantage	

Allogeneic HSCT (with moderate to severe GvHD and/or intensified immuno-suppression)		Posaconazole 200 mg tid suspension or 300 mg tablet qd	A	II	Mainly IFD-attributable mortality, TDM	[569]
--	--	--	---	----	--	-------

748 SoR, Strength of recommendation; QoE, Quality of evidence; qd, once daily; bid, twice daily; tid, thrice daily; AML, acute myeloid leukaemia; MDS,

749 myelodysplastic syndrome; TDM, therapeutic drug monitoring; ABLC, amphotericin B lipid complex; L-AmB, Liposomal amphotericin B; HSCT,

750 haematopoietic stem cell transplantation; GvHD, graft versus host disease; IFD, invasive fungal disease

751

752 **Table 27. Targeted therapy of pulmonary disease – First line**

Population	Intention	Intervention	SoR	QoE <sup>1</sup>	QoE <sup>2</sup>	QoE <sup>3</sup>	Comment	Ref.
<sup>1</sup> Neutropenia (non- allo HSCT recipients)	To increase response and survival rate	Isavuconazole 200 mg iv tid day 1-2, then 200 mg qd oral	A	I	II <sub>t</sub>	II <sub>t</sub>	D III, if mould active azole prophylaxis less adverse effects than voriconazole	[173, 512, 633, 634]
<sup>2</sup> Allo-HSCT (during neutropenia)		Voriconazole 2x 6 mg/kg IV (oral 400 mg bid) on day 1, then 2x 4 mg/kg IV (oral 200 to 300 mg bid)	A	I	II <sub>t</sub>	II <sub>t</sub>	C III for start with oral; D III, if prior mould active azole prophylaxis; TDM	[170, 172, 512, 635]
		L-AmB 3 mg/kg	B	II	II <sub>t</sub>	II <sub>t</sub>		[171]
<sup>3</sup> Allo-HSCT (w/o neutropenia) or other non-		Combination of voriconazole 6/4 mg/kg bid (after one week oral possible (300 mg bid)) + anidulafungin 200/100 mg	C	I	II <sub>t</sub>	II <sub>t</sub>	No significant difference compared to voriconazole, in GM positive (subgroup) better survival; TDM	[172, 635]
		Caspofungin 70 mg qd day 1, followed by 50 mg qd (if body weight <80kg)	C	II	II	II		[618-620]

neutropenic patients		Itraconazole 200 mg q12h iv on day 1, then 200 mg/qd	C	III	II <sub>t,a</sub>	II <sub>t,a</sub>	D III for start with oral, TDM D III, if mould active azole prophylaxis	[512, 542]
		AmB lipid complex (ABLC) 5 mg/kg	C	III	III	III		[636]
		Micafungin 100 mg	C	III	III	III		[637-639]
		AmB colloidal dispersion (ABCD) 4-6 mg/kg	D	I	II <sub>t</sub>	II <sub>t</sub>		[142]
		Conventional AmB 1-1.5 mg/kg	D	I	II <sub>t</sub>	II <sub>t</sub>		[170]
		Other combinations	D	III	III	III	Efficacy unproven	[640]
Life-threatening haemoptysis	Bridging until neutrophil recovery	Arterial embolization, emergency surgical intervention	B	III	III	III		[641]

753 SoR, Strength of recommendation; QoE, Quality of evidence; allo-HSCT, allogeneic haematopoietic stem cell transplantation; bid, twice daily; tid, thrice

754 daily, qd, once daily; IA, invasive aspergillosis; IV, intravenous; TDM, therapeutic drug monitoring; GM, galactomannan

755 **Table 28. Targeted therapy of extrapulmonary disease – First line**

Population	Intention	Intervention	SoR	QoE	Comment	Ref
Suspected or proven IA of the central nervous system	To increase response and survival rate	Surgical debridement, if surgically possible	A	II <sub>u</sub>		[642, 643]
		Voriconazole	A	II <sub>u</sub>	N=5/5	[170]
					N=81, 48 proven cases, 33 probable cases, TDM recommended targeting trough concentration of 2-5.5 mg/L	[642]
		Posaconazole	D	III	8 patients documented in studies (5 failures)	[644]
		Itraconazole	D	III		
		Lipid formulations of AmB	B	III	Case collections, animal data	[645-647]
		cAmB	D	I	Renal toxicity	[189, 648-650]
		Echinocandins	D	III	Insufficient tissue penetration	[646]

Patients with clinical suspicion of or proven invasive sinus aspergillosis	To cure	Surgery	A	III	Need to be considered on an individual basis and decision	
		Local antifungal therapy	C	III		
Voriconazole		A	II <sub>t</sub>	N=8/7, TDM recommended	[170, 651]	
L-AmB		A	II <sub>t</sub>	Active against mucormycosis as well since mixed infections occur or cannot be differentiated	[171]	
Posaconazole, itraconazole, echinocandins		C	III	Not well specified in studies, TDM recommended for posaconazole and itraconazole	[652, 653]	
Patients with invasive sinus aspergillosis (all levels of certainty: suspected through proven)						

756 SoR, Strength of recommendation; QoE, Quality of evidence; TDM, therapeutic drug monitoring; AmB, Amphotericin B, cAmB, conventional amphotericin B;

757 L-AmB, liposomal amphotericin B

758

759 **Table 29. Fever-driven (“empiric”) approach**

Population	Intention	Intervention	SoR	QoE	Comment	Ref
Chemotherapy for haematological malignancies or HSCT, neutropenia $<500/\mu\text{L} \geq 96$ h, fever ( $>38^{\circ}\text{C}$ ), and parenteral broad spectrum antibacterial therapy $\geq 96$ h (some centres consider 48h)	Reduction in the incidence of IA and/or related mortality	Caspofungin 70 mg qd day 1, followed by 50 mg qd (if body weight $<80\text{kg}$ )	A	I	Caspofungin was associated with a significantly higher rate of survival than L-AmB (subgroup analysis).	[188]
		L-AmB 3 mg/kg	B	I	Less toxicity in comparison to cAmB but more renal toxicity compared to echinocandin	[188, 189]
		Voriconazole 6 mg/kg bid IV (oral 400 mg bid) on day 1, then 4 mg/kg bid IV (oral 200 to 300 mg bid)	B	II	Failed the 10% non-inferiority cut-off when compared with L-AmB, but first-line for aspergillosis. Activity of azoles empirical therapy for persistent fever may be limited in patients receiving prophylaxis with an agent of the same class. TDM*	[190]
		Itraconazole 200 mg qd iv	C	II	Activity of azoles empirical therapy for persistent fever may be limited in patients receiving prophylaxis with an agent of the same class. TDM*	[666]
		ABLC 5 mg/kg qd	C	I	Infusion-related toxicity (fever, chills, hypoxia)	[667]



		ABCD 4 mg/kg	C	I	Same as above	[668]
		cAmB 0.5-1 mg/kg qd	D	I	Poor tolerance due to extreme toxicity	[189, 342, 649, 650, 666, 668]
		Micafungin 100 mg qd	B	II		[669]
		Fluconazole	D	II <sub>r</sub>	No activity against Aspergillus	[670]

760 SoR, Strength of recommendation; QoE, Quality of evidence; L-AmB, liposomal amphotericin B; cAmB, conventional amphotericin B; IV, intravenous; TDM,

761 therapeutic drug monitoring; ABLC, amphotericin B lipid complex; ABCD, amphotericin B colloidal dispersion

762 **Table 30. Non-haematological patients at high risk**

Population	Intention	Intervention	SoR	QoE	Ref.
SOT lung with pre-transplantation colonization and <i>Aspergillus</i> in intraoperative culture OR CMV disease OR higher donor age OR prolonged ischaemia time OR receiving daclizumab OR bronchial anastomotic ischemia OR bronchial stent OR single lung SOT	To identify patients with high risk of IA	Consider prophylaxis	B	III	[210, 226, 692] [215, 693-695]
SOT lung with repeated acute and chronic rejection			B	II <sub>t</sub>	[696, 697]
SOT heart with re-operation, CMV infection, haemodialysis, other episode of IA in the program within 2 months	To identify patients with high risk of IA	Consider prophylaxis	A	II <sub>h</sub>	[204]
SOT heart with airborne <i>Aspergillus</i> spores in ICU			A	II	[203, 204]
SOT heart with sirolimus OR tacrolimus OR hypogammaglobulinemia			B	II <sub>h</sub>	[212, 698]
SOT liver with one of the following characteristics: requirement for dialysis OR retransplantation OR fulminant hepatic failure OR MELD score >30	To identify patients with high risk of IA	Consider prophylaxis	B	II <sub>h</sub>	[210, 211, 217, 224, 308, 311, 607, 699-702]

SOT liver with one of the following characteristics: ICU admission or corticosteroid requirement previous 2-4 weeks to transplant OR >15 units of packed red blood cells during transplant surgery OR reoperation involving the intraabdominal cavity OR choledochojejunostomy			C	III	
SOT kidney with one of the following characteristics: Pre-transplant COPD OR delayed graft function OR post-transplant blood stream infection OR acute graft rejection	To identify patients with high risk of IA	Consider prophylaxis	A	II <sub>h</sub>	[228]
COPD with one of the following characteristics: high (systemic) cumulative glucocorticosteroid dose OR refractory to antibiotic therapy OR admission to the intensive-care unit	To identify patients with high risk of IA	Consider prophylaxis	A	II <sub>t</sub>	[232, 257, 703, 704]
HIV with CD4 count <100 cells/μl	To identify patients with high risk of IA	Consider prophylaxis	A	II <sub>h</sub>	[232]
ICU patients with either COPD OR requiring glucocorticosteroids therapy	To identify patients with high risk of IA	Consider prophylaxis	A	II <sub>h</sub>	[257, 703, 704]
ICU patients with either acute liver failure OR burns OR severe bacterial infection OR malnutrition			B	III	

ICU or SOT recipients with Increased environmental exposure	To identify patients with high risk of IA	Consider prophylaxis	A	II	[203, 204, 705, 706]
Liver insufficiency	To identify patients with high risk of IA	Consider prophylaxis	B	II <sub>h</sub>	[244, 707]
Burn patients with positive fungal cultures	To identify patients with high risk of IA	Consider prophylaxis	A	II <sub>h</sub>	[708, 709]
Percentage of total body surface area burn injury; length of stay			B	III	[706]
Patient receiving one of the following: TNF- $\alpha$ blockers, basiliximab, daclizumab, infliximab, etanercept, alemtuzumab, adalimumab, rituximab, abatacept	To identify populations at high risk of IA	Consider prophylaxis	C	III	No reference found.

763 SoR, Strength of recommendation; QoE, Quality of evidence; IA, invasive aspergillosis; CMV, cytomegalovirus; ICU, intensive care unit; COPD, chronic

764 obstructive pulmonary disease; BAL, bronchoalveolar lavage

765

766 **Table 31. Diagnosis-driven (“pre-emptive”) approach in non-haematological patients**

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
COPD	To diagnose IA	Respiratory culture	A	II <sub>u</sub>	Isolation of <i>Aspergillus</i> in culture from admitted patients with COPD represents IA in at least 22% of patients	[257, 281, 282, 710]
COPD	To diagnose IA	GM BAL	B	II <sub>u</sub>	Sensitivity/specificity of BAL GM >1.0 cut-off is 67% / 96%, at GM >0.5 cut-off is 89% / 88%	[281]
Underlying respiratory disease	To diagnose IA	Lateral flow device BAL	C	II	Sensitivity / specificity 77% / 92%  (Not commercially available at the time of writing)	[285]
HIV	To diagnose IA	Direct microscopy	A	II <sub>h</sub>	50% positive	[232]
HIV	To diagnose IA	GM BAL	B	II <sub>u</sub>	53% positive	[232]
HIV	To diagnose IA	GM serum	B	II <sub>u</sub>	34% positive	[232]
HIV	To diagnose IA	Histology	A	II <sub>u</sub>	75% positive	[232]
ICU	To diagnose IA	BDG serum	B	II <sub>u</sub>	Autopsy study, non-haematological immunocompromised critically	[429]

					ill patients with lower respiratory tract infection. Using 140 pg/ml cut-off, sensitivity/specificity 100% / 70%	
ICU	To diagnose IA	BDG serum	B	II <sub>u</sub>	BDG appeared a mean of 6.5 days before <i>Aspergillus</i> was grown	[711]
ICU	To diagnose IA	Respiratory culture	B	II <sub>u</sub>		[89, 712, 713]
ICU	To diagnose IA	GM BAL	C	II <sub>u</sub>	Using cut-off ODI 0.5 sensitivity/specificity 88-90% / 87-100%	[89, 712, 713]
ICU	To diagnose IA	SeptiFast®	C	II <sub>h</sub>	Sensitivity/specificity 66% / 98%, PPV 93%, NPV 88%	[714, 715]
Non haematological	To diagnose IA	Culture	A	II <sub>h</sub>	Very low PPV of <i>Aspergillus</i> spp. culture from respiratory samples	[197]
Non haematological	To diagnose IA	Culture	A	II <sub>h</sub>	Sensitivity of BAL higher for non-neutropenic patients	[52]
Non-haematological	To diagnose IA	GM serum	C	II	Using cut-off of 0.5 ng/ml sensitivity/specificity 60% / 89%	[710]

Non-haematological	To diagnose IA	MycAssay Aspergillus®	C	II	Sensitivity, specificity, PPV, and NPV of first sample/any sample were 87%/93%, 87%/82%, 34%/34%, 92%/100%	[278]
SOT, any	To diagnose IA	Respiratory culture	D	II	Low sensitivity and specificity	[87, 282]
SOT, any	To diagnose IA	GM BAL	B	II	Using cut-off ODI 1.0 sensitivity/specificity 100% / 91%	[716]
SOT, any	To diagnose IA	High-resolution chest computed tomography	A	III	Bilateral bronchial wall thickening and centrilobular opacities, tree-in-bud pattern (65%), ground-glass opacities and/or bilateral areas of consolidation (23%)	[214, 717]
SOT, any	To diagnose IA	Lateral flow device BAL	C	II	N=11 SOT	[284, 434, 718]
SOT Heart	To diagnose IA	Respiratory culture	A	II <sub>h</sub>	Overall positive predictive value (PPV) 60-70%, PPV 88-100% with respiratory specimens other than sputum; recovery of <i>A. fumigatus</i> PPV 78-91%	[271]
SOT Heart	To diagnose IA	High-resolution computed tomography	A	II <sub>h</sub>	Provided significant additional information in 41%; positive with a normal chest X-ray in 18%	[274]

		of the thorax				
SOT Lung	To diagnose IA	BDG serum	C	II <sub>u</sub>	Sensitivity/specificity 64%, 9%, PPV 14%, NPV 50%	[719]
SOT Lung	To diagnose IA	GM BAL	B	II	Using cut-off ODI 1.5 sensitivity/specificity 100% / 90%	[87, 88, 720, 721]
SOT Lung	To diagnose IA	PCR of respiratory samples	B	II		[88]

767 SoR, Strength of recommendation; QoE, Quality of evidence; COPD, chronic obstructive pulmonary disease; BDG,  $\beta$ -D-glucan; IA, invasive aspergillosis; ICU,  
768 intensive care unit; SOT, solid organ transplantation; PPV, positive predictive value; GM, galactomannan; ODI, optical density index; NPV, negative predictive  
769 value; BAL, bronchoalveolar lavage; PCR, polymerase chain reaction



770 **Table 32. Treatment in non-haematological patients**

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
HIV	To treat IA	Voriconazole	A	III	Consider drug-drug interactions with antiretroviral drugs.	[722]
SOT Heart	To treat IA	Itraconazole	C	III	6 patients cured with itraconazole 200-400 mg/d  Erratic absorption and interaction with calcineurin inhibitors and other agents	[723]
SOT, any	To treat IA	Voriconazole	A	III	e.g. Herbrecht study 11 SOT; voriconazole increases the levels of anti-calcineurin immunosuppressors, TDM; monitor liver function tests especially in liver transplant recipients.	[170, 214, 287, 333, 607-609, 673, 724-726]
SOT, any	To treat IA	L-AmB	A	II		[678, 727, 728]
SOT, any	To treat IA	Voriconazole &	B	II	40 SOT voriconazole & caspofungin (n=40) vs amphotericin B (n=47).	[289]

		caspofungin			Survival benefit in pts with <i>A. fumigatus</i> or renal insufficiency	
SOT, if voriconazole contraindicated	To treat IA	Caspofungin	B	III	Complete response 83%; response 7/9 monotherapy and 7/10 combination	[621, 622, 686, 729]

771 SoR, Strength of recommendation; QoE, Quality of evidence; IA, invasive aspergillosis; SOT, solid organ transplantation; L-AmB, Liposomal amphotericin B; SOT,

772 solid organ transplantation; TDM, therapeutic drug monitoring

773

774 **Table 33. Prophylaxis in non-haematological patients**

Population	Intervention	Intention	SoR	QoE	Comment	Reference
SOT Lung	Universal* prophylaxis	To prevent IA	A	I	Invasive fungal infection appeared at a median of 35 days	[304, 315, 730]
	Targeted* prophylaxis	To prevent IA	C	III		[315, 694, 731]
	Inhaled cAmB	To prevent IA	B	II <sub>h</sub>	25 mg/day for 4 days, followed by 25 mg/week for 7 weeks. More adverse events in inhaled deoxycholate vs lipid-based  Breakthrough IA in 7-10%	[732, 733]
	Inhaled lipid-based AmB	To prevent IA	A	I	More adverse events with inhaled deoxycholate vs lipid-based but similar efficacy; various possible protocols: 50mg/day for 4 days, then 50mg/week for 7 weeks; 50mg/day for 2 weeks, then once weekly for 10 weeks; 25mg thrice weekly between day 1 and day 60 post SOT and once weekly between day 60 and day 180	[724, 732-735]

	Voriconazole	To prevent IA	A	III	Voriconazole 2x200 mg/d more hepatotoxic than itraconazole 2x200 mg/d. Usual duration of prophylaxis 3-6 months; monitor liver and skin toxicity	[303, 304, 315, 731, 736]
	Voriconazole pre-emptive, if colonized	To prevent IA	B	II <sub>u</sub>	Breakthrough IA <2% at 6 months	[731]
	Voriconazole for three months	To prevent IA	C	II	No effect of voriconazole on the incidence of IA (45% vs 49%)	[303]
SOT Heart	Universal* prophylaxis with itraconazole or inhaled AmB	To prevent IA	C	I		[214, 737, 738]
	Universal* prophylaxis with itraconazole or inhaled AmB	To prevent IA	C	II	IA rates 5% without prophylaxis, 1.5% with itraconazole 2x200 mg, 0% with inhaled AmB	[214, 737, 738]
	Targeted* prophylaxis with echinocandins	To prevent IA	A	II <sub>t</sub>	Prophylaxis in 10% of patients, IA rate reduced from 9% to 2%, attributable mortality from 6% to 2%; duration dependant of risk	[215]

					factors persistence	
SOT Liver	Targeted* prophylaxis with lipid AmB	To prevent IA	B	III	IA rate reduced, mortality unaffected	[607, 739-741]
	Targeted* prophylaxis with echinocandins	To prevent IA	A	I	Standard dosed echinocandins reduced IA rate; duration of prophylaxis usually 21 days post SOT	[217, 308, 311, 742]

775 SoR, Strength of recommendation; QoE, Quality of evidence; \* targeted prophylaxis = only if additional risk factors; universal prophylaxis = to all patients in

776 population; IA, invasive aspergillosis; SOT, solid organ transplantation; AmB, Amphotericin B; cAmB, conventional amphotericin B deoxycholate

777

778 **Table 34. Prophylaxis in children at high risk**

Population	Intention	Intervention	SoR	QoE	Comment	Ref
<p>Allogeneic HSCT, pre-engraftment phase;</p> <p>Allogeneic HSCT, post-engraftment phase, GvHD and augmented immunosuppression;</p> <p>High-risk patients with de novo or recurrent leukaemia, bone marrow failure syndromes with prolonged and profound neutropenia</p>	Prevention of IA	Itraconazole	A/B*	II <sub>t</sub>	TDM recommended; Approved indication; not approved EU < 18 years	[122, 559, 570-579]
		Posaconazole	A	II <sub>t</sub>	TDM recommended; only supportive paediatric data for ≥ 13 years of age	[136, 137, 338, 553, 569, 580-586]
		Voriconazole	A	II <sub>t</sub>	Not approved for <2 years; Inference from efficacy from HSCT trials and supportive studies; TDM recommended	[130, 131, 135, 546, 567, 568, 587-593]
		Liposomal amphotericin B	B	II <sub>t</sub> /III*	Not approved for prophylaxis; Optimal dose of alternate administration unknown; Alternative if triazoles are not tolerated / contraindicated	[563, 594-599]

		Micafungin	B	II <sub>t</sub> /III*	No definite evidence (trend only) for prophylactic efficacy against <i>Aspergillus</i> spp. Alternative if triazoles are not tolerated or contraindicated	[560, 600-604]
Chronic granulomatous disease (CGD) patients	Prevention of IA	Itraconazole	A	II	Approved indication; not approved in the EU for < 18 years; TDM recommended	[122, 575-578, 605, 606]
		Posaconazole	A	III	Not EU approved for children < 18 years; TDM recommended; PK and safety data for children ≥ 4 years	[136, 137, 582-585]

779 \* SoR = B for allogeneic HSCT post-engraftment phase, GvHD (graft versus host disease) and augmented immunosuppression

780 \* QoE = III for allogeneic HSCT post-engraftment phase, GvHD and augmented immunosuppression

781 SoR, Strength of recommendation; QoE, Quality of evidence; IA, invasive aspergillosis; TDM, therapeutic drug monitoring; HSCT, haematopoietic stem cell  
782 transplantation

783

784 **Table 35. Treatment in children**

Population	Intention	Intervention	SoR	QoE	Comment	Ref
Any paediatric population other than neonates	Treatment proven/probable IA	Voriconazole 18 mg/kg/d iv day 1, followed by 16 mg/kg/d iv or 18 mg/kg/d po in 2 divided dosages (up to 14 years and < 50 kg); if >15 yrs or >12 yrs and >50 kg use adult dosing recommendations	A	II <sub>t</sub>	Not approved in patients <2 yrs; TDM recommended.	[130, 131, 135, 170, 333, 546, 589-592, 607-613]
Any paediatric population other than neonates	Treatment proven/probable IA	L-AmB 3 mg/kg/d	B	II <sub>t</sub>	Comparison between 2 dosages of L-AmB, no comparison to voriconazole	[171, 597, 599, 614-617]
Any paediatric population other than neonates	Treatment proven/probable IA	Caspofungin 70 mg/m <sup>2</sup> day 1, followed by 50 mg/m <sup>2</sup> /d (max. 70 mg/d)	C	II <sub>t</sub>	Study prematurely stopped due to low accrual	[616, 618-628]
Neonates	Treatment proven/probable IA	L-AmB 3 mg/kg/d	A	III		[629-632]

785 SoR, Strength of recommendation; QoE, Quality of evidence; IA, invasive aspergillosis; TDM, therapeutic drug monitoring; L-AmB, liposomal amphotericin B



786 **Table 36. Secondary prophylaxis**

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
Previous IA and undergoing allogeneic HSCT or entering risk period with non-resectable foci of <i>Aspergillus</i> disease	To reduce risk of IA recurrence	Secondary prophylaxis with an <i>Aspergillus</i> active antifungal proven to be effective in the actual patient	A	II	Results compared to historical data, mostly in allogeneic HSCT setting	[654-659]
		Voriconazole	A	II <sub>h</sub>	IA: 31/45 pts, 1 year cumulative incidence of IFD 6.7±3.6%, TDM	[654]
		Caspofungin 70 mg day 1, followed by 50 mg/d IV until stable engraftment, followed by 400 mg itraconazole suspension PO	B	II <sub>h</sub>		[658]
		L-AmB followed by voriconazole	C	II	Fungal infection related mortality 28% despite lipid-based AmB	[657, 660]
Previous IA and with resectable foci of <i>Aspergillus</i> disease	To reduce risk of IA recurrence	Surgical resection following by secondary prophylaxis	B	III	Timing and methods of surgery important. Concomitant administration of appropriate antifungal compound justified.	[661-665]

before entering risk period					Indication for surgical intervention by appropriate specialist. Interdisciplinary consensus needed.	
--------------------------------	--	--	--	--	--	--

787 SoR, Strength of recommendation; QoE, Quality of evidence; HSCT, haematopoietic stem cell transplantation; IA, invasive aspergillosis, IFD, invasive fungal

788 disease; TDM, therapeutic drug monitoring, PO, per os; L-AmB, liposomal amphotericin B

789 **Table 37. Antifungal drugs in refractory disease**

Population	Intention	Intervention	SoR	QoE	Comment	Ref
Haematological patients with refractory IA	Achieve complete or partial response, or stable disease, improve survival	Switch to another drug class	A	III		
		Any combination	C	III	No prospective study demonstrated superiority of combination therapy over monotherapy	[671]
		Voriconazole	A	II		[333, 672-674]
		L-AmB 3-5 mg/kg	B	II	Majority voted for BII others for AII	[598, 675, 676]
		ABLC 5 mg/kg	C	II		[636, 676-678]
		ABCD			No longer commercially available	[679, 680]
		Caspofungin 70 mg qd day 1, followed by 50 mg qd (if body weight <80kg)	B	II	Very few data in case of voriconazole/posaconazole failure	[335, 674, 681-687]
		Micafungin 75-200 mg qd	C	II		[638, 688]

		Posaconazole 200 mg qid or 400 bid suspension or 300 mg tablet bid day 1, followed by 300 mg qd	B	II		[138, 336, 689, 690]
		Itraconazole	D	III	In case of refractoriness to voriconazole	
		Itraconazole oral forms	C	II	Poor bioavailability	[126]
		Itraconazole IV formulation			Commercially not available everywhere	[542, 691]

790 SoR, Strength of recommendation; QoE, Quality of evidence; L-AmB, Liposomal amphotericin B; ABLC, amphotericin B lipid complex; ABCD, amphotericin B

791 colloidal dispersion; IV, intravenous; TDM, therapeutic drug monitoring; qd, once daily; bid, twice daily; qid, four times daily


792

793 **Table 38. Chronic pulmonary aspergillosis**

Population	Intention	Intervention	SoR	QoE	Comment	Ref.
Cavitary or nodular pulmonary infiltrate in non-immuno-compromised patients	Diagnosis or exclusion of CPA	Direct microscopy for hyphae	A	II <sub>t</sub>	Positive microscopy is a strong indicator of infection, not studied in CPA, but in ABPA	[743]
		Histology	A	II	In CPA histology distinguishes between CNPA and CCPA	[744]
		Fungal culture (respiratory secretion)	A	III	Bacterial culture plates are less sensitive than fungal culture plates	[269]
Cavitary or nodular pulmonary infiltrate in non-immuno-compromised patients	Diagnosis or exclusion of CPA	<i>Aspergillus</i> IgG antibodies	A	II	IgG and precipitins test standardization incomplete	[364]
CPA patients with progressive disease	Control of infection	Itraconazole: Start 200 mg bid, adjust with TDM	A	II	No data to indicate which agent is preferable	[364, 745]

		Voriconazole Start 150-200 mg bid, adjust with TDM			Voriconazole preferred for CNPA and patients with fungal balls to minimize risk of resistance	[366, 746, 747]
		Posaconazole 400 mg bid (oral suspension) 300 mg qd (delayed release tablets)	B	II	Higher rate of adverse events, if some adverse events with itraconazole and voriconazole	[748]

794 SoR, Strength of recommendation; QoE, Quality of evidence; CPA, chronic pulmonary aspergillosis; ABPA, allergic bronchopulmonary aspergillosis; SAIA,  
795 subacute invasive aspergillosis; CNPA, chronic necrotising pulmonary aspergillosis; CCPA, chronic cavitary pulmonary aspergillosis; qd, once daily; bid, twice  
796 daily; TDM, therapeutic drug monitoring  
797



## References

- 1 Arendrup MC, Boekhout T, Akova M, et al. Escmid and ecmm joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. *Clin Microbiol Infect.* 2014; **20 Suppl 3**: 76-98.
- 2 Chowdhary A, Meis JF, Guarro J, et al. Escmid and ecmm joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: Diseases caused by black fungi. *Clin Microbiol Infect.* 2014; **20 Suppl 3**: 47-75.
- 3 Cornely OA, Arikan-Akdagli S, Dannaoui E, et al. Escmid and ecmm joint clinical guidelines for the diagnosis and management of mucormycosis 2013. *Clin Microbiol Infect.* 2014; **20 Suppl 3**: 5-26.
- 4 Cornely OA, Bassetti M, Calandra T, et al. Escmid\* guideline for the diagnosis and management of candida diseases 2012: Non-neutropenic adult patients. *Clin Microbiol Infect.* 2012; **18 Suppl 7**: 19-37.
- 5 Cuenca-Estrella M, Verweij PE, Arendrup MC, et al. Escmid\* guideline for the diagnosis and management of candida diseases 2012: Diagnostic procedures. *Clin Microbiol Infect.* 2012; **18 Suppl 7**: 9-18.
- 6 Hope WW, Castagnola E, Groll AH, et al. Escmid\* guideline for the diagnosis and management of candida diseases 2012: Prevention and management of invasive infections in neonates and children caused by candida spp. *Clin Microbiol Infect.* 2012; **18 Suppl 7**: 38-52.
- 7 Lortholary O, Petrikos G, Akova M, et al. Escmid\* guideline for the diagnosis and management of candida diseases 2012: Patients with hiv infection or aids. *Clin Microbiol Infect.* 2012; **18 Suppl 7**: 68-77.
- 8 Tortorano AM, Richardson M, Roilides E, et al. Escmid and ecmm joint guidelines on diagnosis and management of hyalohyphomycosis: *Fusarium* spp., *scedosporium* spp. And others. *Clin Microbiol Infect.* 2014; **20 Suppl 3**: 27-46.



- 826 9 Ullmann AJ, Akova M, Herbrecht R, et al. Escmid\* guideline for the diagnosis and  
827 management of candida diseases 2012: Adults with haematological malignancies and after  
828 haematopoietic stem cell transplantation (hct). *Clin Microbiol Infect.* 2012; **18 Suppl 7**: 53-67.
- 829 10 Ullmann AJ, Cornely OA, Donnelly JP, et al. Escmid\* guideline for the diagnosis and  
830 management of candida diseases 2012: Developing european guidelines in clinical  
831 microbiology and infectious diseases. *Clin Microbiol Infect.* 2012; **18 Suppl 7**: 1-8.
- 832 11 Denning DW, Cadranel J, Beigelman-Aubry C, et al. Chronic pulmonary aspergillosis:  
833 Rationale and clinical guidelines for diagnosis and management. *Eur Respir J.* 2016; **47**: 45-68.
- 834 12 Cornely OA, Cuenca-Estrella M, Meis JF, Ullmann AJ. European society of clinical  
835 microbiology and infectious diseases (escmid) fungal infection study group (efisg) and  
836 european confederation of medical mycology (ecmm) 2013 joint guidelines on diagnosis and  
837 management of rare and emerging fungal diseases. *Clin Microbiol Infect.* 2014; **20 Suppl 3**: 1-  
838 4.
- 839 13 Marchiori E, Irion KL. Commentary on: "Analysis of initial and follow-up ct findings in patients  
840 with invasive pulmonary aspergillosis after solid organ transplantation". *Clin Radiol.* 2012; **67**:  
841 1153-1154.
- 842 14 Bergeron A, Porcher R, Sulahian A, et al. The strategy for the diagnosis of invasive pulmonary  
843 aspergillosis should depend on both the underlying condition and the leukocyte count of  
844 patients with hematologic malignancies. *Blood.* 2012; **119**: 1831-1837; quiz 1956.
- 845 15 Lim C, Seo JB, Park SY, et al. Analysis of initial and follow-up ct findings in patients with  
846 invasive pulmonary aspergillosis after solid organ transplantation. *Clin Radiol.* 2012; **67**:  
847 1179-1186.
- 848 16 Wingard JR. New approaches to invasive fungal infections in acute leukemia and  
849 hematopoietic stem cell transplant patients. *Best practice & research Clinical haematology.*  
850 2007; **20**: 99-107.
- 851 17 Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary  
852 aspergillosis: Clinical significance of the halo sign. *Clin Infect Dis.* 2007; **44**: 373-379.
- 853 18 Greene R. The radiological spectrum of pulmonary aspergillosis. *Medical mycology.* 2005; **43**  
854 **Suppl 1**: S147-154.

- 855 19 Heussel CP, Kauczor HU, Heussel G, Fischer B, Mildenerger P, Thelen M. Early detection of  
856 pneumonia in febrile neutropenic patients: Use of thin-section ct. *AJR American journal of*  
857 *roentgenology*. 1997; **169**: 1347-1353.
- 858 20 Heussel CP, Kauczor HU, Heussel GE, et al. Pneumonia in febrile neutropenic patients and in  
859 bone marrow and blood stem-cell transplant recipients: Use of high-resolution computed  
860 tomography. *J Clin Oncol*. 1999; **17**: 796-805.
- 861 21 Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary  
862 aspergillosis in neutropenic patients using early thoracic computed tomographic scan and  
863 surgery. *J Clin Oncol*. 1997; **15**: 139-147.
- 864 22 Caillot D, Mannone L, Cuisenier B, Couaillier JF. Role of early diagnosis and aggressive surgery  
865 in the management of invasive pulmonary aspergillosis in neutropenic patients. *Clin*  
866 *Microbiol Infect*. 2001; **7 Suppl 2**: 54-61.
- 867 23 Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary  
868 zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. *Clin Infect Dis*.  
869 2005; **41**: 60-66.
- 870 24 Stanzani M, Battista G, Sassi C, et al. Computed tomographic pulmonary angiography for  
871 diagnosis of invasive mold diseases in patients with hematological malignancies. *Clin Infect*  
872 *Dis*. 2012; **54**: 610-616.
- 873 25 Stanzani M, Sassi C, Lewis RE, et al. High resolution computed tomography angiography  
874 improves the radiographic diagnosis of invasive mold disease in patients with hematological  
875 malignancies. *Clin Infect Dis*. 2015; **60**: 1603-1610.
- 876 26 Sonnet S, Buitrago-Tellez CH, Tamm M, Christen S, Steinbrich W. Direct detection of  
877 angioinvasive pulmonary aspergillosis in immunosuppressed patients: Preliminary results  
878 with high-resolution 16-mdct angiography. *AJR American journal of roentgenology*. 2005;  
879 **184**: 746-751.
- 880 27 Sodhi KS, Khandelwal N, Saxena AK, et al. Rapid lung mri in children with pulmonary  
881 infections: Time to change our diagnostic algorithms. *J Magn Reson Imaging*. 2016; **43**: 1196-  
882 1206.

883 28 Maschmeyer G, Carratala J, Buchheidt D, et al. Diagnosis and antimicrobial therapy of lung  
884 infiltrates in febrile neutropenic patients (allogeneic sct excluded): Updated guidelines of the  
885 infectious diseases working party (agiho) of the german society of hematology and medical  
886 oncology (dgho). *Ann Oncol*. 2015; **26**: 21-33.

887 29 Rieger C, Herzog P, Eibel R, Fiegl M, Ostermann H. Pulmonary mri--a new approach for the  
888 evaluation of febrile neutropenic patients with malignancies. *Support Care Cancer*. 2008; **16**:  
889 599-606.

890 30 Araz O, Karaman A, Ucar EY, Bilen Y, Durur Subasi I. Dce-mri findings of invasive aspergillosis  
891 in patient with acute myeloid leukemia. *Clin Respir J*. 2014; **8**: 248-250.

892 31 Blum U, Windfuhr M, Buitrago-Tellez C, Sigmund G, Herbst EW, Langer M. Invasive  
893 pulmonary aspergillosis. Mri, ct, and plain radiographic findings and their contribution for  
894 early diagnosis. *Chest*. 1994; **106**: 1156-1161.

895 32 Yan C, Tan X, Wei Q, et al. Lung mri of invasive fungal infection at 3 tesla: Evaluation of five  
896 different pulse sequences and comparison with multidetector computed tomography (mdct).  
897 *Eur Radiol*. 2015; **25**: 550-557.

898 33 Hot A, Maunoury C, Poiree S, et al. Diagnostic contribution of positron emission tomography  
899 with [18f]fluorodeoxyglucose for invasive fungal infections. *Clin Microbiol Infect*. 2011; **17**:  
900 409-417.

901 34 Camus V, Edet-Sanson A, Bubenheim M, et al. (1)(8)f-fdg-pet/ct imaging in patients with  
902 febrile neutropenia and haematological malignancies. *Anticancer research*. 2015; **35**: 2999-  
903 3005.

904 35 Desoubeaux G, Bailly E, Chandenier J. Diagnosis of invasive pulmonary aspergillosis: Updates  
905 and recommendations. *Med Mal Infect*. 2014; **44**: 89-101.

906 36 Bruno C, Minniti S, Vassanelli A, Pozzi-Mucelli R. Comparison of ct features of aspergillus and  
907 bacterial pneumonia in severely neutropenic patients. *Journal of thoracic imaging*. 2007; **22**:  
908 160-165.

909 37 Nucci M, Nouer SA, Graziutti M, Kumar NS, Barlogie B, Anaissie E. Probable invasive  
910 aspergillosis without prespecified radiologic findings: Proposal for inclusion of a new

911 category of aspergillosis and implications for studying novel therapies. *Clin Infect Dis*. 2010;  
912 **51**: 1273-1280.

913 38 Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of  
914 invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in  
915 patients with neutropenia. *J Clin Oncol*. 2001; **19**: 253-259.

916 39 Kami M, Kishi Y, Hamaki T, et al. The value of the chest computed tomography halo sign in  
917 the diagnosis of invasive pulmonary aspergillosis. An autopsy-based retrospective study of 48  
918 patients. *Mycoses*. 2002; **45**: 287-294.

919 40 Kuhlman JE, Fishman EK, Burch PA, Karp JE, Zerhouni EA, Siegelman SS. Invasive pulmonary  
920 aspergillosis in acute leukemia. The contribution of ct to early diagnosis and aggressive  
921 management. *Chest*. 1987; **92**: 95-99.

922 41 Franquet T, Gimenez A, Hidalgo A. Imaging of opportunistic fungal infections in  
923 immunocompromised patient. *Eur J Radiol*. 2004; **51**: 130-138.

924 42 Horger M, Hebart H, Einsele H, et al. Initial ct manifestations of invasive pulmonary  
925 aspergillosis in 45 non-hiv immunocompromised patients: Association with patient outcome?  
926 *Eur J Radiol*. 2005; **55**: 437-444.

927 43 Althoff Souza C, Muller NL, Marchiori E, Escuissato DL, Franquet T. Pulmonary invasive  
928 aspergillosis and candidiasis in immunocompromised patients: A comparative study of the  
929 high-resolution ct findings. *Journal of thoracic imaging*. 2006; **21**: 184-189.

930 44 Horger M, Einsele H, Schumacher U, et al. Invasive pulmonary aspergillosis: Frequency and  
931 meaning of the "hypodense sign" on unenhanced ct. *The British journal of radiology*. 2005;  
932 **78**: 697-703.

933 45 Marchiori E, Godoy MC, Zanetti G, Hochegger B, Rodrigues RS. The reversed halo sign.  
934 Another ct finding useful for distinguish invasive pulmonary aspergillosis and pulmonary  
935 lymphoma. *Eur J Radiol*. 2011; **79**: e96-97.

936 46 Kojima R, Tateishi U, Kami M, et al. Chest computed tomography of late invasive aspergillosis  
937 after allogeneic hematopoietic stem cell transplantation. *Biology of blood and marrow*  
938 *transplantation : journal of the American Society for Blood and Marrow Transplantation*.  
939 2005; **11**: 506-511.

940 47 Logan PM, Primack SL, Miller RR, Muller NL. Invasive aspergillosis of the airways:  
941 Radiographic, ct, and pathologic findings. *Radiology*. 1994; **193**: 383-388.

942 48 Liss B, Vehreschild JJ, Bangard C, et al. Our 2015 approach to invasive pulmonary  
943 aspergillosis. *Mycoses*. 2015; **58**: 375-382.

944 49 Azoulay E, Mokart D, Lambert J, et al. Diagnostic strategy for hematology and oncology  
945 patients with acute respiratory failure: Randomized controlled trial. *Am J Respir Crit Care*  
946 *Med*. 2010; **182**: 1038-1046.

947 50 Hummel M, Rudert S, Hof H, Hehlmann R, Buchheidt D. Diagnostic yield of bronchoscopy  
948 with bronchoalveolar lavage in febrile patients with hematologic malignancies and  
949 pulmonary infiltrates. *Ann Hematol*. 2008; **87**: 291-297.

950 51 Boersma WG, Erjavec Z, van der Werf TS, de Vries-Hosper HG, Gouw AS, Manson WL.  
951 Bronchoscopic diagnosis of pulmonary infiltrates in granulocytopenic patients with  
952 hematologic malignancies: Bal versus psb and pbal. *Respiratory medicine*. 2007; **101**: 317-  
953 325.

954 52 Cornillet A, Camus C, Nimubona S, et al. Comparison of epidemiological, clinical, and  
955 biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: A 6-  
956 year survey. *Clin Infect Dis*. 2006; **43**: 577-584.

957 53 Jain P, Sandur S, Meli Y, Arroliga AC, Stoller JK, Mehta AC. Role of flexible bronchoscopy in  
958 immunocompromised patients with lung infiltrates. *Chest*. 2004; **125**: 712-722.

959 54 Peikert T, Rana S, Edell ES. Safety, diagnostic yield, and therapeutic implications of flexible  
960 bronchoscopy in patients with febrile neutropenia and pulmonary infiltrates. *Mayo Clinic*  
961 *proceedings*. 2005; **80**: 1414-1420.

962 55 Ramila E, Sureda A, Martino R, et al. Bronchoscopy guided by high-resolution computed  
963 tomography for the diagnosis of pulmonary infections in patients with hematologic  
964 malignancies and normal plain chest x-ray. *Haematologica*. 2000; **85**: 961-966.

965 56 Becker MJ, Lugtenburg EJ, Cornelissen JJ, Van Der Schee C, Hoogsteden HC, De Marie S.  
966 Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid  
967 and serum in haematological patients at risk for invasive pulmonary aspergillosis. *Br J*  
968 *Haematol*. 2003; **121**: 448-457.

969 57 de Bazelaire C, Coffin A, Cohen-Zarade S, et al. Ct-guided biopsies in lung infections in  
970 patients with haematological malignancies. *Diagnostic and interventional imaging*. 2013; **94**:  
971 202-215.

972 58 Reinwald M, Spiess B, Heinz WJ, et al. Aspergillus pcr-based investigation of fresh tissue and  
973 effusion samples in patients with suspected invasive aspergillosis enhances diagnostic  
974 capabilities. *Journal of clinical microbiology*. 2013; **51**: 4178-4185.

975 59 Gupta S, Sultenfuss M, Romaguera JE, et al. Ct-guided percutaneous lung biopsies in patients  
976 with haematologic malignancies and undiagnosed pulmonary lesions. *Hematol Oncol*. 2010;  
977 **28**: 75-81.

978 60 Shi JM, Cai Z, Huang H, et al. Role of ct-guided percutaneous lung biopsy in diagnosis of  
979 pulmonary fungal infection in patients with hematologic diseases. *International journal of*  
980 *hematology*. 2009; **89**: 624-627.

981 61 Lass-Flörl C, Resch G, Nachbaur D, et al. The value of computed tomography-guided  
982 percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised  
983 patients. *Clin Infect Dis*. 2007; **45**: e101-104.

984 62 Rickerts V, Mousset S, Lambrecht E, et al. Comparison of histopathological analysis, culture,  
985 and polymerase chain reaction assays to detect invasive mold infections from biopsy  
986 specimens. *Clin Infect Dis*. 2007; **44**: 1078-1083.

987 63 Carrafiello G, Lagana D, Nosari AM, et al. Utility of computed tomography (ct) and of fine  
988 needle aspiration biopsy (fnab) in early diagnosis of fungal pulmonary infections. Study of  
989 infections from filamentous fungi in haematologically immunodeficient patients. *La*  
990 *Radiologia medica*. 2006; **111**: 33-41.

991 64 Nosari A, Anghilieri M, Carrafiello G, et al. Utility of percutaneous lung biopsy for diagnosing  
992 filamentous fungal infections in hematologic malignancies. *Haematologica*. 2003; **88**: 1405-  
993 1409.

994 65 Manhire A, Charig M, Clelland C, et al. Guidelines for radiologically guided lung biopsy.  
995 *Thorax*. 2003; **58**: 920-936.

996 66 Georgiadou SP, Sampsonas FL, Rice D, Granger JM, Swisher S, Kontoyiannis DP. Open-lung  
997 biopsy in patients with undiagnosed lung lesions referred at a tertiary cancer center is safe

998 and reveals noncancerous, noninfectious entities as the most common diagnoses. *Eur J Clin*  
999 *Microbiol Infect Dis.* 2013; **32**: 101-105.

1000 67 Armenian SH, Hoffman JA, Butturini AM, Kapoor N, Mascarenhas L. Invasive diagnostic  
1001 procedures for pulmonary infiltrates in pediatric hematopoietic stem cell transplant  
1002 recipients. *Pediatr Transplant.* 2007; **11**: 736-742.

1003 68 Zihlif M, Khanchandani G, Ahmed HP, Soubani AO. Surgical lung biopsy in patients with  
1004 hematological malignancy or hematopoietic stem cell transplantation and unexplained  
1005 pulmonary infiltrates: Improved outcome with specific diagnosis. *Am J Hematol.* 2005; **78**:  
1006 94-99.

1007 69 Wingard JR, Hiemenz JW, Jantz MA. How i manage pulmonary nodular lesions and nodular  
1008 infiltrates in patients with hematologic malignancies or undergoing hematopoietic cell  
1009 transplantation. *Blood.* 2012; **120**: 1791-1800.

1010 70 Choi YR, An JY, Kim MK, et al. The diagnostic efficacy and safety of endobronchial ultrasound-  
1011 guided transbronchial needle aspiration as an initial diagnostic tool. *Korean J Intern Med.*  
1012 2013; **28**: 660-667.

1013 71 Casal RF, Adachi R, Jimenez CA, Sarkiss M, Morice RC, Eapen GA. Diagnosis of invasive  
1014 aspergillus tracheobronchitis facilitated by endobronchial ultrasound-guided transbronchial  
1015 needle aspiration: A case report. *Journal of medical case reports.* 2009; **3**: 9290.

1016 72 Aragaki-Nakahodo A, Benzaquen S, Kirschner M. Coinfection by nocardia beijingensis and  
1017 nocardia arthritidis in an immunocompromised patient diagnosed by endobronchial  
1018 ultrasound guided transbronchial needle aspiration (ebus-tbna). *Respir Med Case Rep.* 2014;  
1019 **12**: 22-23.

1020 73 Thery A, Espitalier F, Cassagnau E, Durand N, Malard O. Clinical features and outcome of  
1021 sphenoid sinus aspergillosis: A retrospective series of 15 cases. *European annals of*  
1022 *otorhinolaryngology, head and neck diseases.* 2012; **129**: 179-184.

1023 74 Miyamoto Y, Sakamoto Y, Ohuchi M, et al. Orbital apex syndrome caused by invasive  
1024 aspergillosis as an adverse effect of systemic chemotherapy for metastatic colorectal cancer:  
1025 A case report. *Anticancer research.* 2016; **36**: 821-823.

1026 75 Yuan L, Prayson RA. Optic nerve aspergillosis. *Journal of clinical neuroscience : official journal*  
1027 *of the Neurosurgical Society of Australasia*. 2015; **22**: 1191-1193.

1028 76 Marzolf G, Sabou M, Lannes B, et al. Magnetic resonance imaging of cerebral aspergillosis:  
1029 Imaging and pathological correlations. *PLoS One*. 2016; **11**: e0152475.

1030 77 Ashdown BC, Tien RD, Felsberg GJ. Aspergillosis of the brain and paranasal sinuses in  
1031 immunocompromised patients: Ct and mr imaging findings. *AJR American journal of*  
1032 *roentgenology*. 1994; **162**: 155-159.

1033 78 DeLone DR, Goldstein RA, Petermann G, et al. Disseminated aspergillosis involving the brain:  
1034 Distribution and imaging characteristics. *AJNR American journal of neuroradiology*. 1999; **20**:  
1035 1597-1604.

1036 79 Guermazi A, Gluckman E, Tabti B, Miaux Y. Invasive central nervous system aspergillosis in  
1037 bone marrow transplantation recipients: An overview. *Eur Radiol*. 2003; **13**: 377-388.

1038 80 Rüchel R, Schaffrinski M. Versatile fluorescent staining of fungi in clinical specimens by using  
1039 the optical brightener blankophor. *Journal of clinical microbiology*. 1999; **37**: 2694-2696.

1040 81 Fraczek MG, Kirwan MB, Moore CB, Morris J, Denning DW, Richardson MD. Volume  
1041 dependency for culture of fungi from respiratory secretions and increased sensitivity of  
1042 aspergillus quantitative pcr. *Mycoses*. 2014; **57**: 69-78.

1043 82 Maertens JA, Klont R, Masson C, et al. Optimization of the cutoff value for the aspergillus  
1044 double-sandwich enzyme immunoassay. *Clin Infect Dis*. 2007; **44**: 1329-1336.

1045 83 Duarte RF, Sanchez-Ortega I, Cuesta I, et al. Serum galactomannan-based early detection of  
1046 invasive aspergillosis in hematology patients receiving effective antimold prophylaxis. *Clin*  
1047 *Infect Dis*. 2014; **59**: 1696-1702.

1048 84 Teering S, Verreth A, Peeters A, et al. Prognostic value of serum galactomannan in mixed icu  
1049 patients: A retrospective observational study. *Anaesthesiol Intensive Ther*. 2014; **46**: 145-154.

1050 85 Nouér SA, Nucci M, Kumar NS, Graziutti M, Barlogie B, Anaissie E. Earlier response  
1051 assessment in invasive aspergillosis based on the kinetics of serum aspergillus  
1052 galactomannan: Proposal for a new definition. *Clin Infect Dis*. 2011; **53**: 671-676.



1053 86 D'Haese J, Theunissen K, Vermeulen E, et al. Detection of galactomannan in bronchoalveolar  
1054 lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: Analytical and  
1055 clinical validity. *Journal of clinical microbiology*. 2012; **50**: 1258-1263.

1056 87 Pasqualotto AC, Xavier MO, Sanchez LB, et al. Diagnosis of invasive aspergillosis in lung  
1057 transplant recipients by detection of galactomannan in the bronchoalveolar lavage fluid.  
1058 *Transplantation*. 2010; **90**: 306-311.

1059 88 Luong ML, Clancy CJ, Vadnerkar A, et al. Comparison of an aspergillus real-time polymerase  
1060 chain reaction assay with galactomannan testing of bronchoalveolar lavage fluid for the  
1061 diagnosis of invasive pulmonary aspergillosis in lung transplant recipients. *Clin Infect Dis*.  
1062 2011; **52**: 1218-1226.

1063 89 Meersseman W, Lagrou K, Maertens J, et al. Galactomannan in bronchoalveolar lavage fluid:  
1064 A tool for diagnosing aspergillosis in intensive care unit patients. *Am J Respir Crit Care Med*.  
1065 2008; **177**: 27-34.

1066 90 Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas  
1067 ME.  $\beta$ -d-glucan assay for the diagnosis of invasive fungal infections: A meta-analysis. *Clin*  
1068 *Infect Dis*. 2011; **52**: 750-770.

1069 91 Prattes J, Lackner M, Eigl S, et al. Diagnostic accuracy of the aspergillus -specific  
1070 bronchoalveolar lavage lateral-flow assay in haematological malignancy patients. *Mycoses*.  
1071 2015; **58**: 461-469.

1072 92 Boch T, Reinwald M, Postina P, et al. Identification of invasive fungal diseases in  
1073 immunocompromised patients by combining an aspergillus specific pcr with a multifungal  
1074 DNA-microarray from primary clinical samples. *Mycoses*. 2015; **58**: 735-745.

1075 93 Boch T, Spiess B, Cornely OA, et al. Diagnosis of invasive fungal infections in haematological  
1076 patients by combined use of galactomannan, 1,3-beta-d-glucan, aspergillus pcr, multifungal  
1077 DNA-microarray, and aspergillus azole resistance pcrs in blood and bronchoalveolar lavage  
1078 samples: Results of a prospective multicentre study. *Clin Microbiol Infect*. 2016.

1079 94 Springer J, Morton CO, Perry M, et al. Multicenter comparison of serum and whole-blood  
1080 specimens for detection of aspergillus DNA in high-risk hematological patients. *Journal of*  
1081 *clinical microbiology*. 2013; **51**: 1445-1450.

1082 95 Springer J, White PL, Hamilton S, et al. Comparison of performance characteristics of  
1083 aspergillus pcr in testing a range of blood-based samples in accordance with international  
1084 methodological recommendations. *Journal of clinical microbiology*. 2016; **54**: 705-711.

1085 96 White PL, Wiederhold NP, Loeffler J, et al. Comparison of nonculture blood-based tests for  
1086 diagnosing invasive aspergillosis in an animal model. *Journal of clinical microbiology*. 2016;  
1087 **54**: 960-966.

1088 97 White PL, Barnes RA, Springer J, et al. Clinical performance of aspergillus pcr for testing  
1089 serum and plasma: A study by the european aspergillus pcr initiative. *Journal of clinical*  
1090 *microbiology*. 2015; **53**: 2832-2837.

1091 98 Rogers TR, Morton CO, Springer J, et al. Combined real-time pcr and galactomannan  
1092 surveillance improves diagnosis of invasive aspergillosis in high risk patients with  
1093 haematological malignancies. *Br J Haematol*. 2013; **161**: 517-524.

1094 99 Aguado JM, Vazquez L, Fernandez-Ruiz M, et al. Serum galactomannan versus a combination  
1095 of galactomannan and polymerase chain reaction-based aspergillus DNA detection for early  
1096 therapy of invasive aspergillosis in high-risk hematological patients: A randomized controlled  
1097 trial. *Clin Infect Dis*. 2015; **60**: 405-414.

1098 100 Vermeulen E, Lagrou K, Verweij PE. Azole resistance in aspergillus fumigatus: A growing  
1099 public health concern. *Curr Opin Infect Dis*. 2013; **26**: 493-500.

1100 101 Chowdhary A, Kathuria S, Xu J, Meis JF. Emergence of azole-resistant aspergillus fumigatus  
1101 strains due to agricultural azole use creates an increasing threat to human health. *PLoS*  
1102 *pathogens*. 2013; **9**: e1003633.

1103 102 Koehler P, Hamprecht A, Bader O, et al. Epidemiology of invasive aspergillosis and azole  
1104 resistance in patients with acute leukaemia: The sepia study. *International journal of*  
1105 *antimicrobial agents*. 2017; **49**: 218-223.

1106 103 Van Der Linden JW, Warris A, Verweij PE. Aspergillus species intrinsically resistant to  
1107 antifungal agents. *Medical mycology*. 2011; **49 Suppl 1**: S82-89.

1108 104 Anderson JB. Evolution of antifungal-drug resistance: Mechanisms and pathogen fitness. *Nat*  
1109 *Rev Microbiol*. 2005; **3**: 547-556.

1110 105 van der Linden JW, Arendrup MC, Warris A, et al. Prospective multicenter international  
1111 surveillance of azole resistance in aspergillus fumigatus. *Emerg Infect Dis*. 2015; **21**: 1041-  
1112 1044.

1113 106 Chowdhary A, Sharma C, van den Boom M, et al. Multi-azole-resistant aspergillus fumigatus  
1114 in the environment in tanzania. *J Antimicrob Chemother*. 2014; **69**: 2979-2983.

1115 107 Verweij PE, Chowdhary A, Melchers WJ, Meis JF. Azole resistance in aspergillus fumigatus:  
1116 Can we retain the clinical use of mold-active antifungal azoles? *Clin Infect Dis*. 2016; **62**: 362-  
1117 368.

1118 108 Ozmerdiven GE, Ak S, Ener B, et al. First determination of azole resistance in aspergillus  
1119 fumigatus strains carrying the tr34/l98h mutations in turkey. *J Infect Chemother*. 2015; **21**:  
1120 581-586.

1121 109 Astvad KM, Jensen RH, Hassan TM, et al. First detection of tr46/y121f/t289a and tr34/l98h  
1122 alterations in aspergillus fumigatus isolates from azole-naive patients in denmark despite  
1123 negative findings in the environment. *Antimicrob Agents Chemother*. 2014; **58**: 5096-5101.

1124 110 Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ. Azole resistance in aspergillus  
1125 fumigatus: A side-effect of environmental fungicide use? *Lancet Infect Dis*. 2009; **9**: 789-795.

1126 111 Stensvold CR, Nistrup Jørgensen L, M CA. Azole-resistant invasive aspergillosis: Relationship  
1127 to agriculture. *Curr Fungal Infect Rep*. 2012; **6**: 178-191.

1128 112 Bowyer P, Denning DW. Environmental fungicides and triazole resistance in aspergillus. *Pest*  
1129 *Manag Sci*. 2014; **70**: 173-178.

1130 113 van der Linden JW, Snelders E, Kampinga GA, et al. Clinical implications of azole resistance in  
1131 aspergillus fumigatus, the netherlands, 2007-2009. *Emerg Infect Dis*. 2011; **17**: 1846-1854.

1132 114 van der Linden JW, Camps SM, Kampinga GA, et al. Aspergillosis due to voriconazole highly  
1133 resistant aspergillus fumigatus and recovery of genetically related resistant isolates from  
1134 domiciles. *Clin Infect Dis*. 2013; **57**: 513-520.

1135 115 Howard SJ, Cerar D, Anderson MJ, et al. Frequency and evolution of azole resistance in  
1136 aspergillus fumigatus associated with treatment failure. *Emerg Infect Dis*. 2009; **15**: 1068-  
1137 1076.

1138 116 Camps SM, van der Linden JW, Li Y, et al. Rapid induction of multiple resistance mechanisms  
1139 in aspergillus fumigatus during azole therapy: A case study and review of the literature.  
1140 *Antimicrob Agents Chemother.* 2012; **56**: 10-16.

1141 117 Ahmad S, Joseph L, Hagen F, Meis JF, Khan Z. Concomitant occurrence of itraconazole-  
1142 resistant and -susceptible strains of aspergillus fumigatus in routine cultures. *J Antimicrob*  
1143 *Chemother.* 2015; **70**: 412-415.

1144 118 Arendrup MC, Verweij PE, Mouton JW, Lagrou K, Meletiadis J. Multicentre validation of 4-  
1145 well azole agar plates as a screening method for detection of clinically relevant azole-  
1146 resistant aspergillus fumigatus. *J Antimicrob Chemother.* 2017; **72**: 3325-3333.

1147 119 Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: Established and  
1148 emerging indications. *Antimicrob Agents Chemother.* 2009; **53**: 24-34.

1149 120 Tricot G, Joosten E, Boogaerts MA, Vande-Pitte J, Cauwenbergh G. Ketoconazole vs.  
1150 Itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: Preliminary  
1151 results of two nonrandomized studies. *Rev Infect Diseases.* **9**: S94-S95.

1152 121 Morgenstern GR, Prentice AG, Grant Prentice H, et al. A randomized controlled trial of  
1153 itraconazole versus fluconazole for the prevention of fungal infections in patients with  
1154 haematological malignancies. *Br J Haematol.* 1999; **105**: 901-911.

1155 122 Glasmacher A, Hahn C, Molitor E, Marklein G, Sauerbruch T, Schmidt-Wolf I. Itraconazole  
1156 trough concentrations in antifungal prophylaxis with six different dosing regimens using  
1157 hydroxypropyl- $\beta$ -cyclodextrin oral solution or coated-pellet capsules. *Mycoses.* 1999; **42**:  
1158 591-600.

1159 123 Glasmacher A, Hahn C, Leutner C, et al. Breakthrough invasive fungal infections in  
1160 neutropenic patients after prophylaxis with itraconazole. *Mycoses.* 1999; **42**: 443-451.

1161 124 Glasmacher A, Prentice A, Gorschlüter M, et al. Itraconazole prevents invasive fungal  
1162 infections in neutropenic patients treated for hematologic malignancies: Evidence from a  
1163 meta-analysis of 3,597 patients. *J Clin Oncol.* 2003; **21**: 4615-4626.

1164 125 Boogaerts MA, Verhoef GE, Zachee P, Demuyneck H, Verbist L, De Beule K. Antifungal  
1165 prophylaxis with itraconazole in prolonged neutropenia: Correlation with plasma levels.  
1166 *Mycoses.* 1989; **32 Suppl 1**: 103-108.

1167 126 Denning DW, Lee JY, Hostetler JS, et al. Niaid mycoses study group multicenter trial of oral  
1168 itraconazole therapy for invasive aspergillosis. *Am J Med.* 1994; **97**: 135-144.

1169 127 Lestner JM, Roberts SA, Moore CB, Howard SJ, Denning DW, Hope WW. Toxicodynamics of  
1170 itraconazole: Implications for therapeutic drug monitoring. *Clin Infect Dis.* 2009; **49**: 928-930.

1171 128 Pascual A, Csajka C, Buclin T, et al. Challenging recommended oral and intravenous  
1172 voriconazole doses for improved efficacy and safety: Population pharmacokinetics-based  
1173 analysis of adult patients with invasive fungal infections. *Clin Infect Dis.* 2012; **55**: 381-390.

1174 129 Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug  
1175 monitoring in patients with invasive mycoses improves efficacy and safety outcomes. *Clin*  
1176 *Infect Dis.* 2008; **46**: 201-211.

1177 130 Park WB, Kim N-H, Kim K-H, et al. The effect of therapeutic drug monitoring on safety and  
1178 efficacy of voriconazole in invasive fungal infections: A randomized controlled trial. *Clin Infect*  
1179 *Dis.* 2012; **55**: 1080-1087.

1180 131 Troke PF, Hockey HP, Hope WW. Observational study of the clinical efficacy of voriconazole  
1181 and its relationship to plasma concentrations in patients. *Antimicrob Agents Chemother.*  
1182 2011; **55**: 4782-4788.

1183 132 Trifilio S, Singhal S, Williams S, et al. Breakthrough fungal infections after allogeneic  
1184 hematopoietic stem cell transplantation in patients on prophylactic voriconazole. *Bone*  
1185 *Marrow Transplant.* 2007; **40**: 451-456.

1186 133 Dolton MJ, Ray JE, Chen SCA, Ng K, Pont LG, McLachlan AJ. Multicenter study of voriconazole  
1187 pharmacokinetics and therapeutic drug monitoring. *Antimicrob Agents Chemother.* 2012; **56**:  
1188 4793-4799.

1189 134 Neely M, Margol A, Fu X, et al. Achieving target voriconazole concentrations more accurately  
1190 in children and adolescents. *Antimicrob Agents Chemother.* 2015; **59**: 3090-3097.

1191 135 Friberg LE, Ravva P, Karlsson MO, Liu P. Integrated population pharmacokinetic analysis of  
1192 voriconazole in children, adolescents and adults. *Antimicrob Agents Chemother.* 2012; **56**:  
1193 3032-3042.

1194 136 Jang SH, Colangelo PM, Gobburu JVS. Exposure--response of posaconazole used for  
1195 prophylaxis against invasive fungal infections: Evaluating the need to adjust doses based on  
1196 drug concentrations in plasma. *Clinical Pharmacology & Therapeutics*. 2010; **88**: 115-119.

1197 137 Cornely OA, Ullmann AJ. Lack of evidence for exposure-response relationship in the use of  
1198 posaconazole as prophylaxis against invasive fungal infections. *Clinical pharmacology and*  
1199 *therapeutics*. 2011; **89**: 351-352.

1200 138 Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in  
1201 patients who are refractory to or intolerant of conventional therapy: An externally controlled  
1202 trial. *Clin Infect Dis*. 2007; **44**: 2-12.

1203 139 European Medicine A. Assessment report: Noxafil. 2014.

1204 140 Cornely OA, Robertson MN, Haider S, et al. Pharmacokinetics and safety results from the  
1205 phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of  
1206 invasive fungal disease *Journal of Antimicrobial Chemotherapy*. 2017.

1207 141 Cornely OA, Duarte RF, Haider S, et al. Phase 3 pharmacokinetics and safety study of a  
1208 posaconazole tablet formulation in patients at risk for invasive fungal disease. *J Antimicrob*  
1209 *Chemother*. 2016; **71**: 1747.

1210 142 Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of  
1211 amphotericin b colloidal dispersion versus amphotericin b for treatment of invasive  
1212 aspergillosis in immunocompromised patients. *Clin Infect Dis*. 2002; **35**: 359-366.

1213 143 Stamm AM, Diasio RB, Dismukes WE, et al. Toxicity of amphotericin b plus flucytosine in 194  
1214 patients with cryptococcal meningitis. *Am J Med*. 1987; **83**: 236-242.

1215 144 Pasqualotto AC, Howard SJ, Moore CB, Denning DW. Flucytosine therapeutic monitoring: 15  
1216 years experience from the uk. *J Antimicrob Chemother*. 2007; **59**: 791-793.

1217 145 Walsh TJ, Dixon DM. Nosocomial aspergillosis: Environmental microbiology, hospital  
1218 epidemiology, diagnosis and treatment. *European journal of epidemiology*. 1989; **5**: 131-142.

1219 146 Goodley JM, Clayton YM, Hay RJ. Environmental sampling for aspergilli during building  
1220 construction on a hospital site. *The Journal of hospital infection*. 1994; **26**: 27-35.

1221 147 Perraud M, Piens MA, Nicoloyannis N, Girard P, Sepetjan M, Garin JP. Invasive nosocomial  
1222 pulmonary aspergillosis: Risk factors and hospital building works. *Epidemiol Infect.* 1987; **99**:  
1223 407-412.

1224 148 Opal SM, Asp AA, Cannady PB, Jr., Morse PL, Burton LJ, Hammer PG, 2nd. Efficacy of infection  
1225 control measures during a nosocomial outbreak of disseminated aspergillosis associated with  
1226 hospital construction. *The Journal of infectious diseases.* 1986; **153**: 634-637.

1227 149 Weems JJ, Jr., Davis BJ, Tablan OC, Kaufman L, Martone WJ. Construction activity: An  
1228 independent risk factor for invasive aspergillosis and zygomycosis in patients with  
1229 hematologic malignancy. *Infect Control.* 1987; **8**: 71-75.

1230 150 Meheust D, Le Cann P, Reboux G, Millon L, Gangneux JP. Indoor fungal contamination: Health  
1231 risks and measurement methods in hospitals, homes and workplaces. *Crit Rev Microbiol.*  
1232 2014; **40**: 248-260.

1233 151 Sherertz RJ, Belani A, Kramer BS, et al. Impact of air filtration on nosocomial aspergillus  
1234 infections. Unique risk of bone marrow transplant recipients. *The American journal of*  
1235 *medicine.* 1987; **83**: 709-718.

1236 152 Barnes RA, Rogers TR. Control of an outbreak of nosocomial aspergillosis by laminar air-flow  
1237 isolation. *The Journal of hospital infection.* 1989; **14**: 89-94.

1238 153 Thio CL, Smith D, Merz WG, et al. Refinements of environmental assessment during an  
1239 outbreak investigation of invasive aspergillosis in a leukemia and bone marrow transplant  
1240 unit. *Infect Control Hosp Epidemiol.* 2000; **21**: 18-23.

1241 154 Hahn T, Cummings KM, Michalek AM, Lipman BJ, Segal BH, McCarthy PL, Jr. Efficacy of high-  
1242 efficiency particulate air filtration in preventing aspergillosis in immunocompromised  
1243 patients with hematologic malignancies. *Infect Control Hosp Epidemiol.* 2002; **23**: 525-531.

1244 155 Maschmeyer G, Neuburger S, Fritz L, et al. A prospective, randomised study on the use of  
1245 well-fitting masks for prevention of invasive aspergillosis in high-risk patients. *Ann Oncol.*  
1246 2009; **20**: 1560-1564.

1247 156 Anaissie EJ, Stratton SL, Dignani MC, et al. Pathogenic aspergillus species recovered from a  
1248 hospital water system: A 3-year prospective study. *Clin Infect Dis.* 2002; **34**: 780-789.

1249 157 Anaissie EJ, Penzak SR, Dignani MC. The hospital water supply as a source of nosocomial  
1250 infections: A plea for action. *Archives of internal medicine*. 2002; **162**: 1483-1492.

1251 158 Anaissie EJ, Stratton SL, Dignani MC, et al. Cleaning patient shower facilities: A novel  
1252 approach to reducing patient exposure to aerosolized aspergillus species and other  
1253 opportunistic molds. *Clin Infect Dis*. 2002; **35**: E86-88.

1254 159 Anaissie EJ, Stratton SL, Dignani MC, et al. Pathogenic molds (including aspergillus species) in  
1255 hospital water distribution systems: A 3-year prospective study and clinical implications for  
1256 patients with hematologic malignancies. *Blood*. 2003; **101**: 2542-2546.

1257 160 Lee LD, Hachem RY, Berkheiser M, Hackett B, Jiang Y, Raad, II. Hospital environment and  
1258 invasive aspergillosis in patients with hematologic malignancy. *Am J Infect Control*. 2012; **40**:  
1259 247-249.

1260 161 Mahieu LM, De Dooy JJ, Van Laer FA, Jansens H, Ieven MM. A prospective study on factors  
1261 influencing aspergillus spore load in the air during renovation works in a neonatal intensive  
1262 care unit. *The Journal of hospital infection*. 2000; **45**: 191-197 [Record as supplied by  
1263 publisher].

1264 162 Rüping MJ, Gerlach S, Fischer G, et al. Environmental and clinical epidemiology of aspergillus  
1265 terreus: Data from a prospective surveillance study. *The Journal of hospital infection*. 2011;  
1266 **78**: 226-230.

1267 163 Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic  
1268 malignancies in a tertiary care cancer center: An autopsy study over a 15-year period (1989-  
1269 2003). *Haematologica*. 2006; **91**: 986-989.

1270 164 Sinko J, Csomor J, Nikolova R, et al. Invasive fungal disease in allogeneic hematopoietic stem  
1271 cell transplant recipients: An autopsy-driven survey. *Transpl Infect Dis*. 2008; **10**: 106-109.

1272 165 Lewis RE, Cahyame-Zuniga L, Leventakos K, et al. Epidemiology and sites of involvement of  
1273 invasive fungal infections in patients with haematological malignancies: A 20-year autopsy  
1274 study. *Mycoses*. 2013; **56**: 638-645.

1275 166 Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould  
1276 infections in hematopoietic stem cell transplant recipients. *Clin Infect Dis*. 2002; **34**: 909-917.



1277 167 Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of aspergillus infections in a  
1278 large cohort of patients undergoing bone marrow transplantation. *The Journal of infectious*  
1279 *diseases*. 1997; **175**: 1459-1466.

1280 168 Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection  
1281 in adult hematopoietic stem cell transplant recipients: Analysis of multicenter prospective  
1282 antifungal therapy (path) alliance registry. *Clin Infect Dis*. 2009; **48**: 265-273.

1283 169 De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from  
1284 the european organization for research and treatment of cancer/invasive fungal infections  
1285 cooperative group and the national institute of allergy and infectious diseases mycoses study  
1286 group (eortc/msg) consensus group. *Clin Infect Dis*. 2008; **46**: 1813-1821.

1287 170 Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin b for  
1288 primary therapy of invasive aspergillosis. *N Engl J Med*. 2002; **347**: 408-415.

1289 171 Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin b as initial therapy for  
1290 invasive mold infection: A randomized trial comparing a high-loading dose regimen with  
1291 standard dosing (ambiload trial). *Clin Infect Dis*. 2007; **44**: 1289-1297.

1292 172 Marr KA, Schlamm HT, Herbrecht R, et al. Combination antifungal therapy for invasive  
1293 aspergillosis: A randomized trial. *Annals of internal medicine*. 2015; **162**: 81-89.

1294 173 Maertens JA, Raad, II, Marr KA, et al. Isavuconazole versus voriconazole for primary  
1295 treatment of invasive mould disease caused by aspergillus and other filamentous fungi  
1296 (secure): A phase 3, randomised-controlled, non-inferiority trial. *Lancet*. 2016; **387**: 760-769.

1297 174 Ofran Y, Avivi I, Oliven A, et al. Granulocyte transfusions for neutropenic patients with life-  
1298 threatening infections: A single centre experience in 47 patients, who received 348  
1299 granulocyte transfusions. *Vox Sang*. 2007; **93**: 363-369.

1300 175 Safdar A, Rodriguez GH, Lichtiger B, et al. Recombinant interferon gamma1b immune  
1301 enhancement in 20 patients with hematologic malignancies and systemic opportunistic  
1302 infections treated with donor granulocyte transfusions. *Cancer*. 2006; **106**: 2664-2671.

1303 176 Sachs UJ, Reiter A, Walter T, Bein G, Woessmann W. Safety and efficacy of therapeutic early  
1304 onset granulocyte transfusions in pediatric patients with neutropenia and severe infections.  
1305 *Transfusion*. 2006; **46**: 1909-1914.

1306 177 Dignani MC, Rex JH, Chan KW, et al. Immunomodulation with interferon-gamma and colony-  
1307 stimulating factors for refractory fungal infections in patients with leukemia. *Cancer*. 2005;  
1308 **104**: 199-204.

1309 178 Lee JJ, Chung IJ, Park MR, et al. Clinical efficacy of granulocyte transfusion therapy in patients  
1310 with neutropenia-related infections. *Leukemia*. 2001; **15**: 203-207.

1311 179 Dignani MC, Anaissie EJ, Hester JP, et al. Treatment of neutropenia-related fungal infections  
1312 with granulocyte colony-stimulating factor-elicited white blood cell transfusions: A pilot  
1313 study. *Leukemia*. 1997; **11**: 1621-1630.

1314 180 Massey E, Paulus U, Doree C, Stanworth S. Granulocyte transfusions for preventing infections  
1315 in patients with neutropenia or neutrophil dysfunction. *Cochrane Database Syst Rev*. 2009:  
1316 CD005341.

1317 181 Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for  
1318 cancer patients with prolonged fever and granulocytopenia. *The American journal of*  
1319 *medicine*. 1982; **72**: 101-111.

1320 182 Pizzo PA, Robichaud KJ, Wesley R, Commers JR. Fever in the pediatric and young adult  
1321 patient with cancer. A prospective study of 1001 episodes. *Medicine (Baltimore)*. 1982; **61**:  
1322 153-165.

1323 183 Empiric antifungal therapy in febrile granulocytopenic patients. Eortc international  
1324 antimicrobial therapy cooperative group. *The American journal of medicine*. 1989; **86**: 668-  
1325 672.

1326 184 Goldberg E, Gafter-Gvili A, Robenshtok E, Leibovici L, Paul M. Empirical antifungal therapy for  
1327 patients with neutropenia and persistent fever: Systematic review and meta-analysis. *Eur J*  
1328 *Cancer*. 2008; **44**: 2192-2203.

1329 185 Cordonnier C, Pautas C, Maury S, et al. Empirical versus preemptive antifungal therapy for  
1330 high-risk, febrile, neutropenic patients: A randomized, controlled trial. *Clin Infect Dis*. 2009;  
1331 **48**: 1042-1051.

1332 186 Girmenia C, Micozzi A, Gentile G, et al. Clinically driven diagnostic antifungal approach in  
1333 neutropenic patients: A prospective feasibility study. *J Clin Oncol*. 2010; **28**: 667-674.

1334 187 Pagano L, Caira M, Nosari A, et al. The use and efficacy of empirical versus pre-emptive  
1335 therapy in the management of fungal infections: The hema e-chart project. *Haematologica*.  
1336 2011; **96**: 1366-1370.

1337 188 Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin b for  
1338 empirical antifungal therapy in patients with persistent fever and neutropenia. *N Engl J Med*.  
1339 2004; **351**: 1391-1402.

1340 189 Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin b for empirical therapy in  
1341 patients with persistent fever and neutropenia. National institute of allergy and infectious  
1342 diseases mycoses study group. *N Engl J Med*. 1999; **340**: 764-771.

1343 190 Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin b  
1344 for empirical antifungal therapy in patients with neutropenia and persistent fever. *N Engl J*  
1345 *Med*. 2002; **346**: 225-234.

1346 191 White PL, Parr C, Thornton C, Barnes RA. Evaluation of real-time pcr, galactomannan  
1347 enzyme-linked immunosorbent assay (elisa), and a novel lateral-flow device for diagnosis of  
1348 invasive aspergillosis. *Journal of clinical microbiology*. 2013; **51**: 1510-1516.

1349 192 White PL, Wingard JR, Bretagne S, et al. Aspergillus polymerase chain reaction: Systematic  
1350 review of evidence for clinical use in comparison with antigen testing. *Clin Infect Dis*. 2015;  
1351 **61**: 1293-1303.

1352 193 Liss B, Cornely OA, Hoffmann D, Dimitriou V, Wisplinghoff H. 1,3-beta-d-glucan  
1353 contamination of common antimicrobials-authors' response. *J Antimicrob Chemother*. 2016;  
1354 **71**: 2997-2999.

1355 194 Liss B, Cornely OA, Hoffmann D, Dimitriou V, Wisplinghoff H. 1,3-beta-d-glucan  
1356 contamination of common antimicrobials. *J Antimicrob Chemother*. 2016; **71**: 913-915.

1357 195 Liss B, Cornely OA, Hoffmann D, Dimitriou V, Wisplinghoff H. 1,3-β-d-glucan concentrations in  
1358 blood products predict false positive post-transfusion results. *Mycoses*. 2016; **59**: 39-42.

1359 196 Hammarstrom H, Kondori N, Friman V, Wenneras C. How to interpret serum levels of beta-  
1360 glucan for the diagnosis of invasive fungal infections in adult high-risk hematology patients:  
1361 Optimal cut-off levels and confounding factors. *Eur J Clin Microbiol Infect Dis*. 2015; **34**: 917-  
1362 925.

1363 197 Bouza E, Guinea J, Pelaez T, Perez-Molina J, Alcala L, Munoz P. Workload due to aspergillus  
1364 fumigatus and significance of the organism in the microbiology laboratory of a general  
1365 hospital. *Journal of clinical microbiology*. 2005; **43**: 2075-2079.

1366 198 Montagna MT, Lovero G, Coretti C, et al. Simiff study: Italian fungal registry of mold  
1367 infections in hematological and non-hematological patients. *Infection*. 2014; **42**: 141-151.

1368 199 Garcia-Vidal C, Peghin M, Cervera C, et al. Causes of death in a contemporary cohort of  
1369 patients with invasive aspergillosis. *PLoS One*. 2015; **10**: e0120370.

1370 200 Vena A, Munoz P, Pelaez T, Guinea J, Valerio M, Bouza E. Non-construction related  
1371 aspergillus outbreak in non-haematological patients related to high concentrations of  
1372 airborne spores in non-hepa filtered areas. *ID week, San Diego, Ca*. 2015; **October 7-11**.

1373 201 Ruiz-Camps I, Aguado JM, Almirante B, et al. [recommendations of the spanish society of  
1374 infectious diseases and clinical microbiology (seimc) on the prevention of invasive fungal  
1375 infection due to filamentous fungi]. *Enferm Infecc Microbiol Clin*. 2010; **28**: 172 e171-172  
1376 e121.

1377 202 Guinea J, Pelaez T, Alcala L, Bouza E. Outdoor environmental levels of aspergillus spp. Conidia  
1378 over a wide geographical area. *Medical mycology*. 2006; **44**: 349-356.

1379 203 Pelaez T, Munoz P, Guinea J, et al. Outbreak of invasive aspergillosis after major heart  
1380 surgery caused by spores in the air of the intensive care unit. *Clin Infect Dis*. 2012; **54**: e24-  
1381 31.

1382 204 Munoz P, Guinea J, Pelaez T, Duran C, Blanco JL, Bouza E. Nosocomial invasive aspergillosis in  
1383 a heart transplant patient acquired during a break in the hepa air filtration system. *Transpl  
1384 Infect Dis*. 2004; **6**: 50-54.

1385 205 Tang HJ, Liu WL, Chang TC, et al. Multiple brain abscesses due to aspergillus fumigatus in a  
1386 patient with liver cirrhosis: A case report. *Medicine (Baltimore)*. 2016; **95**: e2813.

1387 206 Pilmis B, Puel A, Lortholary O, Lanternier F. New clinical phenotypes of fungal infections in  
1388 special hosts. *Clin Microbiol Infect*. 2016.

1389 207 Falcone M, Concia E, Iori I, et al. Identification and management of invasive mycoses in  
1390 internal medicine: A road-map for physicians. *Intern Emerg Med*. 2014; **9**: 501-511.

1391 208 Peghin M, Ruiz-Camps I, Garcia-Vidal C, et al. Unusual forms of subacute invasive pulmonary  
1392 aspergillosis in patients with solid tumors. *J Infect*. 2014; **69**: 387-395.

1393 209 Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant  
1394 recipients: Results of the transplant-associated infection surveillance network (transnet). *Clin*  
1395 *Infect Dis*. 2010; **50**: 1101-1111.

1396 210 Gavalda J, Len O, San Juan R, et al. Risk factors for invasive aspergillosis in solid-organ  
1397 transplant recipients: A case-control study. *Clin Infect Dis*. 2005; **41**: 52-59.

1398 211 Singh N, Husain S, Practice ASTIDCo. Aspergillosis in solid organ transplantation. *Am J*  
1399 *Transplant*. 2013; **13 Suppl 4**: 228-241.

1400 212 Singh N, Limaye AP, Forrest G, et al. Late-onset invasive aspergillosis in organ transplant  
1401 recipients in the current era. *Medical mycology*. 2006; **44**: 445-449.

1402 213 Gavalda J, Meije Y, Fortun J, et al. Invasive fungal infections in solid organ transplant  
1403 recipients. *Clin Microbiol Infect*. 2014; **20 Suppl 7**: 27-48.

1404 214 Munoz P, Ceron I, Valerio M, et al. Invasive aspergillosis among heart transplant recipients: A  
1405 24-year perspective. *J Heart Lung Transplant*. 2014; **33**: 278-288.

1406 215 Munoz P, Valerio M, Palomo J, et al. Targeted antifungal prophylaxis in heart transplant  
1407 recipients. *Transplantation*. 2013; **96**: 664-669.

1408 216 Barchiesi F, Mazzocato S, Mazzanti S, et al. Invasive aspergillosis in liver transplant recipients:  
1409 Epidemiology, clinical characteristics, treatment, and outcomes in 116 cases. *Liver Transpl*.  
1410 2015; **21**: 204-212.

1411 217 Winston DJ, Limaye AP, Pelletier S, et al. Randomized, double-blind trial of anidulafungin  
1412 versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant  
1413 recipients. *Am J Transplant*. 2014; **14**: 2758-2764.

1414 218 Lichtenstern C, Hochreiter M, Zehnter VD, et al. Pretransplant model for end stage liver  
1415 disease score predicts posttransplant incidence of fungal infections after liver  
1416 transplantation. *Mycoses*. 2013; **56**: 350-357.

1417 219 Ohkubo T, Sugawara Y, Takayama T, Kokudo N, Makuuchi M. The risk factors of fungal  
1418 infection in living-donor liver transplantations. *J Hepatobiliary Pancreat Sci.* 2012; **19**: 382-  
1419 388.

1420 220 San-Juan R, Aguado JM, Lumbreras C, et al. Universal prophylaxis with fluconazole for the  
1421 prevention of early invasive fungal infection in low-risk liver transplant recipients.  
1422 *Transplantation.* 2011; **92**: 346-350.

1423 221 Singh N, Wagener MM, Cacciarelli TV, Levitsky J. Antifungal management practices in liver  
1424 transplant recipients. *Am J Transplant.* 2008; **8**: 426-431.

1425 222 Osawa M, Ito Y, Hirai T, et al. Risk factors for invasive aspergillosis in living donor liver  
1426 transplant recipients. *Liver Transpl.* 2007; **13**: 566-570.

1427 223 Pappas PG, Andes D, Schuster M, et al. Invasive fungal infections in low-risk liver transplant  
1428 recipients: A multi-center prospective observational study. *Am J Transplant.* 2006; **6**: 386-  
1429 391.

1430 224 Fortun J, Martin-Davila P, Moreno S, et al. Risk factors for invasive aspergillosis in liver  
1431 transplant recipients. *Liver Transpl.* 2002; **8**: 1065-1070.

1432 225 Singh N, Husain S. Aspergillus infections after lung transplantation: Clinical differences in  
1433 type of transplant and implications for management. *J Heart Lung Transplant.* 2003; **22**: 258-  
1434 266.

1435 226 Weigt SS, Elashoff RM, Huang C, et al. Aspergillus colonization of the lung allograft is a risk  
1436 factor for bronchiolitis obliterans syndrome. *Am J Transplant.* 2009; **9**: 1903-1911.

1437 227 Geltner C, Lass-Flörl C. Invasive pulmonary aspergillosis in organ transplants--focus on lung  
1438 transplants. *Respir Investig.* 2016; **54**: 76-84.

1439 228 Lopez-Medrano F, Silva JT, Fernandez-Ruiz M, et al. Risk factors associated with early invasive  
1440 pulmonary aspergillosis in kidney transplant recipients: Results from a multinational matched  
1441 case-control study. *Am J Transplant.* 2016; **16**: 2148-2157.

1442 229 Gustafson TL, Schaffner W, Lavelly GB, Stratton CW, Johnson HK, Hutcheson RH, Jr. Invasive  
1443 aspergillosis in renal transplant recipients: Correlation with corticosteroid therapy. *The*  
1444 *Journal of infectious diseases.* 1983; **148**: 230-238.

1445 230 Wojtowicz A, Gresnigt MS, Lecompte T, et al. Il1b and defb1 polymorphisms increase  
1446 susceptibility to invasive mold infection after solid-organ transplantation. *The Journal of*  
1447 *infectious diseases*. 2015; **211**: 1646-1657.

1448 231 Wojtowicz A, Lecompte TD, Bibert S, et al. Ptx3 polymorphisms and invasive mold infections  
1449 after solid organ transplant. *Clin Infect Dis*. 2015; **61**: 619-622.

1450 232 Denis B, Guiguet M, de Castro N, et al. Relevance of eortc criteria for the diagnosis of  
1451 invasive aspergillosis in hiv-infected patients, and survival trends over a 20-year period in  
1452 france. *Clin Infect Dis*. 2015; **61**: 1273-1280.

1453 233 Libanore M, Prini E, Mazzetti M, et al. Invasive aspergillosis in italian aids patients. *Infection*.  
1454 2002; **30**: 341-345.

1455 234 Moreno A, Perez-Elias M, Casado J, et al. Role of antiretroviral therapy in long-term survival  
1456 of patients with aids-related pulmonary aspergillosis. *Eur J Clin Microbiol Infect Dis*. 2000; **19**:  
1457 688-693.

1458 235 Mylonakis E, Paliou M, Sax PE, Skolnik PR, Baron MJ, Rich JD. Central nervous system  
1459 aspergillosis in patients with human immunodeficiency virus infection. Report of 6 cases and  
1460 review. *Medicine (Baltimore)*. 2000; **79**: 269-280.

1461 236 Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: Systematic review of the  
1462 literature. *Clin Infect Dis*. 2001; **32**: 358-366.

1463 237 Gastaca M, Aguero F, Rimola A, et al. Liver retransplantation in hiv-infected patients: A  
1464 prospective cohort study. *Am J Transplant*. 2012; **12**: 2465-2476.

1465 238 Moreno A, Cervera C, Fortun J, et al. Epidemiology and outcome of infections in human  
1466 immunodeficiency virus/hepatitis c virus-coinfected liver transplant recipients: A fipse/gesida  
1467 prospective cohort study. *Liver Transpl*. 2012; **18**: 70-81.

1468 239 Woitas RP, Rockstroh JK, Theisen A, Leutner C, Sauerbruch T, Spengler U. Changing role of  
1469 invasive aspergillosis in aids--a case control study. *J Infect*. 1998; **37**: 116-122.

1470 240 Lortholary O, Meyohas MC, Dupont B, et al. Invasive aspergillosis in patients with acquired  
1471 immunodeficiency syndrome: Report of 33 cases. French cooperative study group on  
1472 aspergillosis in aids. *The American journal of medicine*. 1993; **95**: 177-187.

1473 241 Denning DW, Follansbee SE, Scolaro M, Norris S, Edelstein H, Stevens DA. Pulmonary  
1474 aspergillosis in the acquired immunodeficiency syndrome. *N Engl J Med*. 1991; **324**: 654-662.

1475 242 Antinori S, Nebuloni M, Magni C, et al. Trends in the postmortem diagnosis of opportunistic  
1476 invasive fungal infections in patients with aids: A retrospective study of 1,630 autopsies  
1477 performed between 1984 and 2002. *Am J Clin Pathol*. 2009; **132**: 221-227.

1478 243 Chen J, Yang Q, Huang J, Li L. Clinical findings in 19 cases of invasive pulmonary aspergillosis  
1479 with liver cirrhosis. *Multidiscip Respir Med*. 2014; **9**: 1.

1480 244 Jeurissen S, Vogelaers D, Sermijn E, et al. Invasive aspergillosis in patients with cirrhosis, a  
1481 case report and review of the last 10 years. *Acta Clin Belg*. 2013; **68**: 368-375.

1482 245 Vandewoude K, Blot S, Benoit D, Depuydt P, Vogelaers D, Colardyn F. Invasive aspergillosis in  
1483 critically ill patients: Analysis of risk factors for acquisition and mortality. *Acta Clin Belg*. 2004;  
1484 **59**: 251-257.

1485 246 Cheruvattath R, Balan V. Infections in patients with end-stage liver disease. *J Clin*  
1486 *Gastroenterol*. 2007; **41**: 403-411.

1487 247 Falcone M, Massetti AP, Russo A, Vullo V, Venditti M. Invasive aspergillosis in patients with  
1488 liver disease. *Medical mycology*. 2011; **49**: 406-413.

1489 248 Russo A, Giuliano S, Vena A, et al. Predictors of mortality in non-neutropenic patients with  
1490 invasive pulmonary aspergillosis: Does galactomannan have a role? *Diagn Microbiol Infect*  
1491 *Dis*. 2014; **80**: 83-86.

1492 249 Delsuc C, Cottureau A, Frealle E, et al. Putative invasive pulmonary aspergillosis in critically ill  
1493 patients with chronic obstructive pulmonary disease: A matched cohort study. *Crit Care*.  
1494 2015; **19**: 421.

1495 250 Tortorano AM, Dho G, Prigitano A, et al. Invasive fungal infections in the intensive care unit:  
1496 A multicentre, prospective, observational study in Italy (2006-2008). *Mycoses*. 2012; **55**: 73-  
1497 79.

1498 251 Jensen J, Guinea J, Torres-Narbona M, Munoz P, Pelaez T, Bouza E. Post-surgical invasive  
1499 aspergillosis: An uncommon and under-appreciated entity. *J Infect*. 2010; **60**: 162-167.



1500 252 Vehreschild JJ, Brockelmann PJ, Bangard C, et al. Pandemic 2009 influenza a(h1n1) virus  
1501 infection coinciding with invasive pulmonary aspergillosis in neutropenic patients. *Epidemiol*  
1502 *Infect.* 2012; **140**: 1848-1852.

1503 253 Garnacho-Montero J, Amaya-Villar R, Ortiz-Leyba C, et al. Isolation of aspergillus spp. From  
1504 the respiratory tract in critically ill patients: Risk factors, clinical presentation and outcome.  
1505 *Crit Care.* 2005; **9**: R191-199.

1506 254 Koulenti D, Garnacho-Montero J, Blot S. Approach to invasive pulmonary aspergillosis in  
1507 critically ill patients. *Curr Opin Infect Dis.* 2014; **27**: 174-183.

1508 255 Bassetti M, Righi E, De Pascale G, et al. How to manage aspergillosis in non-neutropenic  
1509 intensive care unit patients. *Crit Care.* 2014; **18**: 458.

1510 256 Dimopoulos G, Frantzeskaki F, Poulakou G, Armaganidis A. Invasive aspergillosis in the  
1511 intensive care unit. *Ann N Y Acad Sci.* 2012; **1272**: 31-39.

1512 257 Guinea J, Torres-Narbona M, Gijon P, et al. Pulmonary aspergillosis in patients with chronic  
1513 obstructive pulmonary disease: Incidence, risk factors, and outcome. *Clin Microbiol Infect.*  
1514 2010; **16**: 870-877.

1515 258 Tutar N, Metan G, Koc AN, et al. Invasive pulmonary aspergillosis in patients with chronic  
1516 obstructive pulmonary disease. *Multidiscip Respir Med.* 2013; **8**: 59.

1517 259 Giannella M, Munoz P, Guinea J, Escribano P, Rodriguez-Creixems M, Bouza E. Growth of  
1518 aspergillus in blood cultures: Proof of invasive aspergillosis in patients with chronic  
1519 obstructive pulmonary disease? *Mycoses.* 2013; **56**: 488-490.

1520 260 Eworo A, Munoz P, Yanez JF, et al. [cardiac invasive aspergillosis in a heart transplant  
1521 recipient]. *Rev Iberoam Micol.* 2011; **28**: 134-138.

1522 261 El-Sayed Ahmed MM, Almanfi A, Aftab M, Singh SK, Mallidi HR, Frazier OH. Aspergillus  
1523 mediastinitis after orthotopic heart transplantation: A case report. *Tex Heart Inst J.* 2015; **42**:  
1524 468-470.

1525 262 Wiltberger G, Schmelzle M, Schubert S, et al. Invasive cardiac aspergillosis after orthotopic  
1526 liver transplantation. *Z Gastroenterol.* 2014; **52**: 813-817.

1527 263 Spapen H, Spapen J, Taccone FS, et al. Cerebral aspergillosis in adult critically ill patients: A  
1528 descriptive report of 10 patients from the aspiku cohort. *Int J Antimicrob Agents*. 2014; **43**:  
1529 165-169.

1530 264 Sole A, Ussetti P. [mold infections in lung transplants]. *Rev Iberoam Micol*. 2014; **31**: 229-236.

1531 265 Fortun J, Meije Y, Fresco G, Moreno S. [aspergillosis. Clinical forms and treatment]. *Enferm*  
1532 *Infecc Microbiol Clin*. 2012; **30**: 201-208.

1533 266 Singh N, Sun HY. Iron overload and unique susceptibility of liver transplant recipients to  
1534 disseminated disease due to opportunistic pathogens. *Liver Transpl*. 2008; **14**: 1249-1255.

1535 267 Shields RK, Nguyen MH, Shullo MA, et al. Invasive aspergillosis among heart transplant  
1536 recipients is rare but causes rapid death due to septic shock and multiple organ dysfunction  
1537 syndrome. *Scand J Infect Dis*. 2012; **44**: 982-986.

1538 268 Perfect JR, Cox GM, Lee JY, et al. The impact of culture isolation of aspergillus species: A  
1539 hospital-based survey of aspergillosis. *Clin Infect Dis*. 2001; **33**: 1824-1833.

1540 269 Horvath JA, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive  
1541 pulmonary aspergillosis. *The American journal of medicine*. 1996; **100**: 171-178.

1542 270 Escribano P, Marcos-Zambrano LJ, Pelaez T, et al. Sputum and bronchial secretion samples  
1543 are equally useful as bronchoalveolar lavage samples for the diagnosis of invasive pulmonary  
1544 aspergillosis in selected patients. *Medical mycology*. 2015; **53**: 235-240.

1545 271 Munoz P, Alcala L, Sanchez Conde M, et al. The isolation of aspergillus fumigatus from  
1546 respiratory tract specimens in heart transplant recipients is highly predictive of invasive  
1547 aspergillosis. *Transplantation*. 2003; **75**: 326-329.

1548 272 Barton RC, Hobson RP, McLoughlin H, Morris A, Datta B. Assessment of the significance of  
1549 respiratory culture of aspergillus in the non-neutropenic patient. A critique of published  
1550 diagnostic criteria. *Eur J Clin Microbiol Infect Dis*. 2013; **32**: 923-928.

1551 273 Zaspel U, Denning DW, Lemke AJ, et al. Diagnosis of ipa in hiv: The role of the chest x-ray and  
1552 radiologist. *Eur Radiol*. 2004; **14**: 2030-2037.

1553 274 Munoz P, Vena A, Ceron I, et al. Invasive pulmonary aspergillosis in heart transplant  
1554 recipients: Two radiologic patterns with a different prognosis. *J Heart Lung Transplant*. 2014;  
1555 **33**: 1034-1040.

1556 275 Blot SI, Taccone FS, Van den Abeele AM, et al. A clinical algorithm to diagnose invasive  
1557 pulmonary aspergillosis in critically ill patients. *Am J Respir Crit Care Med*. 2012; **186**: 56-64.

1558 276 Bulpa P, Dive A. Diagnosis of invasive bronchial-pulmonary aspergillosis in patients with  
1559 chronic obstructive respiratory diseases. *Crit Care*. 2011; **15**: 420; author reply 420.

1560 277 Singh N, Winston DJ, Limaye AP, et al. Performance characteristics of galactomannan and  
1561 beta-d-glucan in high-risk liver transplant recipients. *Transplantation*. 2015; **99**: 2543-2550.

1562 278 Guinea J, Padilla C, Escribano P, et al. Evaluation of mycassay aspergillus for diagnosis of  
1563 invasive pulmonary aspergillosis in patients without hematological cancer. *PLoS One*. 2013; **8**:  
1564 e61545.

1565 279 Zarrinfar H, Makimura K, Satoh K, Khodadadi H, Mirhendi H. Incidence of pulmonary  
1566 aspergillosis and correlation of conventional diagnostic methods with nested pcr and real-  
1567 time pcr assay using bal fluid in intensive care unit patients. *J Clin Lab Anal*. 2013; **27**: 181-  
1568 185.

1569 280 Chong GL, van de Sande WW, Dingemans GJ, et al. Validation of a new aspergillus real-time  
1570 pcr assay for direct detection of aspergillus and azole resistance of aspergillus fumigatus on  
1571 bronchoalveolar lavage fluid. *Journal of clinical microbiology*. 2015; **53**: 868-874.

1572 281 Fortun J, Martin-Davila P, Gomez Garcia de la Pedrosa E, et al. Galactomannan in  
1573 bronchoalveolar lavage fluid for diagnosis of invasive aspergillosis in non-hematological  
1574 patients. *J Infect*. 2016; **72**: 738-744.

1575 282 Fortun J, Martin-Davila P, Alvarez ME, et al. False-positive results of aspergillus  
1576 galactomannan antigenemia in liver transplant recipients. *Transplantation*. 2009; **87**: 256-  
1577 260.

1578 283 Cai X, Ni W, Wei C, Cui J. Diagnostic value of the serum galactomannan and (1, 3)-beta-d-  
1579 glucan assays for invasive pulmonary aspergillosis in non-neutropenic patients. *Intern Med*.  
1580 2014; **53**: 2433-2437.

1581 284 Eigl S, Prattes J, Lackner M, et al. Multicenter evaluation of a lateral-flow device test for  
1582 diagnosing invasive pulmonary aspergillosis in icu patients. *Crit Care*. 2015; **19**: 178.

1583 285 Prattes J, Flick H, Pruller F, et al. Novel tests for diagnosis of invasive aspergillosis in patients  
1584 with underlying respiratory diseases. *Am J Respir Crit Care Med*. 2014; **190**: 922-929.

1585 286 Lopez-Medrano F, Fernandez-Ruiz M, Silva JT, et al. Clinical presentation and determinants of  
1586 mortality of invasive pulmonary aspergillosis in kidney transplant recipients: A multinational  
1587 cohort study. *Am J Transplant*. 2016.

1588 287 Cherian T, Giakoustidis A, Yokoyama S, et al. Treatment of refractory cerebral aspergillosis in  
1589 a liver transplant recipient with voriconazole: Case report and review of the literature. *Exp*  
1590 *Clin Transplant*. 2012; **10**: 482-486.

1591 288 Patel DA, Gao X, Stephens JM, Forshag MS, Tarallo M. Us hospital database analysis of  
1592 invasive aspergillosis in the chronic obstructive pulmonary disease non-traditional host. *J*  
1593 *Med Econ*. 2011; **14**: 227-237.

1594 289 Singh N, Limaye AP, Forrest G, et al. Combination of voriconazole and caspofungin as primary  
1595 therapy for invasive aspergillosis in solid organ transplant recipients: A prospective,  
1596 multicenter, observational study. *Transplantation*. 2006; **81**: 320-326.

1597 290 Luong ML, Hosseini-Moghaddam SM, Singer LG, et al. Risk factors for voriconazole  
1598 hepatotoxicity at 12 weeks in lung transplant recipients. *Am J Transplant*. 2012; **12**: 1929-  
1599 1935.

1600 291 Shoham S, Ostrander D, Marr K. Posaconazole liquid suspension in solid organ transplant  
1601 recipients previously treated with voriconazole. *Transpl Infect Dis*. 2015; **17**: 493-496.

1602 292 Hoenigl M, Duettmann W, Raggam RB, et al. Potential factors for inadequate voriconazole  
1603 plasma concentrations in intensive care unit patients and patients with hematological  
1604 malignancies. *Antimicrob Agents Chemother*. 2013; **57**: 3262-3267.

1605 293 Kim SH, Kwon JC, Park C, et al. Therapeutic drug monitoring and safety of intravenous  
1606 voriconazole formulated with sulfobutylether beta-cyclodextrin in haematological patients  
1607 with renal impairment. *Mycoses*. 2016.

1608 294 Guinea J, Escribano P, Marcos-Zambrano LJ, et al. Therapeutic drug monitoring of  
1609 voriconazole helps to decrease the percentage of patients with off-target trough serum  
1610 levels. *Medical mycology*. 2016; **54**: 353-360.

1611 295 Vanstraelen K, Wauters J, Vercammen I, et al. Impact of hypoalbuminemia on voriconazole  
1612 pharmacokinetics in critically ill adult patients. *Antimicrob Agents Chemother*. 2014; **58**:  
1613 6782-6789.

1614 296 Shalhoub S, Luong ML, Howard SJ, et al. Rate of cyp51a mutation in aspergillus fumigatus  
1615 among lung transplant recipients with targeted prophylaxis. *J Antimicrob Chemother*. 2015;  
1616 **70**: 1064-1067.

1617 297 Escribano P, Pelaez T, Munoz P, Bouza E, Guinea J. Is azole resistance in aspergillus fumigatus  
1618 a problem in Spain? *Antimicrob Agents Chemother*. 2013; **57**: 2815-2820.

1619 298 Fuhren J, Voskuil WS, Boel CH, et al. High prevalence of azole resistance in aspergillus  
1620 fumigatus isolates from high-risk patients. *J Antimicrob Chemother*. 2015; **70**: 2894-2898.

1621 299 Egli A, Fuller J, Humar A, et al. Emergence of aspergillus calidoustus infection in the era of  
1622 posttransplantation azole prophylaxis. *Transplantation*. 2012; **94**: 403-410.

1623 300 Kuipers S, Bruggemann RJ, de Sevaux RG, et al. Failure of posaconazole therapy in a renal  
1624 transplant patient with invasive aspergillosis due to aspergillus fumigatus with attenuated  
1625 susceptibility to posaconazole. *Antimicrob Agents Chemother*. 2011; **55**: 3564-3566.

1626 301 Singh N, Suarez JF, Avery R, et al. Immune reconstitution syndrome-like entity in lung  
1627 transplant recipients with invasive aspergillosis. *Transpl Immunol*. 2013; **29**: 109-113.

1628 302 Schaenman JM. Is universal antifungal prophylaxis mandatory in lung transplant patients?  
1629 *Curr Opin Infect Dis*. 2013; **26**: 317-325.

1630 303 Tofte N, Jensen C, Tvede M, Andersen CB, Carlsen J, Iversen M. Use of prophylactic  
1631 voriconazole for three months after lung transplantation does not reduce infection with  
1632 aspergillus: A retrospective study of 147 patients. *Scand J Infect Dis*. 2012; **44**: 835-841.

1633 304 Bhaskaran A, Mumtaz K, Husain S. Anti-aspergillus prophylaxis in lung transplantation: A  
1634 systematic review and meta-analysis. *Curr Infect Dis Rep*. 2013; **15**: 514-525.

1635 305 Koo S, Kubiak DW, Issa NC, et al. A targeted peritransplant antifungal strategy for the  
1636 prevention of invasive fungal disease after lung transplantation: A sequential cohort analysis.  
1637 *Transplantation*. 2012; **94**: 281-286.

1638 306 Munoz P, Rojas L, Cervera C, et al. Poor compliance with antifungal drug use guidelines by  
1639 transplant physicians: A framework for educational guidelines and an international  
1640 consensus on patient safety. *Clin Transplant*. 2012; **26**: 87-96.

1641 307 He SY, Makhzoumi ZH, Singer JP, Chin-Hong PV, Arron ST. Practice variation in aspergillus  
1642 prophylaxis and treatment among lung transplant centers: A national survey. *Transpl Infect*  
1643 *Dis*. 2015; **17**: 14-20.

1644 308 Saliba F, Pascher A, Cointault O, et al. Randomized trial of micafungin for the prevention of  
1645 invasive fungal infection in high-risk liver transplant recipients. *Clin Infect Dis*. 2015; **60**: 997-  
1646 1006.

1647 309 Peghin M, Monforte V, Martin-Gomez MT, et al. 10 years of prophylaxis with nebulized  
1648 liposomal amphotericin b and the changing epidemiology of aspergillus spp. Infection in lung  
1649 transplantation. *Transpl Int*. 2016; **29**: 51-62.

1650 310 Patel TS, Eschenauer GA, Stuckey LJ, Carver PL. Antifungal prophylaxis in lung transplant  
1651 recipients. *Transplantation*. 2016.

1652 311 Fortun J, Muriel A, Martin-Davila P, et al. Caspofungin versus fluconazole as prophylaxis of  
1653 invasive fungal infection in high-risk liver transplantation recipients: A propensity score  
1654 analysis. *Liver Transpl*. 2016; **22**: 427-435.

1655 312 Kato K, Nagao M, Nakano S, et al. Itraconazole prophylaxis for invasive aspergillus infection in  
1656 lung transplantation. *Transpl Infect Dis*. 2014; **16**: 340-343.

1657 313 Balogh J, Gordon Burroughs S, Boktour M, et al. Efficacy and cost-effectiveness of  
1658 voriconazole prophylaxis for prevention of invasive aspergillosis in high-risk liver transplant  
1659 recipients. *Liver Transpl*. 2016; **22**: 163-170.

1660 314 Aguado JM, Varo E, Usetti P, et al. Safety of anidulafungin in solid organ transplant  
1661 recipients. *Liver Transpl*. 2012; **18**: 680-685.

1662 315 Husain S, Zaldonis D, Kusne S, Kwak EJ, Paterson DL, McCurry KR. Variation in antifungal  
1663 prophylaxis strategies in lung transplantation. *Transpl Infect Dis*. 2006; **8**: 213-218.

1664 316 Taccone A, Occhi M, Garaventa A, Manfredini L, Viscoli C. Ct of invasive pulmonary  
1665 aspergillosis in children with cancer. *Pediatr Radiol*. 1993; **23**: 177-180.

1666 317 Archibald S, Park J, Geyer JR, Hawkins DS. Computed tomography in the evaluation of febrile  
1667 neutropenic pediatric oncology patients. *Pediatr Infect Dis J*. 2001; **20**: 5-10.

1668 318 Burgos A, Zaoutis TE, Dvorak CC, et al. Pediatric invasive aspergillosis: A multicenter  
1669 retrospective analysis of 139 contemporary cases. *Pediatrics*. 2008; **121**: e1286-1294.

1670 319 Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay:  
1671 A meta-analysis. *Clin Infect Dis*. 2006; **42**: 1417-1727.

1672 320 Hovi L, Saxen H, Saarinen-Pihkala UM, Vettenranta K, Meri T, Richardson M. Prevention and  
1673 monitoring of invasive fungal infections in pediatric patients with cancer and hematologic  
1674 disorders. *Pediatric blood & cancer*. 2007; **48**: 28-34.

1675 321 Steinbach WJ, Addison RM, McLaughlin L, et al. Prospective aspergillus galactomannan  
1676 antigen testing in pediatric hematopoietic stem cell transplant recipients. *Pediatr Infect Dis J*.  
1677 2007; **26**: 558-564.

1678 322 Hayden R, Pounds S, Knapp K, et al. Galactomannan antigenemia in pediatric oncology  
1679 patients with invasive aspergillosis. *Pediatr Infect Dis J*. 2008; **27**: 815-819.

1680 323 Castagnola E, Furfaro E, Caviglia I, et al. Performance of the galactomannan antigen  
1681 detection test in the diagnosis of invasive aspergillosis in children with cancer or undergoing  
1682 haemopoietic stem cell transplantation. *Clin Microbiol Infect*. 2010; **16**: 1197-1203.

1683 324 Fisher BT, Zaoutis TE, Park JR, et al. Galactomannan antigen testing for diagnosis of invasive  
1684 aspergillosis in pediatric hematology patients. *J Pediatric Infect Dis Soc*. 2012; **1**: 103-111.

1685 325 Choi SH, Kang ES, Eo H, et al. Aspergillus galactomannan antigen assay and invasive  
1686 aspergillosis in pediatric cancer patients and hematopoietic stem cell transplant recipients.  
1687 *Pediatric blood & cancer*. 2013; **60**: 316-322.

1688 326 Jha AK, Bansal D, Chakrabarti A, Shivaprakash MR, Trehan A, Marwaha RK. Serum  
1689 galactomannan assay for the diagnosis of invasive aspergillosis in children with  
1690 haematological malignancies. *Mycoses*. 2013; **56**: 442-448.

1691 327 Dinand V, Anjan M, Oberoi JK, et al. Threshold of galactomannan antigenemia positivity for  
1692 early diagnosis of invasive aspergillosis in neutropenic children. *J Microbiol Immunol Infect.*  
1693 2016; **49**: 66-73.

1694 328 Smith PB, Benjamin DK, Jr., Alexander BD, Johnson MD, Finkelman MA, Steinbach WJ.  
1695 Quantification of 1,3-beta-d-glucan levels in children: Preliminary data for diagnostic use of  
1696 the beta-glucan assay in a pediatric setting. *Clin Vaccine Immunol.* 2007; **14**: 924-925.

1697 329 Zhao L, Tang JY, Wang Y, et al. [value of plasma beta-glucan in early diagnosis of invasive  
1698 fungal infection in children]. *Zhongguo Dang Dai Er Ke Za Zhi.* 2009; **11**: 905-908.

1699 330 Mularoni A, Furfaro E, Faraci M, et al. High levels of beta-d-glucan in immunocompromised  
1700 children with proven invasive fungal disease. *Clin Vaccine Immunol.* 2010; **17**: 882-883.

1701 331 Badiie P, Alborzi A, Karimi M, et al. Diagnostic potential of nested pcr, galactomannan eia,  
1702 and beta-d-glucan for invasive aspergillosis in pediatric patients. *J Infect Dev Ctries.* 2012; **6**:  
1703 352-357.

1704 332 Koltze A, Rath P, Schoning S, et al. Beta-d-glucan screening for detection of invasive fungal  
1705 disease in children undergoing allogeneic hematopoietic stem cell transplantation. *Journal of*  
1706 *clinical microbiology.* 2015; **53**: 2605-2610.

1707 333 Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment  
1708 of acute invasive aspergillosis. *Clin Infect Dis.* 2002; **34**: 563-571.

1709 334 Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis,  
1710 scedosporiosis and other invasive fungal infections in children. *Pediatr Infect Dis J.* 2002; **21**:  
1711 240-248.

1712 335 Maertens J, Raad I, Petrikos G, et al. Efficacy and safety of caspofungin for treatment of  
1713 invasive aspergillosis in patients refractory to or intolerant of conventional antifungal  
1714 therapy. *Clin Infect Dis.* 2004; **39**: 1563-1571.

1715 336 Raad II, Hanna HA, Boktour M, et al. Novel antifungal agents as salvage therapy for invasive  
1716 aspergillosis in patients with hematologic malignancies: Posaconazole compared with high-  
1717 dose lipid formulations of amphotericin b alone or in combination with caspofungin.  
1718 *Leukemia.* 2008; **22**: 496-503.



1719 337 Cornely OA, Maertens J, Bresnik M, Ullmann AJ, Ebrahimi R, Herbrecht R. Treatment  
1720 outcome of invasive mould disease after sequential exposure to azoles and liposomal  
1721 amphotericin b. *J Antimicrob Chemother.* 2010; **65**: 114-117.

1722 338 Winston DJ, Bartoni K, Territo MC, Schiller GJ. Efficacy, safety, and breakthrough infections  
1723 associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem  
1724 cell transplantation recipients. *Biology of blood and marrow transplantation : journal of the*  
1725 *American Society for Blood and Marrow Transplantation.* 2011; **17**: 507-515.

1726 339 De la Serna J, Jarque I, Lopez-Jimenez J, et al. Treatment of invasive fungal infections in high  
1727 risk hematological patients. The outcome with liposomal amphotericin b is not negatively  
1728 affected by prior administration of mold-active azoles. *Rev Esp Quimioter.* 2013; **26**: 64-69.

1729 340 Auberger J, Lass-Flörl C, Aigner M, Clausen J, Gastl G, Nachbaur D. Invasive fungal  
1730 breakthrough infections, fungal colonization and emergence of resistant strains in high-risk  
1731 patients receiving antifungal prophylaxis with posaconazole: Real-life data from a single-  
1732 centre institutional retrospective observational study. *J Antimicrob Chemother.* 2012; **67**:  
1733 2268-2273.

1734 341 Lehrnbecher T, Kalkum M, Champer J, Tramsen L, Schmidt S, Klingebiel T. Immunotherapy in  
1735 invasive fungal infection--focus on invasive aspergillosis. *Current pharmaceutical design.*  
1736 2013; **19**: 3689-3712.

1737 342 Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus  
1738 conventional amphotericin b for the treatment of pyrexia of unknown origin in neutropenic  
1739 patients. *Br J Haematol.* 1997; **98**: 711-718.

1740 343 Maertens JA, Madero L, Reilly AF, et al. A randomized, double-blind, multicenter study of  
1741 caspofungin versus liposomal amphotericin b for empiric antifungal therapy in pediatric  
1742 patients with persistent fever and neutropenia. *Pediatr Infect Dis J.* 2010; **29**: 415-420.

1743 344 Caselli D, Paolicchi O. Empiric antibiotic therapy in a child with cancer and suspected  
1744 septicemia. *Pediatr Rep.* 2012; **4**: e2.

1745 345 Tan BH, Low JG, Chlebicka NL, et al. Galactomannan-guided preemptive vs. Empirical  
1746 antifungals in the persistently febrile neutropenic patient: A prospective randomized study.  
1747 *Int J Infect Dis.* 2011; **15**: e350-356.

1748 346 Castagnola E, Bagnasco F, Amoroso L, et al. Role of management strategies in reducing  
1749 mortality from invasive fungal disease in children with cancer or receiving hemopoietic stem  
1750 cell transplant: A single center 30-year experience. *Pediatr Infect Dis J*. 2014; **33**: 233-237.

1751 347 Borjesson J, Latifi A, Friman O, Beckman MO, Oldner A, Labruto F. Accuracy of low-dose chest  
1752 ct in intensive care patients. *Emerg Radiol*. 2011; **18**: 17-21.

1753 348 Yamamura J, Tornquist K, Buchert R, et al. Simulated low-dose computed tomography in  
1754 oncological patients: A feasibility study. *Journal of computer assisted tomography*. 2010; **34**:  
1755 302-308.

1756 349 Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes  
1757 in clinical trials of invasive fungal diseases: Mycoses study group and european organization  
1758 for research and treatment of cancer consensus criteria. *Clin Infect Dis*. 2008; **47**: 674-683.

1759 350 Vehreschild JJ, Heussel CP, Groll AH, et al. Serial assessment of pulmonary lesion volume by  
1760 computed tomography allows survival prediction in invasive pulmonary aspergillosis. *Eur*  
1761 *Radiol*. 2017.

1762 351 Nouer SA, Nucci M, Kumar NS, Graziutti M, Barlogie B, Anaissie E. Earlier response  
1763 assessment in invasive aspergillosis based on the kinetics of serum aspergillus  
1764 galactomannan: Proposal for a new definition. *Clin Infect Dis*. 2011; **53**: 671-676.

1765 352 Nucci M, Perfect JR. When primary antifungal therapy fails. *Clin Infect Dis*. 2008; **46**: 1426-  
1766 1433.

1767 353 Bennett JE. Salvage therapy for aspergillosis. *Clin Infect Dis*. 2005; **41 Suppl 6**: S387-388.

1768 354 Bergeron A, Porcher R, Menotti J, et al. Prospective evaluation of clinical and biological  
1769 markers to predict the outcome of invasive pulmonary aspergillosis in hematological  
1770 patients. *Journal of clinical microbiology*. 2012; **50**: 823-830.

1771 355 Maertens J, Buve K, Theunissen K, et al. Galactomannan serves as a surrogate endpoint for  
1772 outcome of pulmonary invasive aspergillosis in neutropenic hematology patients. *Cancer*.  
1773 2009; **115**: 355-362.

1774 356 Boutboul F, Alberti C, Leblanc T, et al. Invasive aspergillosis in allogeneic stem cell transplant  
1775 recipients: Increasing antigenemia is associated with progressive disease. *Clin Infect Dis*.  
1776 2002; **34**: 939-943.

1777 357 Miceli MH, Maertens J, Buve K, et al. Immune reconstitution inflammatory syndrome in  
1778 cancer patients with pulmonary aspergillosis recovering from neutropenia: Proof of principle,  
1779 description, and clinical and research implications. *Cancer*. 2007; **110**: 112-120.

1780 358 Almyroudis NG, Kontoyiannis DP, Sepkowitz KA, DePauw BE, Walsh TJ, Segal BH. Issues  
1781 related to the design and interpretation of clinical trials of salvage therapy for invasive mold  
1782 infection. *Clin Infect Dis*. 2006; **43**: 1449-1455.

1783 359 Bergeron A, Porcher R, Menotti J, et al. Prospective evaluation of clinical and biological  
1784 markers to predict the outcome of invasive pulmonary aspergillosis in hematological  
1785 patients. *Journal of clinical microbiology*. 2012; **50**: 823-830.

1786 360 Smith NL, Denning DW. Underlying conditions in chronic pulmonary aspergillosis including  
1787 simple aspergilloma. *Eur Respir J*. 2011; **37**: 865-872.

1788 361 Salzer HJ, Cornely OA. Awareness of predictors of mortality may help improve outcome in  
1789 chronic pulmonary aspergillosis. *Eur Respir J*. 2017; **49**.

1790 362 Muldoon EG, Sharman A, Page I, Bishop P, Denning DW. Aspergillus nodules; another  
1791 presentation of chronic pulmonary aspergillosis. *BMC Pulm Med*. 2016; **16**: 123.

1792 363 Salzer HJ, Heyckendorf J, Kalsdorf B, Rolling T, Lange C. Characterization of patients with  
1793 chronic pulmonary aspergillosis according to the new escmid/ers/ecmm and idsa guidelines.  
1794 *Mycoses*. 2017; **60**: 136-142.

1795 364 Dumollard C, Bailly S, Perriot S, et al. Prospective evaluation of a new aspergillus igg enzyme  
1796 immunoassay kit for diagnosis of chronic and allergic pulmonary aspergillosis. *Journal of*  
1797 *clinical microbiology*. 2016; **54**: 1236-1242.

1798 365 Farid S, Mohamed S, Devbhandari M, et al. Results of surgery for chronic pulmonary  
1799 aspergillosis, optimal antifungal therapy and proposed high risk factors for recurrence--a  
1800 national centre's experience. *J Cardiothorac Surg*. 2013; **8**: 180.

1801 366 Cadranet J, Philippe B, Hennequin C, et al. Voriconazole for chronic pulmonary aspergillosis: A  
1802 prospective multicenter trial. *Eur J Clin Microbiol Infect Dis*. 2012; **31**: 3231-3239.

1803 367 Al-Shair K, Atherton GT, Harris C, Ratcliffe L, Newton PJ, Denning DW. Long-term antifungal  
1804 treatment improves health status in patients with chronic pulmonary aspergillosis: A  
1805 longitudinal analysis. *Clin Infect Dis*. 2013; **57**: 828-835.

1806 368 Pasmans HL, Loosveld OJ, Schouten HC, Thunnissen F, van Engelshoven JM. Invasive  
1807 aspergillosis in immunocompromised patients: Findings on plain film and (hr)ct. *Eur J Radiol.*  
1808 1992; **14**: 37-40.

1809 369 Heussel CP, Kauczor HU, Heussel G, Mildenerberger P, Dueber C. Aneurysms complicating  
1810 inflammatory diseases in immunocompromised hosts: Value of contrast-enhanced ct.  
1811 *European radiology.* 1997; **7**: 316-319.

1812 370 Didier M, Guedin P, Staub F, et al. Pulmonary arterial mycotic pseudoaneurysms in a patient  
1813 with invasive pulmonary aspergillosis. Successful occlusion by coils. *American journal of*  
1814 *respiratory and critical care medicine.* 2014; **190**: 112-113.

1815 371 Denning DW, Kibbler CC, Barnes RA, British Society for Medical M. British society for medical  
1816 mycology proposed standards of care for patients with invasive fungal infections. *Lancet*  
1817 *Infect Dis.* 2003; **3**: 230-240.

1818 372 Vyzantiadis TA, Johnson EM, Kibbler CC. From the patient to the clinical mycology laboratory:  
1819 How can we optimise microscopy and culture methods for mould identification? *J Clin*  
1820 *Pathol.* 2012; **65**: 475-483.

1821 373 Lass-Flörl C, Resch G, Nachbaur D, et al. The value of computed tomography-guided  
1822 percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised  
1823 patients. *Clin Infect Dis.* 2007; **45**: e101-e104.

1824 374 Choi JK, Mauger J, McGowan KL. Immunohistochemical detection of aspergillus species in  
1825 pediatric tissue samples. *Am J Clin Pathol.* 2004; **121**: 18-25.

1826 375 Kaufman L, Standard PG, Jalbert M, Kraft DE. Immunohistologic identification of aspergillus  
1827 spp. And other hyaline fungi by using polyclonal fluorescent antibodies. *Journal of clinical*  
1828 *microbiology.* 1997; **35**: 2206-2209.

1829 376 Verweij PE, Smedts F, Poot T, Bult P, Hoogkamp-Korstanje JA, Meis JF. Immunoperoxidase  
1830 staining for identification of aspergillus species in routinely processed tissue sections. *J Clin*  
1831 *Pathol.* 1996; **49**: 798-801.

1832 377 Hayden RT, Isotalo PA, Parrett T, et al. In situ hybridization for the differentiation of  
1833 aspergillus, fusarium , and pseudallescheria species in tissue section. *Diagn Mol Pathol.*  
1834 2003; **12**: 21-26.

1835 378 Sundaram C, Umabala P, Laxmi V, et al. Pathology of fungal infections of the central nervous  
1836 system: 17 years' experience from southern india. *Histopathology*. 2006; **49**: 396-405.

1837 379 Chander J, Chakrabarti A, Sharma A, Saini JS, Panigarhi D. Evaluation of calcofluor staining in  
1838 the diagnosis of fungal corneal ulcer. *Mycoses*. 1993; **36**: 243-245.

1839 380 Baxter CG, Jones AM, Webb K, Denning DW. Homogenisation of cystic fibrosis sputum by  
1840 sonication--an essential step for aspergillus pcr. *J Microbiol Methods*. 2011; **85**: 75-81.

1841 381 Cuenca-Estrella M, Bassetti M, Lass-Flörl C, Roca C, Richardson M, Rogers TR. Detection and  
1842 investigation of invasive mould disease. *J Antimicrob Chemother*. 2011; **66**: i15-i24.

1843 382 Richardson M, Ellis M. Clinical and laboratory diagnosis. *Hosp Med*. 2000; **61**: 610-614.

1844 383 Alanio A, Beretti JL, Dauphin B, et al. Matrix-assisted laser desorption ionization time-of-flight  
1845 mass spectrometry for fast and accurate identification of clinically relevant aspergillus  
1846 species. *Clin Microbiol Infect*. 2011; **17**: 750-755.

1847 384 Bille E, Dauphin B, Leto J, et al. Maldi-tof ms andromas strategy for the routine identification  
1848 of bacteria, mycobacteria, yeasts, aspergillus spp. And positive blood cultures. *Clin Microbiol*  
1849 *Infect*. 2012; **18**: 1117-1125.

1850 385 De Carolis E, Vella A, Florio AR, et al. Use of matrix-assisted laser desorption ionization-time  
1851 of flight mass spectrometry for caspofungin susceptibility testing of candida and aspergillus  
1852 species. *Journal of clinical microbiology*. 2012; **50**: 2479-2483.

1853 386 Lau AF, Drake SK, Calhoun LB, Henderson CM, Zelazny AM. Development of a clinically  
1854 comprehensive database and a simple procedure for identification of molds from solid media  
1855 by matrix-assisted laser desorption ionization-time of flight mass spectrometry. *Journal of*  
1856 *clinical microbiology*. 2013; **51**: 828-834.

1857 387 Balajee SA, Borman AM, Brandt ME, et al. Sequence-based identification of aspergillus ,  
1858 fusarium , and mucorales species in the clinical mycology laboratory: Where are we and  
1859 where should we go from here? *Journal of clinical microbiology*. 2009; **47**: 877-884.

1860 388 Samson RA, Hong S, Peterson SW, Frisvad JC, Varga J. Polyphasic taxonomy of aspergillus  
1861 section fumigati and its teleomorph neosartorya. *Stud Mycol*. 2007; **59**: 147-203.

1862 389 Caramalho R, Gusmão L, Lackner M, Amorim A, Araujo R. Snapafu: A novel single nucleotide  
1863 polymorphism multiplex assay for *aspergillus fumigatus* direct detection, identification and  
1864 genotyping in clinical specimens. *PLoS One*. 2013; **8**: e75968.

1865 390 Hurst SF, Kidd SE, Morrissey CO, et al. Interlaboratory reproducibility of a single-locus  
1866 sequence-based method for strain typing of *aspergillus fumigatus* *Journal of clinical*  
1867 *microbiology*. 2009; **47**: 1562-1564.

1868 391 Guinea J, García de Viedma D, Peláez T, et al. Molecular epidemiology of *aspergillus*  
1869 *fumigatus* : An in-depth genotypic analysis of isolates involved in an outbreak of invasive  
1870 aspergillosis. *Journal of clinical microbiology*. 2011; **49**: 3498-3503.

1871 392 Rougeron A, Giraud S, Razafimandimby B, Meis JF, Bouchara JP, Klaassen CH. Different  
1872 colonization patterns of *aspergillus terreus* in patients with cystic fibrosis. *Clin Microbiol*  
1873 *Infect*. 2014; **20**: 327-333.

1874 393 Maertens J, Van Eldere J, Verhaegen J, Verbeken E, Verschakelen J, Boogaerts M. Use of  
1875 circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic  
1876 stem cell transplant recipients. *The Journal of infectious diseases*. 2002; **186**: 1297-1306.

1877 394 Leeflang MM, Debets-Ossenkopp YJ, Visser CE, et al. Galactomannan detection for invasive  
1878 aspergillosis in immunocompromised patients. *The Cochraen Collaboration*. 2008; **4**:  
1879 CD007394.

1880 395 Furfaro E, Mikulska M, Miletich F, Viscoli C. Galactomannan: Testing the same sample twice?  
1881 *Transpl Infect Dis*. 2012; **14**: E38-E39.

1882 396 Morrissey CO, Chen SC, Sorrell TC, et al. Galactomannan and pcr versus culture and histology  
1883 for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology  
1884 patients: A randomised controlled trial. *Lancet Infect Dis*. 2013; **13**: 519-528.

1885 397 Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating  
1886 galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged  
1887 neutropenic patients and stem cell transplantation recipients: A prospective validation.  
1888 *Blood*. 2001; **97**: 1604-1610.

1889 398 Hoenigl M, Seeber K, Koidl C, et al. Sensitivity of galactomannan enzyme immunoassay for  
1890 diagnosing breakthrough invasive aspergillosis under antifungal prophylaxis and empirical  
1891 therapy. *Mycoses*. 2013; **56**: 471-476.

1892 399 Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the  
1893 aspergillus galactomannan enzyme immunoassay. *Clin Infect Dis*. 2005; **40**: 1762-1769.

1894 400 Cordonnier C, Botterel F, Ben Amor R, et al. Correlation between galactomannan antigen  
1895 levels in serum and neutrophil counts in haematological patients with invasive aspergillosis.  
1896 *Clin Microbiol Infect*. 2009; **15**: 81-86.

1897 401 Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-  
1898 based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal  
1899 infection: A prospective feasibility study. *Clin Infect Dis*. 2005; **41**: 1242-1250.

1900 402 Guinea J, Jensen J, Peláez T, et al. Value of a single galactomannan determination (platelia)  
1901 for the diagnosis of invasive aspergillosis in non-hematological patients with clinical isolation  
1902 of aspergillus spp. *Medical mycology*. 2008; **46**: 575-579.

1903 403 Husain S, Kwak EJ, Obman A, et al. Prospective assessment of platelia aspergillus  
1904 galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant  
1905 recipients. *Am J Transplant*. 2004; **4**: 796-802.

1906 404 Tabarsi P, Soraghi A, Marjani M, et al. Comparison of serum and bronchoalveolar lavage  
1907 galactomannan in diagnosing invasive aspergillosis in solid-organ transplant recipients. *Exp*  
1908 *Clin Transplant*. 2012; **10**: 278-281.

1909 405 Guigue N, Menotti J, Ribaud P. False positive galactomannan test after ice-pop ingestion. *N*  
1910 *Engl J Med*. 2013; **369**: 97-98.

1911 406 Petraitiene R, Petraitis V, Witt JR, 3rd, et al. Galactomannan antigenemia after infusion of  
1912 gluconate-containing plasma-lyte. *Journal of clinical microbiology*. 2011; **49**: 4330-4332.

1913 407 Martin-Rabadan P, Gijon P, Alonso Fernandez R, Ballesteros M, Anguita J, Bouza E. False-  
1914 positive aspergillus antigenemia due to blood product conditioning fluids. *Clin Infect Dis*.  
1915 2012; **55**: e22-27.

1916 408 Mikulska M, Furfaro E, Del Bono V, et al. Piperacillin/tazobactam (tazocintm) seems to be no  
1917 longer responsible for false-positive results of the galactomannan assay. *J Antimicrob*  
1918 *Chemother.* 2012; **67**: 1746-1748.

1919 409 Vergidis P, Walker RC, Kaul DR, et al. False-positive aspergillus galactomannan assay in solid  
1920 organ transplant recipients with histoplasmosis. *Transpl Infect Dis.* 2012; **14**: 213-217.

1921 410 Huang YT, Hung CC, Liao CH, Sun HY, Chang SC, Chen YC. Detection of circulating  
1922 galactomannan in serum samples for diagnosis of penicillium marneffeii infection and  
1923 cryptococcosis among patients infected with human immunodeficiency virus. *Journal of*  
1924 *clinical microbiology.* 2007; **45**: 2858-2862.

1925 411 Nucci M, Carlesse F, Cappellano P, et al. Earlier diagnosis of invasive fusariosis with  
1926 aspergillus serum galactomannan testing. *PLoS One.* 2014; **9**: e87784.

1927 412 King ST, Stover KR. Considering confounders of the galactomannan index: The role of  
1928 piperacillin-tazobactam. *Clin Infect Dis.* 2014; **58**: 751-752.

1929 413 Chai LY, Kullberg BJ, Johnson EM, et al. Early serum galactomannan trend as a predictor of  
1930 outcome of invasive aspergillosis. *Journal of clinical microbiology.* 2012; **50**: 2330-2336.

1931 414 Luong ML, Clancy CJ, Vadnerkar A, et al. Comparison of an aspergillus real-time polymerase  
1932 chain reaction assay with galactomannan testing of bronchoalveolar lavage fluid for the  
1933 diagnosis of invasive pulmonary aspergillosis in lung transplant recipients. *Clin Infect Dis.*  
1934 2011; **52**: 1218-1226.

1935 415 Reinwald M, Spiess B, Heinz WJ, et al. Diagnosing pulmonary aspergillosis in patients with  
1936 hematological malignancies: A multicenter prospective evaluation of an aspergillus pcr  
1937 assay and a galactomannan elisa in bronchoalveolar lavage sample. *Eur J Haematol.* 2012; **89**:  
1938 120-127.

1939 416 Heng SC, Morrissey O, Chen SC, et al. Utility of bronchoalveolar lavage fluid galactomannan  
1940 alone or in combination with pcr for the diagnosis of invasive aspergillosis in adult  
1941 hematology patients: A systematic review and meta-analysis. *Crit Rev Microbiol.* 2015; **41**:  
1942 124-134.



1943 417 Zou M, Tang L, Zhao S, et al. Systematic review and meta-analysis of detecting  
1944 galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosis. *PLoS*  
1945 *One*. 2012; **7**: e43347.

1946 418 Fisher CE, Stevens AM, Leisenring W, Pergam SA, Boeckh M, Hohl TM. The serum  
1947 galactomannan index predicts mortality in hematopoietic stem cell transplant recipients with  
1948 invasive aspergillosis. *Clin Infect Dis*. 2013; **57**: 1001-1004.

1949 419 Verweij PE, Brinkman K, Kremer HP, Kullberg BJ, Meis JF. Aspergillus meningitis: Diagnosis by  
1950 non-culture-based microbiological methods and management. *Journal of clinical*  
1951 *microbiology*. 1999; **37**: 1186-1189.

1952 420 Viscoli C, Machetti M, Gazzola P, et al. Aspergillus galactomannan antigen in the  
1953 cerebrospinal fluid of bone marrow transplant recipients with probable cerebral aspergillosis.  
1954 *Journal of clinical microbiology*. 2002; **40**: 1496-1499.

1955 421 Klont RR, Mennink-Kersten MA, Verweij PE. Utility of aspergillus antigen detection in  
1956 specimens other than serum specimens. *Clin Infect Dis*. 2004; **39**: 1467-1474.

1957 422 Lu Y, Chen YQ, Guo YL, Qin SM, Wu C, Wang K. Diagnosis of invasive fungal disease using  
1958 serum (1-3)- $\beta$ -d-glucan: A bivariate meta-analysis. *Intern Med*. 2011; **50**: 2783-2791.

1959 423 Lamothe F, Cruciani M, Mengoli C, et al.  $\beta$ -glucan antigenemia assay for the diagnosis of  
1960 invasive fungal infections in patients with hematological malignancies: A systematic review  
1961 and meta-analysis of cohort studies from the third european conference on infections in  
1962 leukemia (ecil-3). *Clin Infect Dis*. 2012; **54**: 633-643.

1963 424 Senn L, Robinson JO, Schmidt S, et al. 1,3-beta-d-glucan antigenemia for early diagnosis of  
1964 invasive fungal infections in neutropenic patients with acute leukemia. *Clin Infect Dis*. 2008;  
1965 **46**: 878-885.

1966 425 Ellis M, Al-Ramadi B, Finkelman M, et al. Assessment of the clinical utility of serial beta-d-  
1967 glucan concentrations in patients with persistent neutropenic fever. *J Med Microbiol*. 2008;  
1968 **57**: 287-295.

1969 426 Kawazu M, Kanda Y, Nannya Y, et al. Prospective comparison of the diagnostic potential of  
1970 real-time pcr, double-sandwich enzyme-linked immunosorbent assay for galactomannan,

1971 and a (1-->3)-beta-d-glucan test in weekly screening for invasive aspergillosis in patients with  
1972 hematological disorders. *Journal of clinical microbiology*. 2004; **42**: 2733-2741.

1973 427 Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-d-glucan as a diagnostic adjunct for invasive fungal  
1974 infections: Validation, cutoff development, and performance in patients with acute  
1975 myelogenous leukemia and myelodysplastic syndrome. *Clin Infect Dis*. 2004; **39**: 199-205.

1976 428 Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1--  
1977 >3) beta-d-glucan assay as an aid to diagnosis of fungal infections in humans. *Clin Infect Dis*.  
1978 2005; **41**: 654-659.

1979 429 De Vlieger G, Lagrou K, Maertens J, Verbeken E, Meersseman W, Van Wijngaerden E. Beta-d-  
1980 glucan detection as a diagnostic test for invasive aspergillosis in immunocompromised  
1981 critically ill patients with symptoms of respiratory infection: An autopsy-based study. *Journal*  
1982 *of clinical microbiology*. 2011; **49**: 3783-3787.

1983 430 Del Bono V, Delfino E, Furfaro E, et al. Clinical performance of the (1,3)-beta-d-glucan assay  
1984 in early diagnosis of nosocomial candida bloodstream infections. *Clin Vaccine Immunol*. 2011;  
1985 **18**: 2113-2117.

1986 431 Acosta J, Catalan M, del Palacio-Pérez-Medel A, et al. Prospective study in critically ill non-  
1987 neutropenic patients: Diagnostic potential of (1,3)-β-d-glucan assay and circulating  
1988 galactomannan for the diagnosis of invasive fungal disease. *Eur J Clin Microbiol Infect Dis*.  
1989 2012; **31**: 721-731.

1990 432 Hoenigl M, Koidl C, Duettmann W, et al. Bronchoalveolar lavage lateral-flow device test for  
1991 invasive pulmonary aspergillosis diagnosis in haematological malignancy and solid organ  
1992 transplant patients. *J Infect*. 2012; **65**: 588-591.

1993 433 Held J, Schmidt T, Thornton CR, Kotter E, Bertz H. Comparison of a novel aspergillus lateral-  
1994 flow device and the platelia© galactomannan assay for the diagnosis of invasive aspergillosis  
1995 following haematopoietic stem cell transplantation. *Infection*. 2013; **41**: 1163-1169.

1996 434 Hoenigl M, Prattes J, Spiess B, et al. Performance of galactomannan, beta-d-glucan,  
1997 aspergillus lateral-flow device, conventional culture, and pcr tests with bronchoalveolar  
1998 lavage fluid for diagnosis of invasive pulmonary aspergillosis. *Journal of clinical microbiology*.  
1999 2014; **52**: 2039-2045.

2000 435 Einsele H, Quabeck K, Müller KD, et al. Prediction of invasive pulmonary aspergillosis from  
2001 colonisation of lower respiratory tract before marrow transplantation. *Lancet*. 1998; **352**:  
2002 1443.

2003 436 Tang CM, Holden DW, Aufauvre-Brown A, Cohen J. The detection of *aspergillus* spp. By the  
2004 polymerase chain reaction and its evaluation in bronchoalveolar lavage fluid. *Am Rev Respir*  
2005 *Dis*. 1993; **148**: 1313-1317.

2006 437 Verweij PE, Latge JP, Rijs AJ, et al. Comparison of antigen detection and pcr assay using  
2007 bronchoalveolar lavage fluid for diagnosing invasive pulmonary aspergillosis in patients  
2008 receiving treatment for hematological malignancies. *Journal of clinical microbiology*. 1995;  
2009 **33**: 3150-3153.

2010 438 Bretagne S, Costa JM, Marmorat-Khuong A, et al. Detection of *aspergillus* species DNA in  
2011 bronchoalveolar lavage samples by competitive pcr. *Journal of clinical microbiology*. 1995;  
2012 **33**: 1164-1168.

2013 439 Jones ME, Fox AJ, Barnes AJ, et al. Pcr-elisa for the early diagnosis of invasive pulmonary  
2014 *aspergillus* infection in neutropenic patients. *J Clin Pathol*. 1998; **51**: 652-656.

2015 440 Skladny H, Buchheidt D, Baust C, et al. Specific detection of *aspergillus* species in blood and  
2016 bronchoalveolar lavage samples of immunocompromised patients by two-step pcr. *Journal of*  
2017 *clinical microbiology*. 1999; **37**: 3865-3871.

2018 441 Buchheidt D, Baust C, Skladny H, et al. Detection of *aspergillus* species in blood and  
2019 bronchoalveolar lavage samples from immunocompromised patients by means of 2-step  
2020 polymerase chain reaction: Clinical results. *Clin Infect Dis*. 2001; **33**: 428-435.

2021 442 Hayette MP, Vaira D, Susin F, et al. Detection of *aspergillus* species DNA by pcr in  
2022 bronchoalveolar lavage fluid. *Journal of clinical microbiology*. 2001; **39**: 2338-2340.

2023 443 Melchers WJ, Verweij PE, van den Hurk P, et al. General primer-mediated pcr for detection of  
2024 *aspergillus* species. *Journal of clinical microbiology*. 1994; **32**: 1710-1717.

2025 444 Buchheidt D, Baust C, Skladny H, Baldus M, Bräuninger S, Hehlmann R. Clinical evaluation of a  
2026 polymerase chain reaction assay to detect *aspergillus* species in bronchoalveolar lavage  
2027 samples of neutropenic patients. *Br J Haematol*. 2002; **116**: 803-811.

2028 445 Raad I, Hanna H, Huaranga A, Sumoza D, Hachem R, Albitar M. Diagnosis of invasive  
2029 pulmonary aspergillosis using polymerase chain reaction-based detection of *aspergillus* in  
2030 bal. *Chest*. 2002; **121**: 1171-1176.

2031 446 Spiess B, Buchheidt D, Baust C, et al. Development of a lightcycler pcr assay for detection and  
2032 quantification of *aspergillus fumigatus* DNA in clinical samples from neutropenic patients.  
2033 *Journal of clinical microbiology*. 2003; **41**: 1811-1818.

2034 447 Meltiadis J, Melchers WJ, Meis JF, van den Hurk P, Jannes G, Verweij PE. Evaluation of a  
2035 polymerase chain reaction reverse hybridization line probe assay for the detection and  
2036 identification of medically important fungi in bronchoalveolar lavage fluids. *Medical*  
2037 *mycology*. 2003; **41**: 65-74.

2038 448 Sanguinetti M, Posteraro B, Pagano L, et al. Comparison of real-time pcr, conventional pcr,  
2039 and galactomannan antigen detection by enzyme-linked immunosorbent assay using  
2040 bronchoalveolar lavage fluid samples from hematology patients for diagnosis of invasive  
2041 pulmonary aspergillosis. *Journal of clinical microbiology*. 2003; **41**: 3922-3925.

2042 449 Rantakokko-Jalava K, Laaksonen S, Issakainen J, et al. Semiquantitative detection by real-time  
2043 pcr of *aspergillus fumigatus* in bronchoalveolar lavage fluids and tissue biopsy specimens  
2044 from patients with invasive aspergillosis. *Journal of clinical microbiology*. 2003; **41**: 4304-  
2045 4311.

2046 450 Lass-Flörl C, Gunsilius E, Gastl G, et al. Diagnosing invasive aspergillosis during antifungal  
2047 therapy by pcr analysis of blood samples. *Journal of clinical microbiology*. 2004; **42**: 4154-  
2048 4157.

2049 451 Musher B, Fredricks D, Leisenring W, Balajee SA, Smith C, Marr KA. *Aspergillus*  
2050 galactomannan enzyme immunoassay and quantitative pcr for diagnosis of invasive  
2051 aspergillosis with bronchoalveolar lavage fluid. *Journal of clinical microbiology*. 2004; **42**:  
2052 5517-5522.

2053 452 Khot PD, Ko DL, Hackman RC, Fredricks DN. Development and optimization of quantitative  
2054 pcr for the diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. *BMC Infect*  
2055 *Dis*. 2008; **8**: 73.

2056 453 Fréal E, Decrucq K, Botterel F, et al. Diagnosis of invasive aspergillosis using  
2057 bronchoalveolar lavage in haematology patients: Influence of bronchoalveolar lavage human  
2058 DNA content on real-time pcr performance. *Eur J Clin Microbiol Infect Dis*. 2009; **28**: 223-232.

2059 454 Torelli R, Sanguinetti M, Moody A, et al. Diagnosis of invasive aspergillosis by a commercial  
2060 real-time pcr assay for aspergillus DNA in bronchoalveolar lavage fluid samples from high-  
2061 risk patients compared to a galactomannan enzyme immunoassay. *Journal of clinical*  
2062 *microbiology*. 2011; **49**: 4273-4278.

2063 455 Buess M, Cathomas G, Halter J, et al. Aspergillus- pcr in bronchoalveolar lavage for detection  
2064 of invasive pulmonary aspergillosis in immunocompromised patients. *BMC Infect Dis*. 2012;  
2065 **12**: 237.

2066 456 Reinwald M, Hummel M, Kovalevskaya E, et al. Therapy with antifungals decreases the  
2067 diagnostic performance of pcr for diagnosing invasive aspergillosis in bronchoalveolar lavage  
2068 samples of patients with haematological malignancies. *J Antimicrob Chemother*. 2012; **67**:  
2069 2260-2267.

2070 457 Orsi CF, Gennari W, Venturelli C, et al. Performance of 2 commercial real-time polymerase  
2071 chain reaction assays for the detection of aspergillus and pneumocystis DNA in  
2072 bronchoalveolar lavage fluid samples from critical care patients. *Diagn Microbiol Infect Dis*.  
2073 2012; **73**: 138-143.

2074 458 Guinea J, Padilla C, Escibano P, et al. Evaluation of mycassayt aspergillus for diagnosis of  
2075 invasive pulmonary aspergillosis in patients without hematological cancer. *PLoS One*. 2013; **8**:  
2076 e61545.

2077 459 Steinmann J, Buer J, Rath PM, Paul A, Saner F. Invasive aspergillosis in two liver transplant  
2078 recipients: Diagnosis by septifast. *Transpl Infect Dis*. 2009; **11**: 175-178.

2079 460 Komatsu H, Fujisawa T, Inui A, et al. Molecular diagnosis of cerebral aspergillosis by sequence  
2080 analysis with panfungal polymerase chain reaction. *J Pediatr Hematol Oncol*. 2004; **26**: 40-44.

2081 461 Kami M, Shirouzu I, Mitani K, et al. Early diagnosis of central nervous system aspergillosis  
2082 with combination use of cerebral diffusion-weighted echo-planar magnetic resonance image  
2083 and polymerase chain reaction of cerebrospinal fluid. *Intern Med*. 1999; **38**: 45-48.

2084 462 Hummel M, Spiess B, Kentouche K, et al. Detection of aspergillus DNA in cerebrospinal fluid  
2085 from patients with cerebral aspergillosis by a nested pcr assay. *Journal of clinical*  
2086 *microbiology*. 2006; **44**: 3989-3993.

2087 463 Badiie P, Alborzi A. Assessment of a real-time pcr method to detect human non-cryptococcal  
2088 fungal meningitis. *Arch Iran Med*. 2011; **14**: 381-384.

2089 464 Mengoli C, Cruciani M, Barnes RA, Loeffler J, Donnelly JP. Use of pcr for diagnosis of invasive  
2090 aspergillosis: Systematic review and meta-analysis. *Lancet Infect Dis*. 2009; **9**: 89-96.

2091 465 White PL, Mengoli C, Bretagne S, et al. Evaluation of aspergillus pcr protocols for testing  
2092 serum specimens. *Journal of clinical microbiology*. 2011; **49**: 3842-3848.

2093 466 White PL, Linton CJ, Perry MD, Johnson EM, Barnes RA. The evolution and evaluation of a  
2094 whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in  
2095 hematology patients in a routine clinical setting. *Clin Infect Dis*. 2006; **42**: 479-486.

2096 467 Lass-Flörl C, Mutschlechner W, Aigner M, et al. Utility of pcr in diagnosis of invasive fungal  
2097 infections: Real-life data from a multicenter study. *Journal of clinical microbiology*. 2013; **51**:  
2098 863-868.

2099 468 Paterson PJ, Seaton S, McLaughlin J, Kibbler CC. Development of molecular methods for the  
2100 identification of aspergillus and emerging moulds in paraffin wax embedded tissue sections.  
2101 *Mol Pathol*. 2003; **56**: 368-370.

2102 469 Paterson PJ, Seaton S, McHugh TD, et al. Validation and clinical application of molecular  
2103 methods for the identification of molds in tissue. *Clin Infect Dis*. 2006; **42**: 51-56.

2104 470 von Eiff M, Roos N, Schulten R, Hesse M, ZÄhlsdorf M, van de Loo J. Pulmonary aspergillosis:  
2105 Early diagnosis improves survival. *Respiration*. 1995; **62**: 341-347.

2106 471 Kappe R, Rimek D. Antibody detection in patients with invasive aspergillosis. *Mycoses*. 2004;  
2107 **47**: 59.

2108 472 Cornillet A, Camus C, Nimubona S, et al. Comparison of epidemiological, clinical, and  
2109 biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: A 6-  
2110 year survey. *Clin Infect Dis*. 2006; **43**: 577-584.

2111 473 Weig M, Frosch M, Tintelnot K, et al. Use of recombinant mitogillin for improved  
2112 serodiagnosis of aspergillus fumigatus -associated diseases. *Journal of clinical microbiology*.  
2113 2001; **39**: 1721-1730.

2114 474 Du C, Wingard JR, Cheng S, Nguyen MH, Clancy C. Serum igg responses against aspergillus  
2115 proteins before hematopoietic stem cell transplantation or chemotherapy identify patients  
2116 who develop invasive aspergillosis. *Biology of blood and marrow transplantation : journal of*  
2117 *the American Society for Blood and Marrow Transplantation*. 2012; **18**: 1927-1934.

2118 475 Holmberg K, Berdischewsky M, Young LS. Serologic immunodiagnosis of of invasive  
2119 aspergillosis. *The Journal of infectious diseases*. 1980; **141**: 656-664.

2120 476 Manso E, Montillo M, De Sio G, D'Amico S, Discepoli G, Leoni P. Value of antigen and  
2121 antibody detection in the serological diagnosis of invasive aspergillosis in patients with  
2122 hematological malignancies. *Eur J Clin Microbiol Infect Dis*. 1994; **13**: 756-760.

2123 477 Mishra SK, Falkenberg S, Masihi KN. Efficacy of enzyme-linked immunosorbent assay in  
2124 serodiagnosis of aspergillosis. *Journal of clinical microbiology*. 1983; **17**: 708-710.

2125 478 Kappe R, Schulze-Berge A, Sonntag HG. Evaluation of eight antibody tests and one antigen  
2126 test for the diagnosis of invasive aspergillosis. *Mycoses*. 1996; **39**: 13-23.

2127 479 Fraczek MG, Bromley M, Buied A, et al. The cdr1b efflux transporter is associated with non-  
2128 cyp51a-mediated itraconazole resistance in aspergillus fumigatus. *J Antimicrob Chemother*.  
2129 2013; **68**: 1486-1496.

2130 480 Bueid A, Howard SJ, Moore CB, et al. Azole antifungal resistance in aspergillus fumigatus:  
2131 2008 and 2009. *J Antimicrob Chemother*. 2010; **65**: 2116-2118.

2132 481 Arendrup MC, Mavridou E, Mortensen KL, et al. Development of azole resistance in  
2133 aspergillus fumigatus during azole therapy associated with change in virulence. *PLoS ONE*.  
2134 2010; **5**: e10080.

2135 482 van der Linden JW, Jansen RR, Bresters D, et al. Azole-resistant central nervous system  
2136 aspergillosis. *Clin Infect Dis*. 2009; **48**: 1111-1113.

2137 483 Badali H, Vaezi A, Haghani I, et al. Environmental study of azole-resistant aspergillus  
2138 fumigatus with tr34/l98h mutations in the cyp51a gene in iran. *Mycoses*. 2013; **56**: 659-663.

2139 484 Chowdhary A, Kathuria S, Xu J, et al. Clonal expansion and emergence of environmental  
2140 multiple-triazole-resistant aspergillus fumigatus strains carrying the tr(3)(4)/I98h mutations  
2141 in the cyp51a gene in india. *PLoS ONE*. 2012; **7**: e52871.

2142 485 Mortensen KL, Mellado E, Lass-Flörl C, Rodríguez-Tudela JL, Johansen HK, Arendrup MC.  
2143 Environmental study of azole-resistant aspergillus fumigatus and other aspergilli in austria,  
2144 denmark, and spain. *Antimicrob Agents Chemother*. 2010; **54**: 4545-4549.

2145 486 Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope WW. Breakpoints for antifungal agents:  
2146 An update from eucast focussing on echinocandins against candida spp. And triazoles against  
2147 aspergillus spp. *Drug Resist Updat*. 2013; **16**: 81-95.

2148 487 Vermeulen E, Maertens J, Schoemans H, Lagrou K. Azole-resistant aspergillus fumigatus due  
2149 to tr46/y121f/t289a mutation emerging in belgium, july 2012. *Euro Surveill*. 2012; **17**.

2150 488 Chowdhary A, Kathuria S, Randhawa HS, Gaur SN, Klaassen CH, Meis JF. Isolation of multiple-  
2151 triazole-resistant aspergillus fumigatus strains carrying the tr/I98h mutations in the cyp51a  
2152 gene in india. *J Antimicrob Chemother*. 2012; **67**: 362-366.

2153 489 Rath PM, Buchheidt D, Spiess B, Arfanis E, Buer J, Steinmann J. First reported case of azole-  
2154 resistant aspergillus fumigatus due to the tr/I98h mutation in germany. *Antimicrob Agents*  
2155 *Chemother*. 2012; **56**: 6060-6061.

2156 490 Balajee SA, Baddley JW, Peterson SW, et al. Aspergillus alabamensis, a new clinically relevant  
2157 species in the section terrei. *Eukaryot Cell*. 2009; **8**: 713-722.

2158 491 Buil JB, van der Lee HAL, Rijs A, et al. Single-center evaluation of an agar-based screening for  
2159 azole resistance in aspergillus fumigatus by using vipcheck. *Antimicrob Agents Chemother*.  
2160 2017; **61**.

2161 492 van Leer-Buter C, Takes RP, Hebeda KM, Melchers WJ, Verweij PE. Aspergillosis--and a  
2162 misleading sensitivity result. *Lancet*. 2007; **370**: 102.

2163 493 Howard SJ, Pasqualotto AC, Anderson MJ, et al. Major variations in aspergillus fumigatus  
2164 arising within aspergillomas in chronic pulmonary aspergillosis. *Mycoses*. 2013; **56**: 434-441.

2165 494 Hope WW, Cuenca-Estrella M, Lass-Flörl C, Arendrup MC, European Committee on  
2166 Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility T. Eucast  
2167 technical note on voriconazole and aspergillus spp. *Clin Microbiol Infect*. 2013; **19**: E278-280.



2168 495 Arendrup MC, Meletiadis J, Mouton JW, et al. Eucast technical note on isavuconazole  
2169 breakpoints for aspergillus, itraconazole breakpoints for candida and updates for the  
2170 antifungal susceptibility testing method documents. *Clin Microbiol Infect.* 2016; **22**: 571  
2171 e571-574.

2172 496 Rex JH, Clinical, Institute LS. *Reference method for broth dilution antifungal susceptibility*  
2173 *testing of filamentous fungi: Approved standard*: Clinical and Laboratory Standards Institute,  
2174 2008.

2175 497 Burgel PR, Baixench MT, Amsellem M, et al. High prevalence of azole-resistant aspergillus  
2176 fumigatus in adults with cystic fibrosis exposed to itraconazole. *Antimicrob Agents*  
2177 *Chemother.* 2012; **56**: 869-874.

2178 498 Araujo R, Espinel-Ingroff A. Comparison of assessment of oxygen consumption, etest, and clsi  
2179 m38-a2 broth microdilution methods for evaluation of the susceptibility of aspergillus  
2180 fumigatus to posaconazole. *Antimicrob Agents Chemother.* 2009; **53**: 4921-4923.

2181 499 Arikan S, Sancak B, Alp S, Hascelik G, McNicholas P. Comparative in vitro activities of  
2182 posaconazole, voriconazole, itraconazole, and amphotericin b against *aspergillus* and  
2183 *rhizopus*, and synergy testing for *rhizopus*. *Medical mycology.* 2008; **46**: 567-573.

2184 500 Guinea J, Pelaez T, Recio S, Torres-Narbona M, Bouza E. In vitro antifungal activities of  
2185 isavuconazole (bal4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete,  
2186 candida, aspergillus, fusarium, and scedosporium species. *Antimicrob Agents Chemother.*  
2187 2008; **52**: 1396-1400.

2188 501 Howard SJ, Harrison E, Bowyer P, Varga J, Denning DW. Cryptic species and azole resistance  
2189 in the aspergillus niger complex. *Antimicrob Agents Chemother.* 2011; **55**: 4802-4809.

2190 502 Denning DW, Radford SA, Oakley KL, Hall L, Johnson EM, Warnock DW. Correlation between  
2191 in-vitro susceptibility testing to itraconazole and in-vivo outcome of aspergillus fumigatus  
2192 infection. *J Antimicrob Chemother.* 1997; **40**: 401-414.

2193 503 Denning DW, Venkateswarlu K, Oakley KL, et al. Itraconazole resistance in aspergillus  
2194 fumigatus. *Antimicrob Agents Chemother.* 1997; **41**: 1364-1368.

2195 504 Rudramurthy SM, Chakrabarti A, Geertsen E, Mouton JW, Meis JF. In vitro activity of  
2196 isavuconazole against 208 aspergillus flavus isolates in comparison with 7 other antifungal

2197 agents: Assessment according to the methodology of the european committee on  
2198 antimicrobial susceptibility testing. *Diagn Microbiol Infect Dis*. 2011; **71**: 370-377.

2199 505 Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M. Echinocandin and triazole  
2200 antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected  
2201 from 2010 to 2011: Application of new clsi clinical breakpoints and epidemiological cutoff  
2202 values for characterization of geographic and temporal trends of antifungal resistance.  
2203 *Journal of clinical microbiology*. 2013; **51**: 2571-2581.

2204 506 Snelders E, van der Lee HA, Kuijpers J, et al. Emergence of azole resistance in aspergillus  
2205 fumigatus and spread of a single resistance mechanism. *PLoS Med*. 2008; **5**: e219.

2206 507 Perkhofer S, Lechner V, Lass-Flörl C, European Committee on Antimicrobial Susceptibility T.  
2207 In vitro activity of isavuconazole against aspergillus species and zygomycetes according to  
2208 the methodology of the european committee on antimicrobial susceptibility testing.  
2209 *Antimicrob Agents Chemother*. 2009; **53**: 1645-1647.

2210 508 Hodiamont CJ, Dolman KM, Ten Berge IJ, Melchers WJ, Verweij PE, Pajkrt D. Multiple-azole-  
2211 resistant aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease  
2212 successfully treated with long-term oral posaconazole and surgery. *Medical mycology*. 2009;  
2213 **47**: 217-220.

2214 509 Mavridou E, Brüggemann RJ, Melchers WJ, Mouton JW, Verweij PE. Efficacy of posaconazole  
2215 against three clinical aspergillus fumigatus isolates with mutations in the cyp51a gene.  
2216 *Antimicrob Agents Chemother*. 2010; **54**: 860-865.

2217 510 Espinel-Ingroff A, Chowdhary A, Gonzalez GM, et al. Multicenter study of isavuconazole mic  
2218 distributions and epidemiological cutoff values for aspergillus spp. For the clsi m38-a2 broth  
2219 microdilution method. *Antimicrob Agents Chemother*. 2013; **57**: 3823-3828.

2220 511 Howard SJ, Lass-Flörl C, Cuenca-Estrella M, Gomez-Lopez A, Arendrup MC. Determination of  
2221 isavuconazole susceptibility of aspergillus and candida species by the eucast method.  
2222 *Antimicrob Agents Chemother*. 2013; **57**: 5426-5431.

2223 512 Gregson L, Goodwin J, Johnson A, et al. In vitro susceptibility of aspergillus fumigatus to  
2224 isavuconazole: Correlation with itraconazole, voriconazole, and posaconazole. *Antimicrob*  
2225 *Agents Chemother*. 2013; **57**: 5778-5780.

2226 513 Lionakis MS, Lewis RE, Chamilos G, Kontoyiannis DP. Aspergillus susceptibility testing in  
2227 patients with cancer and invasive aspergillosis: Difficulties in establishing correlation  
2228 between in vitro susceptibility data and the outcome of initial amphotericin b therapy.  
2229 *Pharmacotherapy*. 2005; **25**: 1174-1180.

2230 514 Mosquera J, Warn PA, Morrissey J, Moore CB, Gil-Lamaignere C, Denning DW. Susceptibility  
2231 testing of aspergillus flavus: Inoculum dependence with itraconazole and lack of correlation  
2232 between susceptibility to amphotericin b in vitro and outcome in vivo. *Antimicrob Agents*  
2233 *Chemother*. 2001; **45**: 1456-1462.

2234 515 Barchiesi F, Spreghini E, Sanguinetti M, et al. Effects of amphotericin b on aspergillus flavus  
2235 clinical isolates with variable susceptibilities to the polyene in an experimental model of  
2236 systemic aspergillosis. *J Antimicrob Chemother*. 2013; **68**: 2587-2591.

2237 516 Hadrich I, Makni F, Neji S, et al. Amphotericin b in vitro resistance is associated with fatal  
2238 aspergillus flavus infection. *Medical mycology*. 2012; **50**: 829-834.

2239 517 Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope WW, European Committee on  
2240 Antimicrobial Susceptibility Testing Subcommittee on Antifungal Susceptibility T. Eucast  
2241 technical note on aspergillus and amphotericin b, itraconazole, and posaconazole. *Clin*  
2242 *Microbiol Infect*. 2012; **18**: E248-250.

2243 518 *European committee on antimicrobial susceptibility testing*. <http://www.eucast.org>

2244 519 Espinel-Ingroff A, Diekema DJ, Fothergill A, et al. Wild-type mic distributions and  
2245 epidemiological cutoff values for the triazoles and six aspergillus spp. For the clsi broth  
2246 microdilution method (m38-a2 document). *Journal of clinical microbiology*. 2010; **48**: 3251-  
2247 3257.

2248 520 Nivoix Y, Velten M, Letscher-Bru V, et al. Factors associated with overall and attributable  
2249 mortality in invasive aspergillosis. *Clin Infect Dis*. 2008; **47**: 1176-1184.

2250 521 Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following  
2251 hematopoietic cell transplantation: Outcomes and prognostic factors associated with  
2252 mortality. *Clin Infect Dis*. 2007; **44**: 531-540.

2253 522 Pagano L, Caira M, Candoni A, et al. Invasive aspergillosis in patients with acute myeloid  
2254 leukemia: A seifem-2008 registry study. *Haematologica*. 2010; **95**: 644-650.

2255 523 Baddley JW, Andes DR, Marr KA, et al. Factors associated with mortality in transplant  
2256 patients with invasive aspergillosis. *Clin Infect Dis*. 2010; **50**: 1559-1567.

2257 524 Lortholary O, Gangneux JP, Sitbon K, et al. Epidemiological trends in invasive aspergillosis in  
2258 france: The saif network (2005-2007). *Clin Microbiol Infect*. 2011; **17**: 1882-1889.

2259 525 Perkhofer S, Lass-Flörl C, Hell M, et al. The nationwide austrian aspergillus registry: A  
2260 prospective data collection on epidemiology, therapy and outcome of invasive mould  
2261 infections in immunocompromised and/or immunosuppressed patients. *Int J Antimicrob*  
2262 *Agents*. 2010; **36**: 531-536.

2263 526 Lass-Flörl C, Alastruey-Izquierdo A, Cuenca-Estrella M, Perkhofer S, Rodríguez-Tudela JL. In  
2264 vitro activities of various antifungal drugs against aspergillus terreus: Global assessment  
2265 using the methodology of the european committee on antimicrobial susceptibility testing.  
2266 *Antimicrob Agents Chemother*. 2009; **53**: 794-795.

2267 527 Kathuria S, Sharma C, Singh PK, et al. Molecular epidemiology and in-vitro antifungal  
2268 susceptibility of aspergillus terreus species complex isolates in delhi, india: Evidence of  
2269 genetic diversity by amplified fragment length polymorphism and microsatellite typing. *PLoS*  
2270 *One*. 2015; **10**: e0118997.

2271 528 Alastruey-Izquierdo A, Cuesta I, Houbaken J, Cuenca-Estrella M, Monzon A, Rodríguez-  
2272 Tudela JL. In vitro activity of nine antifungal agents against clinical isolates of aspergillus  
2273 calidoustus. *Medical mycology*. 2010; **48**: 97-102.

2274 529 Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodríguez-Tudela JL.  
2275 Aspergillus section fumigati: Antifungal susceptibility patterns and sequence-based  
2276 identification. *Antimicrob Agents Chemother*. 2008; **52**: 1244-1251.

2277 530 Datta K, Rhee P, Byrnes E, 3rd, et al. Isavuconazole activity against aspergillus lentulus,  
2278 neosartorya udagawae, and cryptococcus gattii, emerging fungal pathogens with reduced  
2279 azole susceptibility. *Journal of clinical microbiology*. 2013; **51**: 3090-3093.

2280 531 Howard SJ. Multi-resistant aspergillosis due to cryptic species. *Mycopathologia*. 2014; **178**:  
2281 435-439.

2282 532 Falcone EL, Holland SM. Invasive fungal infection in chronic granulomatous disease: Insights  
2283 into pathogenesis and management. *Curr Opin Infect Dis*. 2012; **25**: 658-669.

2284 533 Segal BH, DeCarlo ES, Kwon-Chung KJ, Malech HL, Gallin JI, Holland SM. *Aspergillus nidulans*  
2285 infection in chronic granulomatous disease. *Medicine (Baltimore)*. 1998; **77**: 345-354.

2286 534 Seyedmousavi S, Bruggemann RJ, Melchers WJ, Rijs AJ, Verweij PE, Mouton JW. Efficacy and  
2287 pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive  
2288 aspergillosis. *J Antimicrob Chemother*. 2013; **68**: 385-393.

2289 535 Seyedmousavi S, Mouton JW, Melchers WJ, Bruggemann RJ, Verweij PE. The role of azoles in  
2290 the management of azole-resistant aspergillosis: From the bench to the bedside. *Drug Resist*  
2291 *Updat*. 2014; **17**: 37-50.

2292 536 Newton PJ, Harris C, Morris J, Denning DW. Impact of liposomal amphotericin b therapy on  
2293 chronic pulmonary aspergillosis. *J Infect*. 2016.

2294 537 Verweij PE, Howard SJ, Melchers WJ, Denning DW. Azole-resistance in aspergillus: Proposed  
2295 nomenclature and breakpoints. *Drug Resist Updat*. 2009; **12**: 141-147.

2296 538 Seyedmousavi S, Melchers WJ, Mouton JW, Verweij PE. Pharmacodynamics and dose-  
2297 response relationships of liposomal amphotericin b against different azole-resistant  
2298 *aspergillus fumigatus* isolates in a murine model of disseminated aspergillosis. *Antimicrob*  
2299 *Agents Chemother*. 2013; **57**: 1866-1871.

2300 539 Lepak AJ, Marchillo K, VanHecker J, Andes DR. Impact of in vivo triazole and echinocandin  
2301 combination therapy for invasive pulmonary aspergillosis: Enhanced efficacy against cyp51  
2302 mutant isolates. *Antimicrob Agents Chemother*. 2013; **57**: 5438-5447.

2303 540 Denning DW. Treatment of invasive aspergillosis. *J Infect*. 1994; **28 Suppl 1**: 25-33.

2304 541 Denning DW, Tucker RM, Hanson LH, Stevens DA. Treatment of invasive aspergillosis with  
2305 itraconazole. *The American journal of medicine*. 1989; **86**: 791-800.

2306 542 Caillot D, Bassaris H, McGeer A, et al. Intravenous itraconazole followed by oral itraconazole  
2307 in the treatment of invasive pulmonary aspergillosis in patients with hematologic  
2308 malignancies, chronic granulomatous disease, or aids. *Clin Infect Dis*. 2001; **33**: e83-90.

2309 543 Kim SH, Yim DS, Choi SM, et al. Voriconazole-related severe adverse events: Clinical  
2310 application of therapeutic drug monitoring in korean patients. *Int J Infect Dis*. 2011; **15**: e753-  
2311 758.

2312 544 Ueda K, Nannya Y, Kumano K, et al. Monitoring trough concentration of voriconazole is  
2313 important to ensure successful antifungal therapy and to avoid hepatic damage in patients  
2314 with hematological disorders. *International journal of hematology*. 2009; **89**: 592-599.

2315 545 Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. *Antimicrob*  
2316 *Agents Chemother*. 2006; **50**: 1570-1572.

2317 546 Pieper S, Kolve H, Gumbinger HG, Goletz G, Wurthwein G, Groll AH. Monitoring of  
2318 voriconazole plasma concentrations in immunocompromised paediatric patients. *J*  
2319 *Antimicrob Chemother*. 2012; **67**: 2717-2724.

2320 547 Mitsani D, Nguyen MH, Shields RK, et al. Prospective, observational study of voriconazole  
2321 therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: Factors  
2322 impacting levels of and associations between serum troughs, efficacy, and toxicity.  
2323 *Antimicrob Agents Chemother*. 2012; **56**: 2371-2377.

2324 548 Siopi M, Mavridou E, Mouton JW, Verweij PE, Zerva L, Meletiadis J. Susceptibility breakpoints  
2325 and target values for therapeutic drug monitoring of voriconazole and aspergillus fumigatus  
2326 in an in vitro pharmacokinetic/pharmacodynamic model. *J Antimicrob Chemother*. 2014; **69**:  
2327 1611-1619.

2328 549 Conte JE, Jr., Golden JA, Krishna G, McIver M, Little E, Zurlinden E. Intrapulmonary  
2329 pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy  
2330 subjects. *Antimicrob Agents Chemother*. 2009; **53**: 703-707.

2331 550 Campoli P, Perlin DS, Kristof AS, White TC, Filler SG, Sheppard DC. Pharmacokinetics of  
2332 posaconazole within epithelial cells and fungi: Insights into potential mechanisms of action  
2333 during treatment and prophylaxis. *The Journal of infectious diseases*. 2013; **208**: 1717-1728.

2334 551 Campoli P, Al Abdallah Q, Robitaille R, et al. Concentration of antifungal agents within host  
2335 cell membranes: A new paradigm governing the efficacy of prophylaxis. *Antimicrob Agents*  
2336 *Chemother*. 2011; **55**: 5732-5739.

2337 552 Blennow O, Eliasson E, Pettersson T, et al. Posaconazole concentrations in human tissues  
2338 after allogeneic stem cell transplantation. *Antimicrob Agents Chemother*. 2014; **58**: 4941-  
2339 4943.

2340 553 Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. Fluconazole or itraconazole  
2341 prophylaxis in patients with neutropenia. *N Engl J Med*. 2007; **356**: 348-359.

2342 554 Rijnders BJ, Cornelissen JJ, Slobbe L, et al. Aerosolized liposomal amphotericin b for the  
2343 prevention of invasive pulmonary aspergillosis during prolonged neutropenia: A randomized,  
2344 placebo-controlled trial. *Clin Infect Dis*. 2008; **46**: 1401-1408.

2345 555 Slobbe L, Boersma E, Rijnders BJ. Tolerability of prophylactic aerosolized liposomal  
2346 amphotericin-b and impact on pulmonary function: Data from a randomized placebo-  
2347 controlled trial. *Pulm Pharmacol Ther*. 2008; **21**: 855-859.

2348 556 Mattiuzzi GN, Kantarjian H, Faderl S, et al. Amphotericin b lipid complex as prophylaxis of  
2349 invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic  
2350 syndrome undergoing induction chemotherapy. *Cancer*. 2004; **100**: 581-589.

2351 557 Oren I, Rowe JM, Sprecher H, et al. A prospective randomized trial of itraconazole vs  
2352 fluconazole for the prevention of fungal infections in patients with acute leukemia and  
2353 hematopoietic stem cell transplant recipients. *Bone Marrow Transplant*. 2006; **38**: 127-134.

2354 558 Glasmacher A, Cornely O, Ullmann AJ, et al. An open-label randomized trial comparing  
2355 itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal  
2356 infections in patients with haematological malignancy and profound neutropenia. *J*  
2357 *Antimicrob Chemother*. 2006; **57**: 317-325.

2358 559 Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of  
2359 fungal infections in patients receiving allogeneic stem cell transplants. *Blood*. 2004; **103**:  
2360 1527-1533.

2361 560 van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for  
2362 prophylaxis against invasive fungal infections during neutropenia in patients undergoing  
2363 hematopoietic stem cell transplantation. *Clin Infect Dis*. 2004; **39**: 1407-1416.

2364 561 Park S, Kim K, Jang JH, et al. Randomized trial of micafungin versus fluconazole as prophylaxis  
2365 against invasive fungal infections in hematopoietic stem cell transplant recipients. *J Infect*.  
2366 2016; **73**: 496-505.

2367 562 Cordonnier C, Mohty M, Faucher C, et al. Safety of a weekly high dose of liposomal  
2368 amphotericin b for prophylaxis of invasive fungal infection in immunocompromised patients:  
2369 Prophysome study. *Int J Antimicrob Agents*. 2008; **31**: 135-141.

2370 563 Penack O, Schwartz S, Martus P, et al. Low-dose liposomal amphotericin b in the prevention  
2371 of invasive fungal infections in patients with prolonged neutropenia: Results from a  
2372 randomized, single-center trial. *Ann Oncol*. 2006; **17**: 1306-1312.

2373 564 Annino L, Chierichini A, Anaclerico B, et al. Prospective phase ii single-center study of the  
2374 safety of a single very high dose of liposomal amphotericin b for antifungal prophylaxis in  
2375 patients with acute myeloid leukemia. *Antimicrob Agents Chemother*. 2013; **57**: 2596-2602.

2376 565 Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole versus  
2377 voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell  
2378 transplantation. *Blood*. 2010; **116**: 5111-5118.

2379 566 Cornely OA, Leguay T, Maertens J, et al. Randomized comparison of liposomal amphotericin  
2380 b versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia. *J Antimicrob*  
2381 *Chemother*. 2017; **72**: 2359-2367.

2382 567 Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole versus  
2383 voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell  
2384 transplantation. *Blood*. 2010; **116**: 5111-5118.

2385 568 Marks DI, Pagliuca A, Kibbler CC, et al. Voriconazole versus itraconazole for antifungal  
2386 prophylaxis following allogeneic haematopoietic stem-cell transplantation. *Br J Haematol*.  
2387 2011; **155**: 318-327.

2388 569 Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe  
2389 graft-versus-host disease. *N Engl J Med*. 2007; **356**: 335-347.

2390 570 Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus  
2391 intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic  
2392 hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. *Annals of*  
2393 *internal medicine*. 2003; **138**: 705-713.

2394 571 Marr KA, Leisenring W, Crippa F, et al. Cyclophosphamide metabolism is affected by azole  
2395 antifungals. *Blood*. 2004; **103**: 1557-1559.



2396 572 Menichetti F, Del Favero A, Martino P, et al. Itraconazole oral solution as prophylaxis for  
2397 fungal infections in neutropenic patients with hematologic malignancies: A randomized,  
2398 placebo-controlled, double-blind, multicenter trial. Gimema infection program. Gruppo  
2399 italiano malattie ematologiche dell' adulto. *Clin Infect Dis*. 1999; **28**: 250-255.

2400 573 Prentice HG, Caillot D, Dupont B, Menichetti F, Schuler U. Oral and intravenous itraconazole  
2401 for systemic fungal infections in neutropenic haematological patients: Meeting report.  
2402 London, united kingdom, 20 june 1998. *Acta Haematol*. 1999; **101**: 56-62.

2403 574 Harousseau JL, Dekker AW, Stamatoullas-Bastard A, et al. Itraconazole oral solution for  
2404 primary prophylaxis of fungal infections in patients with hematological malignancy and  
2405 profound neutropenia: A randomized, double-blind, double-placebo, multicenter trial  
2406 comparing itraconazole and amphotericin b. *Antimicrob Agents Chemother*. 2000; **44**: 1887-  
2407 1893.

2408 575 Gallin JI, Alling DW, Malech HL, et al. Itraconazole to prevent fungal infections in chronic  
2409 granulomatous disease. *N Engl J Med*. 2003; **348**: 2416-2422.

2410 576 de Repentigny L, Ratelle J, Leclerc JM, et al. Repeated-dose pharmacokinetics of an oral  
2411 solution of itraconazole in infants and children. *Antimicrob Agents Chemother*. 1998; **42**: 404-  
2412 408.

2413 577 Groll AH, Wood L, Roden M, et al. Safety, pharmacokinetics, and pharmacodynamics of  
2414 cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. *Antimicrob  
2415 Agents Chemother*. 2002; **46**: 2554-2563.

2416 578 Foot AB, Veys PA, Gibson BE. Itraconazole oral solution as antifungal prophylaxis in children  
2417 undergoing stem cell transplantation or intensive chemotherapy for haematological  
2418 disorders. *Bone Marrow Transplant*. 1999; **24**: 1089-1093.

2419 579 Simon A, Besuden M, Vezmar S, et al. Itraconazole prophylaxis in pediatric cancer patients  
2420 receiving conventional chemotherapy or autologous stem cell transplants. *Support Care  
2421 Cancer*. 2007; **15**: 213-220.

2422 580 Ananda-Rajah MR, Grigg A, Downey MT, et al. Comparative clinical effectiveness of  
2423 prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute  
2424 myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-  
2425 year period. *Haematologica*. 2012; **97**: 459-463.

2426 581 Ananda-Rajah MR, Grigg A, Slavin MA. Making sense of posaconazole therapeutic drug  
2427 monitoring: A practical approach. *Curr Opin Infect Dis.* 2012; **25**: 605-611.

2428 582 Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. Pharmacokinetics of oral  
2429 posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-  
2430 host disease. *Pharmacotherapy.* 2007; **27**: 1627-1636.

2431 583 Welzen ME, Bruggemann RJ, Van Den Berg JM, et al. A twice daily posaconazole dosing  
2432 algorithm for children with chronic granulomatous disease. *Pediatr Infect Dis J.* 2011; **30**:  
2433 794-797.

2434 584 Döring M, Müller C, Johann PD, et al. Analysis of posaconazole as oral antifungal prophylaxis  
2435 in pediatric patients under 12 years of age following allogeneic stem cell transplantation.  
2436 *BMC Infect Dis.* 2012; **12**: 263.

2437 585 Lehrnbecher T, Attarbaschi A, Duerken M, et al. Posaconazole salvage treatment in paediatric  
2438 patients: A multicentre survey. *Eur J Clin Microbiol Infect Dis.* 2010; **29**: 1043-1045.

2439 586 Vanstraelen K, Colita A, Bica AM, et al. Pharmacokinetics of posaconazole oral suspension in  
2440 children dosed according to body surface area. *Pediatr Infect Dis J.* 2016; **35**: 183-188.

2441 587 Mattiuzzi GN, Cortes J, Alvarado G, et al. Efficacy and safety of intravenous voriconazole and  
2442 intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous  
2443 leukemia or high-risk myelodysplastic syndrome. *Support Care Cancer.* 2011; **19**: 19-26.

2444 588 Barreto JN, Beach CL, Wolf RC, et al. The incidence of invasive fungal infections in  
2445 neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary  
2446 antifungal prophylaxis with voriconazole. *Am J Hematol.* 2013; **88**: 283-288.

2447 589 Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous  
2448 voriconazole in children after single- or multiple-dose administration. *Antimicrob Agents*  
2449 *Chemother.* 2004; **48**: 2166-2172.

2450 590 Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole  
2451 plasma concentration data from pediatric studies. *Antimicrob Agents Chemother.* 2009; **53**:  
2452 935-944.

2453 591 Driscoll TA, Frangoul H, Nemecek ER, et al. Comparison of pharmacokinetics and safety of  
2454 voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy  
2455 adults. *Antimicrob Agents Chemother.* 2011; **55**: 5780-5789.

2456 592 Driscoll TA, Yu LC, Frangoul H, et al. Comparison of pharmacokinetics and safety of  
2457 voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults.  
2458 *Antimicrob Agents Chemother.* 2011; **55**: 5770-5779.

2459 593 Molina JR, Serrano J, Sanchez-Garcia J, et al. Voriconazole as primary antifungal prophylaxis  
2460 in children undergoing allo-sct. *Bone Marrow Transplant.* 2012; **47**: 562-567.

2461 594 Tollemar J, Ringden O, Andersson S, et al. Prophylactic use of liposomal amphotericin b  
2462 (ambisome) against fungal infections: A randomized trial in bone marrow transplant  
2463 recipients. *Transplant Proc.* 1993; **25**: 1495-1497.

2464 595 Tollemar J, Ringden O, Andersson S, Sundberg B, Ljungman P, Tyden G. Randomized double-  
2465 blind study of liposomal amphotericin b (ambisome) prophylaxis of invasive fungal infections  
2466 in bone marrow transplant recipients. *Bone Marrow Transplant.* 1993; **12**: 577-582.

2467 596 Kelsey SM, Goldman JM, McCann S, et al. Liposomal amphotericin (ambisome) in the  
2468 prophylaxis of fungal infections in neutropenic patients: A randomised, double-blind,  
2469 placebo-controlled study. *Bone Marrow Transplant.* 1999; **23**: 163-168.

2470 597 Hong Y, Shaw PJ, Nath CE, et al. Population pharmacokinetics of liposomal amphotericin b in  
2471 pediatric patients with malignant diseases. *Antimicrob Agents Chemother.* 2006; **50**: 935-942.

2472 598 Ringden O, Meunier F, Tollemar J, et al. Efficacy of amphotericin b encapsulated in liposomes  
2473 (ambisome) in the treatment of invasive fungal infections in immunocompromised patients. *J*  
2474 *Antimicrob Chemother.* 1991; **28 Suppl B**: 73-82.

2475 599 Kolve H, Ahlke E, Fegeler W, Ritter J, Jurgens H, Groll AH. Safety, tolerance and outcome of  
2476 treatment with liposomal amphotericin b in paediatric patients with cancer or undergoing  
2477 haematopoietic stem cell transplantation. *J Antimicrob Chemother.* 2009; **64**: 383-387.

2478 600 Huang X, Chen H, Han M, et al. Multicenter, randomized, open-label study comparing the  
2479 efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal  
2480 infections in patients undergoing hematopoietic stem cell transplant. *Biology of blood and*

2481        *marrow transplantation : journal of the American Society for Blood and Marrow*  
2482        *Transplantation*. 2012; **18**: 1509-1516.

2483    601    Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of  
2484        micafungin (fk463) in febrile neutropenic pediatric patients. *Antimicrob Agents Chemother*.  
2485        2005; **49**: 3317-3324.

2486    602    Hope WW, Seibel NL, Schwartz CL, et al. Population pharmacokinetics of micafungin in  
2487        pediatric patients and implications for antifungal dosing. *Antimicrob Agents Chemother*.  
2488        2007; **51**: 3714-3719.

2489    603    Arrieta AC, Maddison P, Groll AH. Safety of micafungin in pediatric clinical trials. *Pediatr*  
2490        *Infect Dis J*. 2011; **30**: e97-e102.

2491    604    Mehta PA, Vinks AA, Filipovich A, et al. Alternate-day micafungin antifungal prophylaxis in  
2492        pediatric patients undergoing hematopoietic stem cell transplantation: A pharmacokinetic  
2493        study. *Biology of blood and marrow transplantation : journal of the American Society for*  
2494        *Blood and Marrow Transplantation*. 2010; **16**: 1458-1462.

2495    605    Beaute J, Obenga G, Le Mignot L, et al. Epidemiology and outcome of invasive fungal diseases  
2496        in patients with chronic granulomatous disease: A multicenter study in france. *Pediatr Infect*  
2497        *Dis J*. 2011; **30**: 57-62.

2498    606    Mouy R, Veber F, Blanche S, et al. Long-term itraconazole prophylaxis against aspergillus  
2499        infections in thirty-two patients with chronic granulomatous disease. *J Pediatr*. 1994; **125**:  
2500        998-1003.

2501    607    Fortun J, Martin-Davila P, Sanchez MA, et al. Voriconazole in the treatment of invasive mold  
2502        infections in transplant recipients. *Eur J Clin Microbiol Infect Dis*. 2003; **22**: 408-413.

2503    608    Wieland T, Liebold A, Jagiello M, Retzl G, Birnbaum DE. Superiority of voriconazole over  
2504        amphotericin b in the treatment of invasive aspergillosis after heart transplantation. *J Heart*  
2505        *Lung Transplant*. 2005; **24**: 102-104.

2506    609    Veroux M, Corona D, Gagliano M, et al. Voriconazole in the treatment of invasive  
2507        aspergillosis in kidney transplant recipients. *Transplant Proc*. 2007; **39**: 1838-1840.

2508 610 Walsh TJ, Driscoll T, Milligan PA, et al. Pharmacokinetics, safety, and tolerability of  
2509 voriconazole in immunocompromised children. *Antimicrob Agents Chemother.* 2010; **54**:  
2510 4116-4123.

2511 611 Doby EH, Benjamin DK, Jr., Blaschke AJ, et al. Therapeutic monitoring of voriconazole in  
2512 children less than three years of age: A case report and summary of voriconazole  
2513 concentrations for ten children. *Pediatr Infect Dis J.* 2012; **31**: 632-635.

2514 612 Soler-Palacin P, Frick MA, Martin-Nalda A, et al. Voriconazole drug monitoring in the  
2515 management of invasive fungal infection in immunocompromised children: A prospective  
2516 study. *J Antimicrob Chemother.* 2012; **67**: 700-706.

2517 613 Bartelink IH, Wolfs T, Jonker M, et al. Highly variable plasma concentrations of voriconazole  
2518 in pediatric hematopoietic stem cell transplantation patients. *Antimicrob Agents Chemother.*  
2519 2013; **57**: 235-240.

2520 614 Kotwani RN, Gokhale PC, Bodhe PV, Kirodian BG, Kshirsagar NA, Pandya SK. A comparative  
2521 study of plasma concentrations of liposomal amphotericin b (l-amp-lrc-1) in adults, children  
2522 and neonates. *Int J Pharm.* 2002; **238**: 11-15.

2523 615 Bochennek K, Tramsen L, Schedler N, et al. Liposomal amphotericin b twice weekly as  
2524 antifungal prophylaxis in paediatric haematological malignancy patients. *Clin Microbiol*  
2525 *Infect.* 2011; **17**: 1868-1874.

2526 616 Groll AH, Silling G, Young C, et al. Randomized comparison of safety and pharmacokinetics of  
2527 caspofungin, liposomal amphotericin b, and the combination of both in allogeneic  
2528 hematopoietic stem cell recipients. *Antimicrob Agents Chemother.* 2010; **54**: 4143-4149.

2529 617 Sunakawa K, Tsukimoto I, Tsunematsu Y, et al. Evaluation of the safety and efficacy of  
2530 liposomal amphotericin b (l-amb) in children. *J Infect Chemother.* 2012; **18**: 456-465.

2531 618 Herbrecht R, Maertens J, Baila L, et al. Caspofungin first-line therapy for invasive aspergillosis  
2532 in allogeneic hematopoietic stem cell transplant patients: An european organisation for  
2533 research and treatment of cancer study. *Bone Marrow Transplant.* 2010; **45**: 1227-1233.

2534 619 Viscoli C, Herbrecht R, Akan H, et al. An eortc phase ii study of caspofungin as first-line  
2535 therapy of invasive aspergillosis in haematological patients. *J Antimicrob Chemother.* 2009;  
2536 **64**: 1274-1281.

2537 620 Cornely OA, Vehreschild JJ, Vehreschild MJ, et al. Phase ii dose escalation study of  
2538 caspofungin for invasive aspergillosis. *Antimicrob Agents Chemother.* 2011; **55**: 5798-5803.

2539 621 Groetzner J, Kaczmarek I, Wittwer T, et al. Caspofungin as first-line therapy for the treatment  
2540 of invasive aspergillosis after thoracic organ transplantation. *J Heart Lung Transplant.* 2008;  
2541 **27**: 1-6.

2542 622 Winkler M, Pratschke J, Schulz U, et al. Caspofungin for post solid organ transplant invasive  
2543 fungal disease: Results of a retrospective observational study. *Transpl Infect Dis.* 2010; **12**:  
2544 230-237.

2545 623 Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics, safety, and tolerability of  
2546 caspofungin in children and adolescents. *Antimicrob Agents Chemother.* 2005; **49**: 4536-  
2547 4545.

2548 624 Neely M, Jafri HS, Seibel N, et al. Pharmacokinetics and safety of caspofungin in older infants  
2549 and toddlers. *Antimicrob Agents Chemother.* 2009; **53**: 1450-1456.

2550 625 Cesaro S, Giacchino M, Locatelli F, et al. Safety and efficacy of a caspofungin-based  
2551 combination therapy for treatment of proven or probable aspergillosis in pediatric  
2552 hematological patients. *BMC Infect Dis.* 2007; **7**: 28.

2553 626 Zaoutis T, Lehrnbecher T, Groll AH, et al. Safety experience with caspofungin in pediatric  
2554 patients. *Pediatr Infect Dis J.* 2009; **28**: 1132-1135.

2555 627 Zaoutis TE, Jafri HS, Huang LM, et al. A prospective, multicenter study of caspofungin for the  
2556 treatment of documented candida or aspergillus infections in pediatric patients. *Pediatrics.*  
2557 2009; **123**: 877-884.

2558 628 Ngai AL, Bourque MR, Lupinacci RJ, Strohmaier KM, Kartsonis NA. Overview of safety  
2559 experience with caspofungin in clinical trials conducted over the first 15 years: A brief report.  
2560 *Int J Antimicrob Agents.* 2011; **38**: 540-544.

2561 629 Manzoni P, Rizzollo S, Farina D. Response to "is liposomal amphotericin b really safety in  
2562 neonates?". *Early Hum Dev.* 2013; **89**: 37.

2563 630 Karadag-Oncel E, Ozsurekci Y, Yurdakok M, Kara A. Is liposomal amphotericin b really safety  
2564 in neonates? *Early Hum Dev.* 2013; **89**: 35-36.

2565 631 Scarcella A, Pasquariello MB, Giugliano B, Vendemmia M, de Lucia A. Liposomal amphotericin  
2566 b treatment for neonatal fungal infections. *Pediatr Infect Dis J*. 1998; **17**: 146-148.

2567 632 Juster-Reicher A, Flidel-Rimon O, Amitay M, Even-Tov S, Shinwell E, Leibovitz E. High-dose  
2568 liposomal amphotericin b in the therapy of systemic candidiasis in neonates. *Eur J Clin*  
2569 *Microbiol Infect Dis*. 2003; **22**: 603-607.

2570 633 Mellinghoff SC, Bassetti M, Dorfel D, et al. Isavuconazole shortens the qtc interval. *Mycoses*.  
2571 2017.

2572 634 Cornely OA. Isavuconazole: Is there a need for a new antifungal? *J Antimicrob Chemother*.  
2573 2017; **72**: i2-i4.

2574 635 Neofytos D, Ostrander D, Shoham S, et al. Voriconazole therapeutic drug monitoring: Results  
2575 of a prematurely discontinued randomized multicenter trial. *Transpl Infect Dis*. 2015; **17**:  
2576 831-837.

2577 636 Ito JI, Chandrasekar PH, Hooshmand-Rad R. Effectiveness of amphotericin b lipid complex  
2578 (ablc) treatment in allogeneic hematopoietic cell transplant (hct) recipients with invasive  
2579 aspergillosis (ia). *Bone Marrow Transplant*. 2005; **36**: 873-877.

2580 637 Kohno S, Masaoka T, Yamaguchi H, et al. A multicenter, open-label clinical study of  
2581 micafungin (fk463) in the treatment of deep-seated mycosis in japan. *Scand J Infect Dis*.  
2582 2004; **36**: 372-379.

2583 638 Denning DW, Marr KA, Lau WM, et al. Micafungin (fk463), alone or in combination with other  
2584 systemic antifungal agents, for the treatment of acute invasive aspergillosis. *J Infect*. 2006;  
2585 **53**: 337-349.

2586 639 Kontoyiannis DP, Ratanatharathorn V, Young JA, et al. Micafungin alone or in combination  
2587 with other systemic antifungal therapies in hematopoietic stem cell transplant recipients  
2588 with invasive aspergillosis. *Transpl Infect Dis*. 2009; **11**: 89-93.

2589 640 Caillot D, Thiebaut A, Herbrecht R, et al. Liposomal amphotericin b in combination with  
2590 caspofungin for invasive aspergillosis in patients with hematologic malignancies: A  
2591 randomized pilot study (combistrat trial). *Cancer*. 2007; **110**: 2740-2746.

2592 641 Dohen-Becue F, Salez F, Ramon P, et al. [management of hemoptysis in invasive pulmonary  
2593 aspergillosis]. *Revue des maladies respiratoires*. 1998; **15**: 791-796.

2594 642 Schwartz S, Ruhnke M, Ribaud P, et al. Improved outcome in central nervous system  
2595 aspergillosis, using voriconazole treatment. *Blood*. 2005; **106**: 2641-2645.

2596 643 Kourkoumpetis TK, Desalermos A, Muhammed M, Mylonakis E. Central nervous system  
2597 aspergillosis: A series of 14 cases from a general hospital and review of 123 cases from the  
2598 literature. *Medicine (Baltimore)*. 2012; **91**: 328-336.

2599 644 Rüping MJ, Albermann N, Ebinger F, et al. Posaconazole concentrations in the central  
2600 nervous system. *J Antimicrob Chemother*. 2008; **62**: 1468-1470.

2601 645 Coleman JM, Hogg GG, Rosenfeld JV, Waters KD. Invasive central nervous system  
2602 aspergillosis: Cure with liposomal amphotericin b, itraconazole, and radical surgery--case  
2603 report and review of the literature. *Neurosurgery*. 1995; **36**: 858-863.

2604 646 Clemons KV, Espiritu M, Parmar R, Stevens DA. Comparative efficacies of conventional  
2605 amphotericin b, liposomal amphotericin b (ambisome), caspofungin, micafungin, and  
2606 voriconazole alone and in combination against experimental murine central nervous system  
2607 aspergillosis. *Antimicrob Agents Chemother*. 2005; **49**: 4867-4875.

2608 647 Ellis M, Spence D, de Pauw B, et al. An eortc international multicenter randomized trial (eortc  
2609 number 19923) comparing two dosages of liposomal amphotericin b for treatment of  
2610 invasive aspergillosis. *Clin Infect Dis*. 1998; **27**: 1406-1412.

2611 648 Schwartz S, Ruhnke M, Ribaud P, Reed E, Troke P, Thiel E. Poor efficacy of amphotericin b-  
2612 based therapy in cns aspergillosis. *Mycoses*. 2007; **50**: 196-200.

2613 649 Ullmann AJ, Sanz MA, Tramarin A, et al. Prospective study of amphotericin b formulations in  
2614 immunocompromised patients in 4 european countries. *Clin Infect Dis*. 2006; **43**: e29-38.

2615 650 Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated  
2616 with amphotericin b for suspected or proven aspergillosis. *Clin Infect Dis*. 1999; **29**: 1402-  
2617 1407.

2618 651 Girmenia C, Pizzarelli G, Pozzi E, Cimino G, Gentile G, Martino P. Improving outcomes of  
2619 acute invasive aspergillus rhinosinusitis in patients with hematologic malignancies or aplastic  
2620 anemia: The role of voriconazole. *Haematologica*. 2008; **93**: 159-160.



2621 652 Thurtell MJ, Chiu AL, Goold LA, et al. Neuro-ophthalmology of invasive fungal sinusitis: 14  
2622 consecutive patients and a review of the literature. *Clin Experiment Ophthalmol.* 2013; **41**:  
2623 567-576.

2624 653 Daudia A, Jones NS. Advances in management of paranasal sinus aspergillosis. *J Laryngol*  
2625 *Otol.* 2008; **122**: 331-335.

2626 654 Cordonnier C, Rovira M, Maertens J, et al. Voriconazole for secondary prophylaxis of invasive  
2627 fungal infections in allogeneic stem cell transplant recipients: Results of the vosifi study.  
2628 *Haematologica.* 2010; **95**: 1762-1768.

2629 655 Liu F, Wu T, Wang JB, et al. Risk factors for recurrence of invasive fungal infection during  
2630 secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients.  
2631 *Transpl Infect Dis.* 2013; **15**: 243-250.

2632 656 Gerlach S, Vehreschild JJ, Ruping MJTG, Fischer G, Cornely OA. Epidemiology of aspergillus  
2633 spp. At the university hospital of cologne: Molecular typing of environmental and clinical  
2634 isolates. In: *Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen*  
2635 *GHO.* Wien, Österreich: Onkologie, 2008.

2636 657 Allinson K, Kolve H, Gumbinger HG, Vormoor HJ, Ehlert K, Groll AH. Secondary antifungal  
2637 prophylaxis in paediatric allogeneic haematopoietic stem cell recipients. *J Antimicrob*  
2638 *Chemother.* 2008; **61**: 734-742.

2639 658 de Fabritiis P, Spagnoli A, Di Bartolomeo P, et al. Efficacy of caspofungin as secondary  
2640 prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary  
2641 and/or systemic fungal infection. *Bone Marrow Transplant.* 2007; **40**: 245-249.

2642 659 Martino R, Parody R, Fukuda T, et al. Impact of the intensity of the pretransplantation  
2643 conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic  
2644 hematopoietic stem cell transplantation: A retrospective survey of the infectious diseases  
2645 working party of the european group for blood and marrow transplantation. *Blood.* 2006;  
2646 **108**: 2928-2936.

2647 660 Kruger WH, Russmann B, de Wit M, et al. Haemopoietic cell transplantation of patients with  
2648 a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin  
2649 b. *Acta Haematol.* 2005; **113**: 104-108.

- 2650 661 Nosari A, Ravini M, Cairoli R, et al. Surgical resection of persistent pulmonary fungus nodules  
2651 and secondary prophylaxis are effective in preventing fungal relapse in patients receiving  
2652 chemotherapy or bone marrow transplantation for leukemia. *Bone Marrow Transplant*.  
2653 2007; **39**: 631-635.
- 2654 662 Eliashar R, Resnick IB, Goldfarb A, Wohlgelernter J, Gross M. Endoscopic surgery for sinonasal  
2655 invasive aspergillosis in bone marrow transplantation patients. *The Laryngoscope*. 2007; **117**:  
2656 78-81.
- 2657 663 Cesaro S, Cecchetto G, De Corti F, et al. Results of a multicenter retrospective study of a  
2658 combined medical and surgical approach to pulmonary aspergillosis in pediatric neutropenic  
2659 patients. *Pediatric blood & cancer*. 2007; **49**: 909-913.
- 2660 664 Matt P, Bernet F, Habicht J, et al. Predicting outcome after lung resection for invasive  
2661 pulmonary aspergillosis in patients with neutropenia. *Chest*. 2004; **126**: 1783-1788.
- 2662 665 Reichenberger F, Habicht J, Kaim A, et al. Lung resection for invasive pulmonary aspergillosis  
2663 in neutropenic patients with hematologic diseases. *Am J Respir Crit Care Med*. 1998; **158**:  
2664 885-890.
- 2665 666 Boogaerts M, Winston DJ, Bow EJ, et al. Intravenous and oral itraconazole versus intravenous  
2666 amphotericin b deoxycholate as empirical antifungal therapy for persistent fever in  
2667 neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A  
2668 randomized, controlled trial. *Annals of internal medicine*. 2001; **135**: 412-422.
- 2669 667 Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial  
2670 evaluating the safety of liposomal amphotericin b versus amphotericin b lipid complex in the  
2671 empirical treatment of febrile neutropenia. L amph/ablc collaborative study group. *Clin Infect*  
2672 *Dis*. 2000; **31**: 1155-1163.
- 2673 668 White MH, Bowden RA, Sandler ES, et al. Randomized, double-blind clinical trial of  
2674 amphotericin b colloidal dispersion vs. Amphotericin b in the empirical treatment of fever  
2675 and neutropenia. *Clin Infect Dis*. 1998; **27**: 296-302.
- 2676 669 Tamura K, Urabe A, Yoshida M, et al. Efficacy and safety of micafungin, an echinocandin  
2677 antifungal agent, on invasive fungal infections in patients with hematological disorders. *Leuk*  
2678 *Lymphoma*. 2009; **50**: 92-100.

2679 670 Lass-Flörl C. Triazole antifungal agents in invasive fungal infections: A comparative review.  
2680 *Drugs*. 2011; **71**: 2405-2419.

2681 671 Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive  
2682 aspergillosis. *Clin Infect Dis*. 2004; **39**: 797-802.

2683 672 Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or  
2684 refractory fungal infections. *Clin Infect Dis*. 2003; **36**: 1122-1131.

2685 673 Baden LR, Katz JT, Fishman JA, et al. Salvage therapy with voriconazole for invasive fungal  
2686 infections in patients failing or intolerant to standard antifungal therapy. *Transplantation*.  
2687 2003; **76**: 1632-1637.

2688 674 Candoni A, Mestroni R, Damiani D, et al. Caspofungin as first line therapy of pulmonary  
2689 invasive fungal infections in 32 immunocompromised patients with hematologic  
2690 malignancies. *Eur J Haematol*. 2005; **75**: 227-233.

2691 675 Ng TT, Denning DW. Liposomal amphotericin b (ambisome) therapy in invasive fungal  
2692 infections. Evaluation of united kingdom compassionate use data. *Archives of internal  
2693 medicine*. 1995; **155**: 1093-1098.

2694 676 Hachem RY, Boktour MR, Hanna HA, et al. Amphotericin b lipid complex versus liposomal  
2695 amphotericin b monotherapy for invasive aspergillosis in patients with hematologic  
2696 malignancy. *Cancer*. 2008; **112**: 1282-1287.

2697 677 Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin b lipid complex for invasive fungal  
2698 infections: Analysis of safety and efficacy in 556 cases. *Clin Infect Dis*. 1998; **26**: 1383-1396.

2699 678 Chandrasekar PH, Ito JI. Amphotericin b lipid complex in the management of invasive  
2700 aspergillosis in immunocompromised patients. *Clin Infect Dis*. 2005; **40 Suppl 6**: S392-400.

2701 679 Oppenheim BA, Herbrecht R, Kusne S. The safety and efficacy of amphotericin b colloidal  
2702 dispersion in the treatment of invasive mycoses. *Clin Infect Dis*. 1995; **21**: 1145-1153.

2703 680 Herbrecht R, Letscher V, Andres E, Cavalier A. Safety and efficacy of amphotericin b colloidal  
2704 dispersion. An overview. *Chemotherapy*. 1999; **45 Suppl 1**: 67-76.

2705 681 Betts R, Glasmacher A, Maertens J, et al. Efficacy of caspofungin against invasive candida or  
2706 invasive aspergillus infections in neutropenic patients. *Cancer*. 2006; **106**: 466-473.

2707 682 Egerer G, Reichert D, Pletz MW, Kaskel P, Krobot KJ, Maertens J. Caspofungin for treatment  
2708 of invasive aspergillosis in germany: Results of a pre-planned subanalysis of an international  
2709 registry. *Eur J Med Res*. 2012; **17**: 7.

2710 683 Hiemenz JW, Raad, II, Maertens JA, et al. Efficacy of caspofungin as salvage therapy for  
2711 invasive aspergillosis compared to standard therapy in a historical cohort. *Eur J Clin Microbiol*  
2712 *Infect Dis*. 2010; **29**: 1387-1394.

2713 684 Kartsonis NA, Saah AJ, Joy Lipka C, Taylor AF, Sable CA. Salvage therapy with caspofungin for  
2714 invasive aspergillosis: Results from the caspofungin compassionate use study. *J Infect*. 2005;  
2715 **50**: 196-205.

2716 685 Morrissey CO, Slavin MA, O'Reilly MA, et al. Caspofungin as salvage monotherapy for invasive  
2717 aspergillosis in patients with haematological malignancies or following allogeneic stem cell  
2718 transplantation: Efficacy and concomitant cyclosporin a. *Mycoses*. 2007; **50 Suppl 1**: 24-37.

2719 686 Maertens J, Egerer G, Shin WS, et al. Caspofungin use in daily clinical practice for treatment  
2720 of invasive aspergillosis: Results of a prospective observational registry. *BMC Infect Dis*. 2010;  
2721 **10**: 182.

2722 687 Leon-Gil C, Ubeda-Iglesias A, Loza-Vazquez A, et al. Efficacy and safety of caspofungin in  
2723 critically ill patients. Procas study. *Rev Esp Quimioter*. 2012; **25**: 274-282.

2724 688 Enoch DA, Idris SF, Aliyu SH, Micallef C, Sule O, Karas JA. Micafungin for the treatment of  
2725 invasive aspergillosis. *J Infect*. 2014; **68**: 507-526.

2726 689 Hachem RY, Langston AA, Graybill JR, et al. Posaconazole as salvage treatment of invasive  
2727 fungal infections in patients with underlying renal impairment. *J Antimicrob Chemother*.  
2728 2008; **62**: 1386-1391.

2729 690 Heinz WJ, Egerer G, Lellek H, Boehme A, Greiner J. Posaconazole after previous antifungal  
2730 therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective  
2731 analysis. *Mycoses*. 2013; **56**: 304-310.

2732 691 Caillot D. Intravenous itraconazole followed by oral itraconazole for the treatment of  
2733 amphotericin-b-refractory invasive pulmonary aspergillosis. *Acta Haematol*. 2003; **109**: 111-  
2734 118.

2735 692 Luong ML, Chaparro C, Stephenson A, et al. Pretransplant aspergillus colonization of cystic  
2736 fibrosis patients and the incidence of post-lung transplant invasive aspergillosis.  
2737 *Transplantation*. 2014; **97**: 351-357.

2738 693 Monforte V, Roman A, Gavalda J, et al. Nebulized amphotericin b prophylaxis for aspergillus  
2739 infection in lung transplantation: Study of risk factors. *J Heart Lung Transplant*. 2001; **20**:  
2740 1274-1281.

2741 694 Iversen M, Burton CM, Vand S, et al. Aspergillus infection in lung transplant patients:  
2742 Incidence and prognosis. *Eur J Clin Microbiol Infect Dis*. 2007; **26**: 879-886.

2743 695 Hsu JL, Khan MA, Sobel RA, et al. Aspergillus fumigatus invasion increases with progressive  
2744 airway ischemia. *PLoS One*. 2013; **8**: e77136.

2745 696 Sole A, Morant P, Salavert M, Peman J, Morales P, Valencia Lung Transplant G. Aspergillus  
2746 infections in lung transplant recipients: Risk factors and outcome. *Clin Microbiol Infect*. 2005;  
2747 **11**: 359-365.

2748 697 Danziger-Isakov LA, Worley S, Arrigain S, et al. Increased mortality after pulmonary fungal  
2749 infection within the first year after pediatric lung transplantation. *J Heart Lung Transplant*.  
2750 2008; **27**: 655-661.

2751 698 Sarmiento E, Rodriguez-Molina JJ, Fernandez-Yanez J, et al. Igg monitoring to identify the risk  
2752 for development of infection in heart transplant recipients. *Transpl Infect Dis*. 2006; **8**: 49-53.

2753 699 Collins LA, Samore MH, Roberts MS, et al. Risk factors for invasive fungal infections  
2754 complicating orthotopic liver transplantation. *The Journal of infectious diseases*. 1994; **170**:  
2755 644-652.

2756 700 Singh N, Husain S, Practice ASTIDCo. Invasive aspergillosis in solid organ transplant recipients.  
2757 *Am J Transplant*. 2009; **9 Suppl 4**: S180-191.

2758 701 Singh N, Pruett TL, Houston S, et al. Invasive aspergillosis in the recipients of liver  
2759 retransplantation. *Liver Transpl*. 2006; **12**: 1205-1209.

2760 702 Saliba F, Delvart V, Ichai P, et al. Fungal infections after liver transplantation: Outcomes and  
2761 risk factors revisited in the meld era. *Clin Transplant*. 2013; **27**: E454-461.

2762 703 He H, Ding L, Li F, Zhan Q. Clinical features of invasive bronchial-pulmonary aspergillosis in  
2763 critically ill patients with chronic obstructive respiratory diseases: A prospective study. *Crit*  
2764 *Care*. 2011; **15**: R5.

2765 704 Bulpa P, Dive A, Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive  
2766 pulmonary disease. *Eur Respir J*. 2007; **30**: 782-800.

2767 705 Kistemann T, Huneburg H, Exner M, Vacata V, Engelhart S. Role of increased environmental  
2768 aspergillus exposure for patients with chronic obstructive pulmonary disease (copd) treated  
2769 with corticosteroids in an intensive care unit. *Int J Hyg Environ Health*. 2002; **204**: 347-351.

2770 706 Murray CK, Loo FL, Hospenthal DR, et al. Incidence of systemic fungal infection and related  
2771 mortality following severe burns. *Burns*. 2008; **34**: 1108-1112.

2772 707 Lahmer T, Messer M, Schwerdtfeger C, et al. Invasive mycosis in medical intensive care unit  
2773 patients with severe alcoholic hepatitis. *Mycopathologia*. 2014; **177**: 193-197.

2774 708 Ballard J, Edelman L, Saffle J, et al. Positive fungal cultures in burn patients: A multicenter  
2775 review. *J Burn Care Res*. 2008; **29**: 213-221.

2776 709 Horvath EE, Murray CK, Vaughan GM, et al. Fungal wound infection (not colonization) is  
2777 independently associated with mortality in burn patients. *Annals of surgery*. 2007; **245**: 978-  
2778 985.

2779 710 Guinea J, Jensen J, Pelaez T, et al. Value of a single galactomannan determination (platelia)  
2780 for the diagnosis of invasive aspergillosis in non-hematological patients with clinical isolation  
2781 of aspergillus spp. *Medical mycology*. 2008; **46**: 575-579.

2782 711 Acosta J, Catalan M, del Palacio-Perez-Medel A, et al. Prospective study in critically ill non-  
2783 neutropenic patients: Diagnostic potential of (1,3)-beta-d-glucan assay and circulating  
2784 galactomannan for the diagnosis of invasive fungal disease. *Eur J Clin Microbiol Infect Dis*.  
2785 2012; **31**: 721-731.

2786 712 He H, Ding L, Sun B, Li F, Zhan Q. Role of galactomannan determinations in bronchoalveolar  
2787 lavage fluid samples from critically ill patients with chronic obstructive pulmonary disease for  
2788 the diagnosis of invasive pulmonary aspergillosis: A prospective study. *Crit Care*. 2012; **16**:  
2789 R138.

2790 713 Khorvash F, Meidani M, Babaei L, Abbasi S, Ataei B, Yaran M. Galactomannan antigen assay  
2791 from bronchoalveolar lavage fluid in diagnosis of invasive pulmonary aspergillosis in  
2792 intensive care units patients. *Adv Biomed Res.* 2014; **3**: 68.

2793 714 Steinmann J, Buer J, Rath PM. Detection of aspergillus fumigatus in blood samples from  
2794 critically ill patients in intensive care units by use of the septifast assay. *Journal of clinical*  
2795 *microbiology.* 2016; **54**: 1918-1921.

2796 715 Westh H, Lisby G, Breyse F, et al. Multiplex real-time pcr and blood culture for identification  
2797 of bloodstream pathogens in patients with suspected sepsis. *Clin Microbiol Infect.* 2009; **15**:  
2798 544-551.

2799 716 Clancy CJ, Jaber RA, Leather HL, et al. Bronchoalveolar lavage galactomannan in diagnosis of  
2800 invasive pulmonary aspergillosis among solid-organ transplant recipients. *Journal of clinical*  
2801 *microbiology.* 2007; **45**: 1759-1765.

2802 717 Gazzoni FF, Hochhegger B, Severo LC, et al. High-resolution computed tomographic findings  
2803 of aspergillus infection in lung transplant patients. *Eur J Radiol.* 2014; **83**: 79-83.

2804 718 Hoenigl M, Koidl C, Duettmann W, et al. Bronchoalveolar lavage lateral-flow device test for  
2805 invasive pulmonary aspergillosis diagnosis in haematological malignancy and solid organ  
2806 transplant patients. *J Infect.* 2012; **65**: 588-591.

2807 719 Alexander BD, Smith PB, Davis RD, Perfect JR, Reller LB. The (1,3){beta}-d-glucan test as an  
2808 aid to early diagnosis of invasive fungal infections following lung transplantation. *Journal of*  
2809 *clinical microbiology.* 2010; **48**: 4083-4088.

2810 720 Husain S, Kwak EJ, Obman A, et al. Prospective assessment of platelia aspergillus  
2811 galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant  
2812 recipients. *Am J Transplant.* 2004; **4**: 796-802.

2813 721 Husain S, Paterson DL, Studer SM, et al. Aspergillus galactomannan antigen in the  
2814 bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant  
2815 recipients. *Transplantation.* 2007; **83**: 1330-1336.

2816 722 Ambrosioni J, Coll S, Manzardo C, et al. Voriconazole and cobicistat-boosted antiretroviral  
2817 salvage regimen co-administration to treat invasive aspergillosis in an hiv-infected patient. *J*  
2818 *Antimicrob Chemother.* 2016; **71**: 1125-1127.

2819 723 Utili R, Zampino R, De Vivo F, et al. Improved outcome of pulmonary aspergillosis in heart  
2820 transplant recipients with early diagnosis and itraconazole treatment. *Clin Transplant*. 2000;  
2821 **14**: 282-286.

2822 724 Husain S, Capitano B, Corcoran T, et al. Intrapulmonary disposition of amphotericin b after  
2823 aerosolized delivery of amphotericin b lipid complex (abelcet; ablc) in lung transplant  
2824 recipients. *Transplantation*. 2010; **90**: 1215-1219.

2825 725 Mucha K, Foronczewicz B, Orlowski T, et al. Atypical presentation of invasive pulmonary  
2826 aspergillosis in a liver transplant recipient. *Ann Transplant*. 2013; **18**: 238-242.

2827 726 Lopez-Medrano F, Fernandez-Ruiz M, Silva JT, et al. Clinical presentation and determinants of  
2828 mortality of invasive pulmonary aspergillosis in kidney transplant recipients: A multinational  
2829 cohort study. *Am J Transplant*. 2016; **16**: 3220-3234.

2830 727 Kleinberg M. Aspergillosis in the clear outcomes trial: Working toward a real-world clinical  
2831 perspective. *Medical mycology*. 2005; **43 Suppl 1**: S289-294.

2832 728 Linden PK, Coley K, Fontes P, Fung JJ, Kusne S. Invasive aspergillosis in liver transplant  
2833 recipients: Outcome comparison of therapy with amphotericin b lipid complex and a  
2834 historical cohort treated with conventional amphotericin b. *Clin Infect Dis*. 2003; **37**: 17-25.

2835 729 Walter J, Sobottka I, Rogiers X, Broering D, Fischer L. Invasive aspergillosis caused by  
2836 aspergillus terreus in a living donor liver transplant recipient successfully treated by  
2837 caspofungin. *Mycoses*. 2011; **54**: e220-222.

2838 730 Aguilar-Guisado M, Givalda J, Ussetti P, et al. Pneumonia after lung transplantation in the  
2839 resitra cohort: A multicenter prospective study. *Am J Transplant*. 2007; **7**: 1989-1996.

2840 731 Neoh CF, Snell GI, Levvey B, et al. Preemptive treatment with voriconazole in lung transplant  
2841 recipients. *Transpl Infect Dis*. 2013; **15**: 344-353.

2842 732 Drew RH, Dodds Ashley E, Benjamin DK, Jr., Duane Davis R, Palmer SM, Perfect JR.  
2843 Comparative safety of amphotericin b lipid complex and amphotericin b deoxycholate as  
2844 aerosolized antifungal prophylaxis in lung-transplant recipients. *Transplantation*. 2004; **77**:  
2845 232-237.



2846 733 Monforte V, Ussetti P, Gavalda J, et al. Feasibility, tolerability, and outcomes of nebulized  
2847 liposomal amphotericin b for aspergillus infection prevention in lung transplantation. *J Heart*  
2848 *Lung Transplant*. 2010; **29**: 523-530.

2849 734 Monforte V, Lopez-Sanchez A, Zurbano F, et al. Prophylaxis with nebulized liposomal  
2850 amphotericin b for aspergillus infection in lung transplant patients does not cause changes in  
2851 the lipid content of pulmonary surfactant. *J Heart Lung Transplant*. 2013; **32**: 313-319.

2852 735 Borro JM, Sole A, de la Torre M, et al. Efficiency and safety of inhaled amphotericin b lipid  
2853 complex (abelcet) in the prophylaxis of invasive fungal infections following lung  
2854 transplantation. *Transplant Proc*. 2008; **40**: 3090-3093.

2855 736 Williams K, Mansh M, Chin-Hong P, Singer J, Arron ST. Voriconazole-associated cutaneous  
2856 malignancy: A literature review on photocarcinogenesis in organ transplant recipients. *Clin*  
2857 *Infect Dis*. 2014; **58**: 997-1002.

2858 737 Montoya JG, Chaparro SV, Celis D, et al. Invasive aspergillosis in the setting of cardiac  
2859 transplantation. *Clin Infect Dis*. 2003; **37 Suppl 3**: S281-292.

2860 738 Paniagua Martin MJ, Marzoa Rivas R, Barge Caballero E, et al. Efficacy and tolerance of  
2861 different types of prophylaxis for prevention of early aspergillosis after heart transplantation.  
2862 *Transplant Proc*. 2010; **42**: 3014-3016.

2863 739 Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Preemptive prophylaxis with a  
2864 lipid preparation of amphotericin b for invasive fungal infections in liver transplant recipients  
2865 requiring renal replacement therapy. *Transplantation*. 2001; **71**: 910-913.

2866 740 Castroagudin JF, Ponton C, Bustamante M, et al. Prospective interventional study to evaluate  
2867 the efficacy and safety of liposomal amphotericin b as prophylaxis of fungal infections in  
2868 high-risk liver transplant recipients. *Transplant Proc*. 2005; **37**: 3965-3967.

2869 741 Reed A, Herndon JB, Ersoz N, et al. Effect of prophylaxis on fungal infection and costs for  
2870 high-risk liver transplant recipients. *Liver Transpl*. 2007; **13**: 1743-1750.

2871 742 Fortun J, Martin-Davila P, Montejo M, et al. Prophylaxis with caspofungin for invasive fungal  
2872 infections in high-risk liver transplant recipients. *Transplantation*. 2009; **87**: 424-435.

2873 743 Chakrabarti A, Sethi S, Raman DS, Behera D. Eight-year study of allergic bronchopulmonary  
2874 aspergillosis in an indian teaching hospital. *Mycoses*. 2002; **45**: 295-299.

2875 744 Tashiro T, Izumikawa K, Tashiro M, et al. A case series of chronic necrotizing pulmonary  
2876 aspergillosis and a new proposal. *Jpn J Infect Dis.* 2013; **66**: 312-316.

2877 745 Dupont B. Itraconazole therapy in aspergillosis: Study in 49 patients. *J Am Acad Dermatol.*  
2878 1990; **23**: 607-614.

2879 746 Sambatakou H, Dupont B, Lode H, Denning DW. Voriconazole treatment for subacute  
2880 invasive and chronic pulmonary aspergillosis. *The American journal of medicine.* 2006; **119**:  
2881 527 e517-524.

2882 747 Saito T, Fujiuchi S, Tao Y, et al. Efficacy and safety of voriconazole in the treatment of chronic  
2883 pulmonary aspergillosis: Experience in japan. *Infection.* 2012; **40**: 661-667.

2884 748 Felton TW, Baxter C, Moore CB, Roberts SA, Hope WW, Denning DW. Efficacy and safety of  
2885 posaconazole for chronic pulmonary aspergillosis. *Clin Infect Dis.* 2010; **51**: 1383-1391.  
2886

2887 **Transparency Declaration:** Dr. Cornely reports research grants from Actelion, Amplyx, Arsanis,  
2888 Astellas, AstraZeneca, Basilea, Bayer, Cidara, Duke University (NIH UM1AI104681), F2G, Gilead, GSK,  
2889 Leeds University, Matinas, Medicines Company, MedPace, Melinta, Merck/MSD, Miltenyi, Pfizer,  
2890 Rempex, Roche, Sanofi Pasteur, Scynexis, Seres, is a consultant to Amplyx, Actelion, Astellas, Basilea,  
2891 Cidara, Da Volterra, F2G, Gilead, Janssen, Matinas, Menarini, Merck/MSD, Paratek, PSI, Scynexis,  
2892 Seres, Summit, Tetrphase, Vical, and received lecture honoraria from Astellas, Basilea, Gilead,  
2893 Merck/MSD and Pfizer, outside the submitted work. Dr. Ader has nothing to disclose. Dr. Aguado  
2894 received honoraria for speaking at symposia organised on behalf of Pfizer, Merck Sharp & Dohme  
2895 (MSD), Schering-Plough and Gilead and was on advisory boards for antifungal agents on behalf of  
2896 MSD, Astellas, Pfizer and Gilead. Dr. Akova has nothing to disclose. Dr. Arendrup reports personal  
2897 fees from MSD and Pfizer, grants from Basilea, Gilead, Amplyx, F2G and Cidara, outside the  
2898 submitted work. Dr. Arikan-Akdagli reports non-financial support from Pfizer, outside the submitted  
2899 work. Dr. Barnes reports personal fees from Gilead, Basilia and Biomerieux, grants from EORTC,  
2900 outside the submitted work. Dr. Beigelman-Aubry reports personal fees from Gilead, outside the  
2901 submitted work. Dr. Blot reports grants from Pfizer, outside the submitted work. Dr. Bouza has  
2902 nothing to disclose. Dr. Brüggemann has received grants and consultancy fees as well as speaker  
2903 fees from MSD, Pfizer, Gilead and Astellas. All contracts were with Radboudumc and all payments  
2904 have been received by Radboudumc. Dr. Buchheidt reports personal fees and non-financial support  
2905 from Astellas, personal fees from Basilea, grants, personal fees and non-financial support from  
2906 Gilead, personal fees and non-financial support from Merck Sharp & Dohme/Merck, grants,  
2907 personal fees and non-financial support from Pfizer, outside the submitted work. Dr. Cadranel  
2908 reports personal fees from MSD, outside the submitted work. Dr. Castagnola reports personal fees  
2909 from Astellas Pharma, non-financial support from Gilead, outside the submitted work. Dr.  
2910 Chakrabarti has nothing to disclose. Dr. Cuenca-Estrella reports grants and other from Gilead and  
2911 MSD, grants from Amplyx, Cidara, Scynexis and F2G, other from Astellas, outside the submitted  
2912 work. Dr. Denning and family hold Founder shares in F2G Ltd, a University of Manchester spin-out

2913 antifungal discovery company. He acts or has recently acted as a consultant to Astellas, Sigma Tau,  
2914 Basilea, Scynexis, Cidara, Biosergen, Quintiles, Pulmatrix, Pulmocide and Zambon. In the last 3 years,  
2915 he has been paid for talks on behalf of Astellas, Dynamiker, Gilead, Merck and Pfizer. He is a  
2916 longstanding member of the Infectious Disease Society of America Aspergillosis Guidelines group,  
2917 the European Society for Clinical Microbiology and Infectious Diseases Aspergillosis Guidelines  
2918 group and the British Society for Medical Mycology Standards of Care committee. In addition, Dr.  
2919 Denning has a patent Assays for Fungal Infection licensed. Dr. Dimopoulos has nothing to disclose.  
2920 Dr. Fortún has nothing to disclose. Dr. Gangneux reports grants and personal fees from Pfizer, MSD,  
2921 Gilead and Astellas during the conduct of the study. Dr. Garbino has nothing to disclose. Dr. Groll  
2922 reports grants and personal fees from Gilead, Merck, Sharp & Dohme and Pfizer, personal fees from  
2923 Astellas and Basilea, outside the submitted work. Dr. Heinz reports personal fees from Astellas,  
2924 Gilead and Basilea, grants and personal fees from MSD Sharp & Dohme / Merck and Pfizer, outside  
2925 the submitted work. Dr. Herbrecht reports personal fees from Astellas, Basilea, Gilead, MSD and  
2926 Pfizer, outside the submitted work. Dr. Heussel reports personal fees from Boehringer Ingelheim,  
2927 Novartis, Gilead, Intermune and Fresenius, grants from Siemens, Pfizer and Boehringer Ingelheim,  
2928 lecture fees from Gilead, MSD, Pfizer, Intermune, Novartis, Basilea and Bayer, outside the submitted  
2929 work. Dr. Heussel has a patent for Method and Device For Representing the Microstructure of the  
2930 Lungs licensed. Dr. Kibbler reports personal fees from Gilead, outside the submitted work. Dr.  
2931 Klimko reports personal fees from Astellas and Pfizer, and grants and personal fees from Merck,  
2932 outside the submitted work. Dr. Kullberg reports personal fees from Astellas, Amplyx, Cidara, Gilead,  
2933 Pfizer and Scynexis, outside the submitted work. Dr. Lagrou reports grants, personal fees and non-  
2934 financial support from MSD, Pfizer and Gilead, personal fees from Abbott, outside the submitted  
2935 work. Dr. Lange reports personal fees from Chiesi, Gilead, Abbvie, MSD, Becton Dickinson, Janssen,  
2936 Lucane, Novartis, Thermofisher, and Transgene, outside the submitted work. Dr. Lass-Flörl reports  
2937 grants, personal fees and other from Astellas Pharma and Gilead, personal fees and other from  
2938 Pfizer, other from Merck Sharp and Dohme and Basilea, outside the submitted work. Dr.

2939 Lehrnbecher reports grants, personal fees and non-financial support from Gilead Sciences, personal  
2940 fees and non-financial support from Astellas and Merck/MSD, personal fees from Basilea, outside  
2941 the submitted work. Dr. Lewis reports personal fees from Gilead, grants and personal fees from  
2942 Merck, personal fees from Cidara, outside the submitted work. Dr. Loeffler has nothing to disclose.  
2943 Dr. Lotholary has nothing to disclose. Dr. Maertens reports grants, personal fees and non-financial  
2944 support from MSD, Astellas, Pfizer and Gilead, personal fees and non-financial support from Basilea  
2945 and F2G, personal fees from Scynexis, during the conduct of the study. Dr. Marchetti has nothing to  
2946 disclose. Dr. Meis reports personal fees and grants for consultancy from Astellas, MSD and Scynexis,  
2947 grants from F2G and Pulmozyme, personal fees and grants for lectures including service on speakers  
2948 bureaus from Merck, Gilead and TEVA, grants for travel and accommodation from Nordic-Pharma,  
2949 outside the submitted work. Dr. Muñoz has nothing to disclose. Dr. Pagano reports grants and  
2950 personal fees from Gilead, personal fees from MSD, Pfizer, Novartis, Janssen and Basilea, outside  
2951 the submitted work. Dr. Ribaud has nothing to disclose. Dr. Richardson reports other from  
2952 Associates of Cape Cod, personal fees from Gilead and MSD, other from Gilead, during the conduct  
2953 of the study. Dr. Roilides reports grants, personal fees and non-financial support from Astellas,  
2954 Gilead Merck and Pfizer, outside the submitted work. Dr. Ruhnke reports personal fees from Basilea  
2955 and Scynexis for board membership, personal fees from Basilea and Janssen for lectures including  
2956 service on speakers bureaus, personal fees from Janssen for development of educational  
2957 presentation, outside the submitted work. Dr. Sanguinetti has nothing to disclose. Dr. Sheppard  
2958 reports grants and personal fees from Merck, outside the submitted work. Dr. Sinko reports  
2959 personal fees (honoraria, fees for consulting, lectures, speakers bureaus) from Pfizer, Merck,  
2960 Astellas. Dr. Skiada has nothing to disclose. Dr. Ullmann reports personal fees from Pfizer, Astellas,  
2961 MSD and Gilead, outside the submitted work. Dr. Vehreschild reports personal fees, non-financial  
2962 support and other from Astellas, during the conduct of the study; grants and personal fees from  
2963 Astellas and Merck/MSD, grants from Seres Therapeutics and DaVolterra, grants and personal fees  
2964 from Gilead, personal fees from Berlin Chemie, Falk Foundation, Organobalance and Pfizer, outside

2965 the submitted work. Dr. Verweij reports grants from Gilead Sciences, MSD and F2G, outside the  
2966 submitted work. Dr. Viscoli reports personal fees from MSD, Gilead, Pfizer, Angelini, Astellas and  
2967 Basilea, outside the submitted work. Dr. Warris reports grants from Gilead, other from Gilead and  
2968 Basilea, outside the submitted work.